

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
mazindol	3H-Imidazo[2,1-a]isoindol-5-ol, 5-(4-chlorophenyl)-2,5-dihydro- [CAS]	22232-71-9	US 3763178	Anorectic/Antiobesity	Obesity
Mazipredone					
MC-5723		13085-08-0	US 6043259	Cardiovascular	Unspecified
MCC-478	(2-amino-6-(4-methoxyphenylthio)-9-[2-(phosphonomethoxy)ethyl]purine bis(2,2,2-trifluoroethyl) ester)				
MCI-154	3(2H)-Pyridazinone, 4,5-dihydro-6-[4-(4-pyridinylamino)phenyl]-monohydrochloride [CAS]	98326-32-0 98326-33-1	EP 145019	Antiviral, other Cardio stimulant	Infection, hepatitis-B virus Heart failure
m-Cresyl Acetate		122-46-3			
MDAM	Gamma-Methylene-10-deazaaminopterin			Anticancer, antimetabolite	Cancer, general
MDI-101			US 4885311	Antiacne	Acne
MDI-403		403849-94-5	US 4677120	Antiacne	Acne
MDL-100907	4-Piperidinemethanol, Alpha-(2,3-dimethoxyphenyl)-1-(2-(4-fluorophenyl)ethyl)-, (R)- [CAS]	139290-65-6		Hypnotic/Sedative	Sleep disorder, general
mebendazole	methyl-5-benzoylbenzimidazole-2-carbamate	31431-39-7	GB 1307306	Anthelmintic	
mebeverine	Benzoic acid, 3,4-dimethoxy-, 4-[ethyl(2-(4-methoxyphenyl)-1-methylethylamino)butyl ester] [CAS]	3625-06-7		Antispasmodic	Irritable bowel syndrome
Mebhydroline		524-81-2			
Mebrofenin		78266-06-5			
Mebutamate		64-55-1			
mecamylamine	Bicyclo(2.2.1)heptan-2-amine, N,2,3,3-tetramethyl- [CAS]	60-40-2		Neurological	Unspecified
Mechlorethamine		51-75-2			
Mechlorethamine Oxide		302-70-5			

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
meclizine	4-Thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, 6-[[[(hexahydro-1H-azepin-1-yl)methyl]ene]amino]-3,3-dimethyl-7-oxo-, [2S-(2Alpha,5Alpha,6 beta.)]- [CAS]	32887-01-7 32887-03-9	GB 1293590	Penicillin, injectable	Infection, general
Meclizine		569-65-3			
Meclocycline		2013-58-3			
meclorfenamate	Benzoic acid, 2-[[2,6-dichloro-3-methylphenyl]amino]-, monosodium salt [CAS]	6385-02-0 544-62-2		Antiarthritic, other	Arthritis, osteo
Meclofenamic Acid		644-62-2			
Meclofenoxate		51-68-3			
Mecloqualone		340-57-8			
Mecysteine		18598-63-5			
Medazepam		12/6/2898			
medifloxamine	Ethanamine, N,N-dimethyl-2,2-diphenoxy- [CAS]	32359-34-5	FR M5498	Antidepressant	
Medrogestone		977-79-7			
Medronic Acid		1984-15-2			
medroxyprogesterone	Pregn-4-ene-3,20-dione, 17-(acetyloxy)-6-methyl-, (6Alpha)	71-58-9 520-85-4		Formulation, fixed-dose combinations	Contraceptive, female
Medrysone		2668-66-8			
Mefenamic Acid		61-68-7			
Mefenorex		17243-57-1			
Mefexamide		1227-61-8			
mefloquine	4-Quinolinemethanol, Alpha-2-piperidinyl-2,8-bis(trifluoromethyl)-, (R*, S*)-(±)-[CAS]	51773-92-3 53230-10-7 69191-18-0	GB 1594282	Antimalarial	
Mefruside		7195-27-9			
Megestrol		595-33-5			
Meglumine		22154-43-4 131-49-7			
meglutol	2-hydroxy-2-methyl-1,3-propandicarboxylic acid	503-49-1	US 3629449	Hypolipemic/Antiatherosclerosis	Hyperlipidaemia, general

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
melagatran	Glycine, N-[(1R)-2-[(2S)-2-[[[4-(aminomino)methyl]phenyl]methyl]amino]carbonyl]-1-azetidinyl]-1-cyclohexyl-2-oxoethyl]- [CAS]	159776-70-2	WO 9616671	Antithrombotic	Thrombosis, general
melanocortin-4 agonist	N-[(3R)-1,2,3,4-Tetrahydroisquinolinium-3-ylcarbonyl]-(1R)-1-(4-chlorobenzyl)-2-[4-cyclohexyl-4-(1H-1,2,4-triazol-1-yl)methyl]piperidin-1-yl]-2-oxoethylamine(1)			Anorectic/Antiobesity	Obesity
Melarsoprol		494-79-1			
Melengestrol		5633-18-1			
melevodopa	Alanine, 3-(3,4-dihydroxyphenyl)-methyl ester [CAS]	7101-51-1	EP 252290	Antiparkinsonian	Parkinson's disease
Melinamide		14417-88-0			
Melitracen		5118-29-6			
meloxicam	2H-1,2-Benzothiazine-3-carboxamide, 4-hydroxy-2-methyl-N-(5-methyl-2-thiazolyl)-, 1,1-dioxide- [CAS]	71125-38-7	US 4233299	Antiarthritic, other	Arthritis, rheumatoid
melperone	1-Butanone, 1-(4-fluorophenyl)-4-(4-methyl-1-piperidinyl)- [CAS]	1622-79-3 3575-80-2	BE 651144	Neuroleptic	
Melphalan		148-82-3			
meluadrine	Benzenemethanol, 2-chloro-Alpha-(((1,1-dimethylmethyl)amino)methyl)-4-hydroxy-, (R)-, (R*)-2,3-dihydroxybutanedioate (1:1) (salt) [CAS]	134865-37-5	EP 420120	Labour inhibitor	Labour, preterm
menantline	Tricyclo[3.3.1.1 ^{3,7}]decan-1-amine, 3,5-dimethyl [CAS]	41100-52-1 19982-08-2	EP 392059	Cognition enhancer	Dementia, AIDS-related
MEN-10700	Acetamide, 2-[[[(5R,6S)-6-[(1R)-1-hydroxyethyl]-2-methyl-7-oxo-4-thia-1-azabicyclo[3.2.0]hept-2-en-3-yl]methyl]methylamino]- [CAS]	195874-55-6	WO 9406803	Beta-lactam antibiotic	Infection, general

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
MEN-10755	5,12-Naphthacenedione, 7-[[4-O-(3-amino-2,3,6-trideoxy-Alpha-L-lyxohexopyranosyl)-2,6-dideoxy-Alpha-L-lyxohexopyranosyl]oxy]-7,8,9,10-tetrahydro-6,9,11-trihydroxy-9-(hydroxyacetyl)-, hydrochloride, (7S,9S)- [CAS]	169317-77-5	WO 9509173	Anticancer, antibiotic	Cancer, breast
Menadiol		481-85-6			
Menadione		58-27-5			
Menadoxime		573-01-3			
Menbutone		3562-99-0			
Menogaril		71628-96-1			
MENT	7Alpha-Methyl-19-nortestosterone				
menthol	Cyclohexanol, 5-methyl-2-(1-methylethyl)- [CAS]	1490-04-6 89-78-1		Formulation, transdermal, systemic	Contraceptive, male
Menthyl Valerate		89-47-4			
Meobentine		46464-11-3			
Meparylzol		77-75-8			
mepartidin	Partricin, methyl ester [CAS]	11121-32-7	US 3780173	Antifungal	Infection, Candida, general
Mepazine		60-89-9			
Mepenzolate Bromide		76-90-4			
Meperidine		57-42-1			
Mephenesin		59-47-2			
Mephenoxalone		70-07-5			
Mephentermine		100-92-5			
Mephénytoin		50-12-4			
Mephobarbital		115-38-8			
Mepindolol		23694-81-7			
Mepitiostane		21362-69-6			
mepivacaine	N-(2,6-Dimethylphenyl)-1-methyl-2-piperidinecarboxamide	96-88-8		Formulation, modified-release, >24hr	Pain, post-operative
Mepixanox		17854-59-0			

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
Meprednisone		1247-42-3			
Meprobamate		57-53-4			
meprosicillin	Bufa-4,20,22-trienolide, 3-[(6-deoxy-4-O-methyl- α -L-mannopyranosyloxy]-14-hydroxy-, (3 β)- [CAS]				
meprozolam	Phenol, 3-(3-ethylhexahydro-1-methyl-1H-azepin-3-yl)- [CAS]	33396-37-1	DE 1910207	Cardio stimulant	Heart failure
meprozolam	10H-Phenothiazine, 10-(1-azabicyclo[2.2.2]oct-3-ylmethyl)- [CAS]	54340-58-8			
meprozolam	azabicyclo[2.2.2]oct-3-ylmethyl)- [CAS]	59263-76-2	GB 1285025	Analgesic, other	Pain, general
Meralein		29216-28-2	GB 1250534	Antiallergic, non-asthma	
Meralluride		4386-35-0			
Merbromin		8069-64-5			
Mercurtomerin		129-16-8			
Mercumallylic Acid		21259-76-7			
Mercuric Chloride, Ammoniated		86-36-2			
Mercuric Oleate		10124-48-8			
Mercuric Oxycyanide		1191-80-6			
		1335-31-5			
merimepodib	Carbamic acid, ((3-(((3-methoxy-4-(5-oxazolyl)phenyl)amino)carbonyl)amino)phenyl)methyl)- (3S)-tetrahydro-3-furanyl ester [CAS]	198821-22-6	US 5807876	Antiviral, other	Infection, hepatitis-C virus
meropenem	1-Azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid, 3-[5-[(dimethylamino)carbonyl]-3-pyrrolidinylthio]-6-(1-hydroxyethyl)-4-methyl-7-oxo-, [4R-[3(3S*,5S*),4 α ,5 β ,6 β (R*)]]- [CAS]	96036-03-2	EP 126587	Beta-lactam antibiotic	Infection, respiratory tract, lower
Mersalyl		492-18-2			
Mesalamine		89-57-6			
mesalazine	Benzoic acid, 5-amino-2-hydroxy- [CAS]	89-57-6	WO 5541170	Formulation, oral, other	Colitis, ulcerative
Mesna		19767-45-4			
Mesoridazine		5588-33-0			

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
Mestanolone		521-11-9			
Mesterolone		1424-00-6			
Mestranol		72-33-3			
Mesulfen		135-58-0			
Metaclozepam		84031-17-4			
Metampicillin		6489-97-0			
Metapramine		21730-16-5			
Metaproterenol		586-06-1			
Metaraminol		54-49-9			
Metazocine		3734-52-9			
		17692-51-2			
metergoline	Carbamic acid, [[(8S)-1,6-dimethylergolin-8-yl]methyl]-, phenylmethyl ester [CAS]	21631-37-8	GB 1401935	Antiprolactin	Amenorrhoea
metformin	Imidodicarbonimidic diamide, N,N-dimethyl- [CAS]	2706-42-5		Formulation, modified-release, <=24hr	Diabetes, Type II
		657-24-9			
Methacholine		62-51-1			
Methacycline		914-00-1			
Methadone		76-99-3			
Methafurylene		531-06-6			
Methamphetamine		537-46-2			
Methandriol		521-10-8			
Methandrostenolone		72-63-9			
Methantheline		53-46-3			
Methapyrilene		91-80-5			
Methaqualone		72-44-6			
Metharbital		50-11-3			
Methazolamide		554-57-4			
Methdilazine		1982-37-2			
Methenamine		100-97-0			
Methenolone		153-00-4			
Methestrol		130-73-4			
Methetoin		5696-06-0			
Methicillin		132-92-3			

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
Methimazole		60-56-0			
Methiodal		126-31-8			
Methioninic Acid		503-40-2			
Methionine		63-68-3			
Methisazone		1910-68-5			
Methitural		467-43-6			
Methixene		212/4969			
Methocarbamol		532-03-6			
Methohexital		22151-68-4			
methotrexate	L-Glutamic acid, N-[4-[[[(2,4-diamino-6-pteridinyl)methyl]methylamino]benzoyl]]-[CAS]	59-05-2	US 2512572	Anticancer, antimetabolite	Cancer, general
Methotrimeprazine		60-99-1			
Methoxamine		390-28-3			
Methoxsalen		298-81-7			
Methoxyflurane		76-38-0			
Methoxyphenamine		93-30-1			
Methoxypromazine		61-01-8			
Methscopolamine		155-41-9			
Methsuximide		77-41-8			
Methyclothiazide		135-07-9			
Methyl Blue		28983-56-4			
Methyl Nicotinate		93-60-7			
Methyl Propyl Ether		557-17-5			
Methyl Salicylate		119-36-8			
Methyl tert-Butyl Ether		1634-04-4			
Methylbenzethonium Chloride		25155-18-4			
Methylcobalamin		13422-55-4			
methylidopa	[L-Tyrosine, 3-hydroxy-Alpha-methyl-][CAS]	555-30-6		Formulation, modified-release, <=24hr	Hypertension, general
Methylene Blue		61-73-4			
Methylergonovine		113-42-8			

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
Methylhexaneamine		105-41-9			
methyphenidate	2-Piperidineacetic acid, Alpha-phenyl-, methyl ester [CAS]	113-45-1 298-59-9		Formulation, modified-release, multi	Attention deficit disorder
Methylprednisolone		83-43-2			
methy/prednisolone aceponate	Pregna-1,4-diene-3,20-dione, 21-(acetylloxy)-11-hydroxy-6-methyl-17-(1-oxopropoxy)-, (6Alpha, 11β)- [CAS]	86401-95-8	EP 72547	Antipruritic/inflamm, allergic	Pruritus
methy/prednisolone suleptanate	Pregna-1,4-diene-3,20-dione, 11,17-dihydroxy-6-methyl-21-[[8-[methyl(2-sulfoethyl)amino]-1,8-dioxoacetyl]oxy]-, monosodium salt, (6Alpha, 11β)- [CAS]	90350-40-6	JP 59137500	Antiasthma	Asthma
Methylthiouracil		56-04-2			
Methyltrienolone		965-93-5			
Methypyrrolon		125-64-4			
Methysergide		361-37-5			
Metiazinic Acid		13993-65-2			
metipranolol	Phenol, 4-[2-hydroxy-3-[(1-methylethyl)amino]propoxy]-2,3,6-trimethyl-, 1-acetate [CAS]	22664-55-7	GB 1206148	Antihypertensive, adrenergic	
metoclopramide	Benzamide, 4-amino-5-chloro-N-[2-(diethylamino)ethyl]-2-methoxy- [CAS]	364-62-5 7601-55-0 388-51-2		Formulation, modified-release, <=24hr	Gastro-oesophageal reflux
Metocurine Iodide					
Metofenazate					
metolazone	6-Quinazolinesulfonamide, 7-chloro-1,2,3,4-tetrahydro-2-methyl-3-(2-methylphenyl)-4-oxo- [CAS]	17560-51-9	US 4517179	Antihypertensive, diuretic	
Metopimazine		14008-44-7			
Metopon		143-52-2			
metoprolol	2-Propanol, 1-[4-(2-methoxyethyl)phenoxy]-3-[(1-methylethyl)amino]-, (+)- [CAS]	51384-51-1 56392-17-7 37350-58-6		Formulation, modified-release, other	Hypertension, general
Metralindole		54188-38-4			
Metrizamide		31112-62-6			
Metrizoic Acid		1949-45-7			
Metron S		13946-02-6			

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
Metirapone		54-36-4			
Metirosine		672-87-7			
Mexazolam		31868-18-5			
Mexenone		1641-17-4			
Mexiletine		31828-71-4			
	4-Thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, 3,3-dimethyl-6-[[[3-(methylsulfonyl)-2-oxo-1-imidazolidinyl]carbonyl]amino]phenylacetyl- [CAS]	42057-22-7 51481-65-3 72539-76-5	GB 1301961	Penicillin, injectable	Infection, general
mezlocillin					
MFH-244	Benzenecarboximidic acid, 3,4,5-trihydroxy-, ethyl ester, hydrochloride	95933-76-9	US 4623659	Cardiovascular	Reperfusion injury
mianserin		21535-47-7 24219-97-4	GB 1173783	Antidepressant	Depression, general
Mibefradil		116644-53-2			
Miboplatin		103775-75-3			
Micafungin		235114-32-6			
	1H-Imidazole, 1-(2,4-dichlorophenyl)-2[2,4-dichlorophenyl]methoxy[ethyl]	22916-47-8		Formulation, modified-release, other	Infection, Candida, general
miconazole					
Micronomicin		52093-21-7			
midaxifylline	1H-Purine-2,6-dione, 8-(1-aminocyclopentyl)-3,7-dihydro-1,3-dipropyl- [CAS]	151159-23-8	US 5378844	Cardiovascular	Unspecified
midazolam	4H-Imidazo[1,5-a][1,4]benzodiazepine, 8-chloro-6-(2-fluorophenyl)-1-methyl- [CAS]	59467-70-8 59467-94-6	US 4280957	Anaesthetic, injectable	
midecamycin	Leucomycin V, 3,4B-dipropanoate [CAS]	35457-80-8	US 3761588	Macrolide antibiotic	Infection, general
midecamycin acetate	Leucomycin V, 3B,9-diacetate 3,4B-dipropanoate [CAS]	55881-07-7	JP 49124087	Macrolide antibiotic	Infection, general
midesteine	2-Thiophenecarboxylic acid, S-[1-methyl-2-oxo-2-[(tetrahydro-2-oxo-3-(thienyl)amino]ethyl] ester [CAS]	94149-41-4	EP 120534	COPD treatment	Emphysema, general

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
midodrine	Acetamide, 2-amino-N-[2-(2,5-dimethoxyphenyl)-2-hydroxyethyl]- [CAS]	42318-56-0 42794-76-3	EP 164571	Urological	Incontinence
midostaurin	Benzamide, N-(2,3,10,11,12,13-hexahydro-10-methoxy-9-methyl-1-oxo-9,13-epoxy-1H,9H-dilindolo[1,2,3-gh:3',2',1'-lm]pyrrolo[3,4-i][1,7]benzodiazolin-11-yl)-N-methyl-, (9Alpha,10B,11B,13Alpha)-[CAS]	120685-11-2	EP 296110	Anticancer, other	Cancer, leukaemia, acute myelogenous
mifepristone	Estra-4,9-dien-3-one, 11-[4-(dimethylamino)phenyl]-17-hydroxy-17-(1-propynyl)-, (11B,17B)- [CAS]	84371-65-3	EP 57115	Abortifacient	Abortion
miglitol	3,4,5-Piperidinetriol, 1-(2-hydroxyethyl)-2-(hydroxymethyl)-, [2R-(2Alpha,3B,4Alpha,5B)]- [CAS]	72432-03-2	EP 55431	Antidiabetic	Diabetes, Type I
miglustat	3,4,5-Piperidinetriol, 1-butyl-2-(hydroxymethyl)-(2R-(2Alpha,3B,4Alpha,5B)) [CAS]	72599-27-0	DE 2758025	Metabolic and enzyme disorders	Gaucher's disease
mildronate	Hydrazinium, 2-(2-carboxyethyl)-1,1,1-trimethyl-, inner salt- [CAS]	76144-81-5	WO 8001068	Cardio stimulant	Heart failure
milnacipran	Cyclopropanecarboxamide, 2-(aminomethyl)-N,N-diethyl-1-phenyl-, cis-(+)-[CAS]	101152-94-7 92623-85-3	US 4478836	Antidepressant	Depression, general
Miloxacin	[3,4'-Bipyridine]-5-carbonitrile, 1,6-dihydro-2-methyl-6-oxo- [CAS]	37065-29-5			
milrinone	Ethanaminium, 2-[[[hexadecyloxy]hydroxyphosphinyloxy]-N,N,N-trimethyl-, hydroxide, inner salt [CAS]	78415-72-2	US 4313951	Cardio stimulant	Heart failure
miltefosine	4-Morpholineethanamine, N-(4-methyl-6-phenyl-3-pyridazinyl)- [CAS]	53949-20-5 58066-85-6 25906-77-5	EP 225608	Anticancer, other	Cancer, skin, general
minaprine		25953-17-7	GB 1345880	Antidepressant	Depression, general

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
minocycline	2-Naphthacene-carboxamide, 4,7-bis(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-, [4S-(4 α),4 α], 5a.alpha., 12a.alpha.)-[CAS]	10118-90-8		Formulation, optimized, microparticles	Infection, oral
minodronic acid	Phosphonic acid, (1-hydroxy-2-imidazo(1,2-a)pyridin-3-ylethylidene)bis-, [CAS]	180064-38-4	EP 354806	Anticancer, other	Cancer, myeloma
minoxidil	2,4-Pyrimidinediamine, 6-(1-piperidinyl)-, 3-oxide [CAS]	38304-91-5	US 4139619	Vasodilator, peripheral	Hypertension, general
Miokamycin		55881-07-7			
mirtazapine	Pyrazino[2,1-a]pyrido[2,3-c][2]benzazepine, 1,2,3,4,10,14b-hexahydro-2-methyl-[CAS]	85650-52-8 61337-67-5	GB 1543171	Antidepressant	Depression, general
misoprostol	Prost-13-en-1- α -oic acid, 11,16-dihydroxy-16-methyl-9-oxo-, methyl ester, (11 α ,13 ϵ)-(4)- [CAS]	59122-46-2 59122-48-4	US 4301146	Prostaglandin	Ulcer, gastric
mitomycin	Erythromycin, 8,9-didehydro-N-demethyl-9-deoxy-6,11-dideoxy-6,9-epoxy-12-O-methyl-N-(1-methylethyl)-11-oxo-, (2E)-2-butenedioate (2:1) [CAS]	154802-96-7	WO 9324509	Gastroprokinetic	Gastro-oesophageal reflux
mitiglinide	Calcium (2S)-2-benzyl-3-(cis-hexahydro-2-isoindolylcarbonyl)propionate, dihydrate-[CAS]	145525-41-3	EP 507534	Antidiabetic	Diabetes, Type II
Mitobronitol		488-41-5			
Mitoguazone		459-86-9			
mitotactol	Galactitol, 1,6-dibromo-1,6-dideoxy- [CAS]	10318-26-0	US 3993781	Anticancer, alkylating	Cancer, cervical

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
mitomycin	Azino[2,3:3,4]pyrrolo[1,2-a]indole-4,7-dione, 6-amino-8-[[[(aminocarbonyloxy)methyl]-1,1a,2,8,8a,8b-hexahydro-8a-methoxy-5-methyl-, [1aS-(1aAlpha,8b,8aAlpha)]- [CAS]	50-07-7		Formulation, parenteral, other	Cancer, stomach
Mitotane		53-19-0			
mitoxantrone	9,10-Anthracenedione, 1,4-dihydroxy-5,8-bis[2-[(2-hydroxyethyl)amino]ethyl]amino]- [CAS]	65271-80-9 70476-82-3	US 4197249	Anticancer, other	Cancer, breast
mitoxantrone	9,10-Anthracenedione, 1,4-dihydroxy-5,8-bis[2-[(2-hydroxyethyl)amino]ethyl]amino]- [CAS]	65271-80-9 70476-82-9		Formulation, optimized, liposomes	Cancer, general
MIV-210	(3'-Fluoro-2'-3'-dideoxy guanosine)			Antiviral, other	Infection, hepatitis-B virus
mivacurium	isoquinolinium, 2,2'-[1-(1,8-dioxo-4-octene-1,8-diyl)]bis(oxy-3,1-propanediyl)]bis[1,2,3,4-tetrahydro-6,7-dimethoxy-2-methyl-1-[(3,4,5-trimethoxyphenyl)methyl]-, dichloride, [R*, R*(E)]- [CAS]				
Mivazerol		106861-44-3	EP 181055	Muscle relaxant	Anaesthesia, adjunct
		125472-02-8			
mizolastine	4(1H)-Pyrimidinone, 2-[[1-[1-(4-fluorophenyl)methyl]-1H-benzimidazol-2-yl]-4-piperidinyl]methylamino]- [CAS]	108612-45-9	EP 217700	Antiallergic, non-asthma	Rhinitis, allergic, general
Mizoribine		50924-49-7			
MKC-733	(R)-N-(3-quinuclidinyl)-7-oxo-4,7-dihydrothieno[3,2-b]pyridine-6-carboxamide hydrochloride	194093-42-0	JP 09216888	Gastroprokinetic	Gastro-oesophageal reflux
MLN-519	6-Oxa-2-azabicyclo[3.2.0]heptane-3,7-dione, 1-[(1S)-1-hydroxy-2-methylpropyl]-4-propyl-, (1R,4R,5S)- [CAS]	211866-70-5	WO 9915183	Neuroprotective	Ischaemia, cerebral
MLN-576	4-Methoxy-benzo[a]phenazine-11-carboxylic acid (2-(dimethylamino)-1-(R)-methyl-ethyl)-amide			Anticancer, other	Cancer, general

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
moclobemide	Benzamide, 4-chloro-N-[2-(4-morpholinyl)ethyl]- [CAS]	71320-77-9	EP 326023	Antidepressant	Depression, general
modafinil	Acetamide, 2-[(diphenylmethyl)sulfinyl]- [CAS]	68693-11-8	DE 2809625	Psychostimulant	Narcolepsy
moexipril	3-Isoquinolinecarboxylic acid, 2-[2-[[1-(ethoxycarbonyl)-3-phenylpropyl]amino]-1-oxopropyl]-1,2,3,4-tetrahydro-6,7-dimethoxy- (3S-(2(R*(R*)),3R*))- [CAS]	103775-10-6 103775-14-0	US 4344949	Antihypertensive, renin system	Hypertension, general
Mofarotene		125533-88-2			
Mofebutazone		2210-63-1			
Mofegiline		119386-96-8			
mofezolac	5-Isoxazoleacetic acid, 3,4-bis(4-methoxyphenyl)- [CAS]	78967-07-4	EP 26928	Analgesic, NSAID	Pain, post-operative
MOL-6131	N-[4-(aminomethyl)benzyl]-8(S)-[1-[4-[2-(4-aminophenyl)-acetamido]butyl]piperidin-4-yl]-2-(naphthalen-1-ylmethyl)-1,3-dioxo-2,3,5,8-tetrahydro-1H-[1,2,4]triazolo[1,2-a]pyridazine-5(R)-carboxamide			Antiasthma	Asthma
Molindone		7416-34-4			
molsidomine	Sydnone imine, N-(ethoxycarbonyl)-3-(4-morpholinyl)- [CAS]	25717-80-0	US 3769283	Vasodilator, coronary	
mometasone	Pregna-1,4-diene-3,20-dione, 9,21-dichloro-11,17-dihydroxy-16-methyl-, (11 β ,16 α)- [CAS]	105102-22-5 83919-23-7	EP 57401	Antipruritic/inflamm, allergic	Psoriasis
Monatepil		103377-41-9			
Monobenzone		103-16-2			
monolaurin	Dodecanoic acid, monoester with 1,2,3-propanetriol [CAS]	27215-38-9	US 4885282	Dermatological	Ichthyosis
montelukast	Cyclopropaneacetic acid, 1-[[[1-[3-[2-(7-Chloro-2-quinolinyl)ethenyl]phenyl]-3-[2-(1-hydroxy-1-methylethyl)phenyl]propyl]thio]methyl]-, [CAS]	151767-02-1 158966-92-8		Antiasthma	Asthma
Monteplase		122007-85-6			

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
Moperone		1050-79-9			
Mopidamol		13665-88-8			
Moprofol		5741-22-0			
moracizine	Carbamic acid, [10-[3-(4-morpholinyl)-1-oxopropyl]-10H-phenothiazin-2-yl]-, ethyl ester [CAS]	29560-58-5 31883-05-3	US 3864487	Antiarrhythmic	Tachycardia, ventricular
Morazone		6536-18-1			
Moricizine		31883-05-3			
Moroxidine		3731-59-7			
Morphazinamide		952-54-5			
		5727-2			
morphine	Morphinan-3,6-diol, 7,8-didehydro-4,5-epoxy-17-methyl- (5 α), [CAS]	6055-06-7 64-31-3		Formulation, parenteral, other	Pain, cancer
morphine-6-glucuronide	morphine-6-glucuronide			Formulation, inhalable, systemic	Pain, general
	Spiro[imidazo[1,2-a]pyridine-3(2H),4'-piperidin]-2-one, 1'-[3-(3-chloro-10,11-dihydro-5H-dibenz[b,f]azepin-5-yl)propyl]hexahydro-, (+/-)- [CAS]	89419-40-9 98043-60-8	US 4337260	Neuroleptic	
mosapramine					
mosapride	Benzamide, 4-amino-5-chloro-2-ethoxy-N-(((4-((4-fluorophenyl)methyl)-2-morpholinyl)methyl)-, [CAS]	112885-41-3 112885-42-4	EP 243959	GI inflammatory/bowel disorders	Gastritis
	Gadolinium, bis(acetato-kappaO)(9,10-diethyl-20,21-bis(2-(2-(2-methoxyethoxy)ethoxy)-4,15-dimethyl-8,11-imino-3,16,16,13-dinitrio-1,18-benzodiazacycloicosine-5,14-dipropanolato-kappaN1, kappaN18, kappaN23, kappaN24, kappaN25), (PB-7-11-233'2'4) [CAS]	246252-06-2		Radio/chemosensitizer	Cancer, brain
motexafin gadolinium					
Motretinide		56281-36-8			
Moveltipril		85856-54-8			
Moxalactam		64952-97-2			
Moxastine		3572-74-5			
Moxaverine		10539-19-2			
Moxestrol		34816-55-2			

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
moxifloxacin	3-Quinolonecarboxylic acid, 1-cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-(octahydro-5H-pyrrolo(3,4-b)pyridin-6-yl)-4-oxo-, hydrochloride (4aS-cis)- [CAS]	186826-86-8 151096-09-2	DE 19546249	Quinolone antibacterial	Infection, respiratory tract, general
moxisylyte	Phenol, 4-[2-(dimethylamino)ethoxy]-2-methyl-5-(1-methylethyl)-, acetate (ester), [CAS]	964-52-3 54-32-0		Male sexual dysfunction	Impotence
moxonidine	5-Pyrimidinamine, 4-chloro-N-(4,5-dihydro-1H-imidazol-2-yl)-6-methoxy-2-methyl- [CAS]	75438-57-2	DE 2849537	Antihypertensive, other	Hypertension, general
M-PGA	(-)-(S)-2-Methyl-2-(1-oxo-2,3-dihydro-1H-isindol-2-yl)pentanedioic acid		US 5712291	Anticancer, other	Cancer, general
MPI-5010	Platinum diamminedichloro-, (SP-4-2) + (R)-4-[1-hydroxy-2-(methylamino)-ethyl]-1,2-benzenediol				
MPI-5020	2,4-(1H,3H)-Pyrimidinedione, 5-fluoro- [CAS]	51-21-8	US 6224883	Formulation, parenteral, other	Cancer, head and neck
MPL		198076-81-2	US 5750146	Formulation, parenteral, other	Cancer, breast
MRS-1754			US 6060481	Immunostimulant, other	Vaccine adjunct
MS-209				Antiasthma	Asthma
MS-275	1-Piperazineethanol, 4-(diphenylacetyl)-Alpha-[(5-quinolinyl)oxy)methyl]-, (2E)-2-butenedioate(2:3) (salt) [CAS]	158681-49-3		Radio/chemosensitizer	Cancer, breast
MS-325					
MS-377	N-(2-Aminophenyl)-4-[N-(pyridin-3-yl-methoxycarbonyl)aminomethyl]benzamide	201688-00-8	EP 839805	Anticancer, antimetabolite	Cancer, lung, general
Mupirocin		12650-69-0		Neuroleptic	Schizophrenia
Muscarine		300-54-9			
Muzolimine		55294-15-0			
MX-1013			US 6153591	Hepatoprotective	Unspecified

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
mycophenolate mofetil	4-Hexenoic acid, 6-(1,3-dihydro-4-hydroxy-6-methoxy-7-methyl-3-oxo-5-isobenzofuran-2-yl)-4-methyl-, 2-(4-morpholinyl)ethyl ester, (E)- [CAS]	116680-01-4 128794-94-5	WO 9119498	Immunosuppressant	Transplant rejection, general
mycophenolic acid	4-Hexenoic acid, 6-(1,3-dihydro-4-hydroxy-6-methoxy-7-methyl-3-oxo-5-isobenzofuran-2-yl)-4-methyl-,	37415-62-6 24280-93-1		Formulation, oral, enteric-coated	Transplant rejection, general
Myrophine		467-18-5			
N- (Hydroxymethyl)nicotina imide		3569-99-1			
N,N,N',N' - Tetraethylphthalamide		83-81-8			
N₂-Formylsulfisomidine		795-13-1			
N₄-β-D- Glucosylsulfanilamide		53274-53-6			
N₄- Sulfanilylsulfanilamide		547-52-4			
Nabilone		51022-71-0			
nabumetone	2-Butanone, 4-(6-methoxy-2-naphthalenyl)- [CAS]	42924-53-8	GB 1476721	Anti-inflammatory	Arthritis, osteo
N-acetylcysteine	L-Cysteine, N-acetyl- [CAS]	616-91-1		Anticancer, other	Cancer, general
N-Acetylmetionine		65-82-7			
nadifloxacin	1H-5H-Benzol[j]quinoline-2-carboxylic acid, 9-fluoro-6,7-dihydro-8-(4-hydroxy-1-piperidinyl)-5-methyl-1-oxo-, (+/-)- [CAS]	124858-35-1	US 4399134	Quinolone antibacterial	Acne
nadolol	2,3-Naphthalenediol, 5-[3-[(1,1-dimethylethyl)amino]-2-hydroxypropoxy]-1,2,3,4-tetrahydro- [CAS]	42200-33-9	US 4346106	Antihypertensive, adrenergic	
Nadoxolol		54063-51-3			

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
mafamostat	Benzoic acid, 4-[(aminoininomethyl)amino]-, 6-[(aminoininomethyl)-2-naphthalenyl ester]-[CAS]	80251-32-7 81525-10-2 82956-11-4	EP 450232	GI inflammatory/bowel disorders	Pancreatitis
mafarelin	Luteinizing hormone-releasing factor (pig), 6-[3-(2-naphthalenyl)-D-alanine]-[CAS]	76932-56-4 86220-42-0	EP 21234	Releasing hormones	Endometriosis
Naftacillin		147-52-4			
Nafronyl		31329-57-4			
naftidrofuryl	2-Furanpropanoic acid, tetrahydro- α -(1-naphthalenylmethyl)-, 2-(diethylamino)ethyl ester	31329-57-4 65472-88-0 65473-14-5		Formulation, modified-release, other	Unspecified
naftifine	1-Naphthalenemethanamine, N-methyl-N-(3-phenyl-2-propenyl)-, (E)- [CAS]	US 4282251		Antifungal	Infection, dermatological
naftopidil	1-Piperazineethanol, 4-(2-methoxyphenyl)- α -(1-naphthalenyloxy)methyl- [CAS]	57149-07-2	US 3997666	Antihypertensive, adrenergic	Hypertension, general
nalbuphine	Morphinan-3,6,14-triol, 17-(cyclobutylmethyl)-4,5-epoxy-, (5 α ,6 α)- [CAS]	20594-83-6 23277-43-2 389-08-2	US 3393197	Analgesic, other	Pain, general
Nalidixic Acid					
nalmeferone	Morphinan-3,14-diol, 17-(cyclopropylmethyl)-4,5-epoxy-6-methylene-, (5 α)- [CAS]	55096-26-9 62-67-9	JP 56167687	Dependence treatment	Poisoning, drug
Nalorphine					
naloxone	Morphinan-6-one, 17-allyl-4,5 α -epoxy-3,14-dihydroxy-, hydrochloride [CAS]	357-08-4 465-65-6		Septic shock treatment	
naltrexone	Morphinan-6-one, 17-(cyclopropylmethyl)-4,5-epoxy-3,14-dihydroxy-, (5 α)- [CAS]	16590-41-3 16676-29-2	US 3332950	Dependence treatment	Addiction, narcotic/opiate
NAMI	Imidazolium trans(imidazole)(dimethylsulfoxide)tetraethylororuthenate (III)			Anticancer, other	Cancer, general

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
namidil	Guanidine, N-cyano-N'-(4-cyanophenyl)-N'-[(1R)-1,2,2-trimethylpropyl]-[CAS]	220641-11-2		Dermatological	Alopecia, general
Nandrolone		434-22-0			
Naphazoline		835-31-4			
Naphthalene		91-20-3			
naproxen betainate	Methanaminium, 1-carboxy-N, N, N-trimethyl- salt with (R)-6-methoxy- α -methyl-2-naphthaleneacetic acid (1:1), sodium salt [CAS]				
naproxen	2-Naphthaleneacetic acid, 6-methoxy- α -methyl-, [CAS]	104124-26-7	US 4672077	Antiarthritic, other	Arthritis, rheumatoid
naratriptan	1H-Indole-5-ethanesulfonamide, N-methyl-3-(1-methyl-4-piperidinyl)- [CAS]	26159-34-2 22204-53-1	GB 121134	Analgesic, NSAID	Pain, general
Narceine		121679-13-8	EP 303507	Antimigraine	Migraine
Narcobarbital		131-28-2			
Natamycin		125-55-3			
		7681-93-8			
mateglinide	D-phenylalanine, N-((4-(1-methylethyl)cyclohexyl)carbonyl)-, trans-[CAS]	105816-04-4	EP 196222	Antidiabetic	Diabetes, Type II
N-Butyldexynojirimycin		72599-27-0			
N-Butylscopolammonium Bromide		149-64-4			
NC-503			US 5643562	Anti-inflammatory	Amyloidosis
NC-631			US 5643562	Cognition enhancer	Alzheimer's disease
NCX-1000			WO 0061604	Hepatoprotective	Cirrhosis, hepatic
NCX-4016	Benzoic acid, 2-(acetyloxy)-, 2-((nitroxy)methyl)phenyl ester [CAS]	175033-36-0	WO 9716405	Symptomatic antidiabetic	Insulin-related metabolic syndrome
NCX-456	Benzoic acid, 5-amino-2-hydroxy-, 4-(nitrooxy)butyl ester [CAS]	256499-26-0		GI inflammatory/bowel disorders	Inflammatory bowel disease

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
NCX-950	Alpha-[[[(1,1-dimethylethyl)amino]methyl]-4-hydroxy]-1,3-benzenedimethanol nitrate			Antiasthma	Asthma
n-Docosanol		661-19-8			
NE-100	Benzeneethanamine, 4-methoxy-3-(2-phenylethoxy)-N,N-dipropyl-, hydrochloride [CAS]	149409-57-4	WO 9307113	Neuroleptic	Schizophrenia
Nealbarbital		561-83-1			
neбивол	2H-1-Benzopyran-2-methanol, Alpha,Alpha-[iminobis(methylene)]bis[6-fluoro-3,4-dihydro]-, (2R*(R*(S*)))-(1+)- [CAS]	118457-14-0 99200-09-6	EP 145067	Antihypertensive, adrenergic	Hypertension, general
neboستنف	N1-(4,4-Dimethylcyclohexyl)-L-isoglutamine	163000-63-3	EP 0688312	Cognition enhancer	Unspecified
Nebracetam		97205-34-0			
nedaplatin	Platinum, diammine[dihydroxyacetato(2-)-O1,O2]-, (SP 4-3)- [CAS]	95734-82-0	EP 216362	Anticancer, alkylating	
nedocromil	4H-Pyranol[3,2-g]quinoline-2,8-dicarboxylic acid, 9-ethyl-6,9-dihydro-4,6-dioxo-10-propyl- [CAS]	69049-73-6 69049-74-7	EP 555718	Antiasthma, Ophthalmological	Rhinitis, allergic, general, Ocular disorder, general
nefazodone	3H-1,2,4-Triazol-3-one, 2-[3-[4-(3-chlorophenyl)-1-piperazinylpropyl]-5-ethyl-2,4-dihydro-4-(2-phenoxylethyl)-, [CAS]	82752-99-6 83366-66-9	US 4338317	Antidepressant	Depression, general
nefiracetam	1-Pyrrolidineacetamide, N-(2,6-dimethylphenyl)-2-oxo- [CAS]	77191-36-7	US 4341790	Cognition enhancer	Dementia, senile, general
nefopam	1H-2,5-Benzoxazocine, 3,4,5,6-tetrahydro-5-methyl-1-phenyl- [CAS]	13669-70-0 23327-57-3	US 3487153	Analgesic, NSAID	
Negamycin		33404-78-3			
nefinavir	3-Isouquinolinecarboxamide, N-(1,1-dimethylethyl)decahydro-2-(2-hydroxy-3-((3-hydroxy-2-methylbenzoyl)amino)-4-(phenylthio)butyl)-, (3S-(2(2S*,3S*),3Alpha,4a,8a,8b))-, [CAS]	159989-65-8 159989-64-7		Antiviral, anti-HIV	Infection, HIV/AIDS
Nemonapride		75272-39-8			
Neostigmine		59-99-4			

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
nepadutant	Cyclo[3-amino-L-alanyl-L-leucyl-N-[2-(acetylamino)-2-deoxy-β-D-glucopyranosyl]-L-asparagyl-L-Alpha-aspartyl-L-tryptophyl-L-phenylalanyl], (4-1)-lactam [CAS]	183747-35-5	WO 9628467	Antiasthma	Asthma
neramexane	1,3,3,5,5-pentamethylcyclohexylamine	202807-80-5 219810-59-0		Dependence treatment	Addiction, alcohol
neridronic acid	Phosphonic acid, (6-amino-1-hydroxyhexylidene)bis- [CAS]	79778-41-9		Musculoskeletal	Osteogenesis imperfecta
Neriifolin		466-07-9			
N-Ethylamphetamine		457-87-4			
neticonazole	1H-Imidazole, 1-[2-(methylthio)-1-[2-(pentyloxy)phenyl]ethenyl]-, monohydrochloride, (E)- [CAS]	130773-02-3 130726-68-0	EP 445540	Antifungal	Infection, Candida, general
netilmicin	D-Streptamine, O-3-deoxy-4-C-methyl-3-(methylamino)-β-L-arabinopyranosyl-(1-6)-O-[2,6-diamino-2,3,4,6-tetra-deoxy-Alpha-D-glycero-hex-4-enopyranosyl-(1-4)]-2-deoxy-N1-ethyl- [CAS]	56391-56-1 56391-57-2	GB 1473733	Aminoglycoside antibiotic	Infection, general
nevirapine	6H-Dipyrrodo[3,2-b:2',3'-e][1,4]diazepin-6-one, 1,1-cyclopropyl-5,11-dihydro-4-methyl- [CAS]	129618-40-2	EP 429987	Antiviral, anti-HIV	Infection, HIV/AIDS
NGD-98-2			WO 9635689	Anxiolytic	Anxiety, general
Nialamide		51-12-7			
Niaprazine		27367-90-4			
Nicametate		3099-52-3			
nicaraven	3-Pyridinecarboxamide, N,N'-(1-methyl-1,2'-ethanediyl)bis- [CAS]	79455-30-4	EP 29602	Neuroprotective	Haemorrhage, subarachnoid
nicardipine	3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-, methyl 2-[methyl(phenylmethyl)amino]ethyl ester [CAS]	54527-84-3 55985-32-5	US 3985758	Neuroprotective	Hypertension, general
nicergoline	Ergoline-8-methanol, 10-methoxy-1,6-dimethyl-, (8b)-, 5-bromo-3-pyridinecarboxylate(ester)	27848-84-6		Formulation, modified-release, other	Unspecified

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
Niceritrol		5868053			
Niclosamide		50-65-7			
Nicoclonate		10571-59-2			
Nicofuranose		15351-13-0			
Nicomol		27959-26-8			
Nicomorphine		639-48-5			
nicorandil	3-Pyridinecarboxamide, N-[2-(nitrooxy)ethyl]- [CAS]	65141-46-0	US 4792564	Vasodilator, coronary	Hypertension, general
Nicotinamide		98-92-0			
nicotine	Pyridine, 3-(1-methyl-2-pyrrolidinyl)-, (S)- [CAS]	54-11-5		Formulation, inhalable, other	Addiction, nicotine
Nicotinic Acid		59-67-6			
Nicotinic Acid Benzyl Ester		94-44-0			
Nicotinyl Alcohol		100-55-0			
nifedipine	4-(2-nitrophenyl)-2,6-dimethyl-3,5-dicarboxymethoxy-1,4-dihydropyridine	21829-25-4	GB 1173862	Vasodilator, coronary	Hypertension, general
nifekalant	2,4-(1H,3H)-Pyrimidinedione, 6-[[2-[(2-nitrophenyl)propyl]amino]ethyl]amino]-1,3-dimethyl-, [CAS]	130636-43-0 130656-51-8	EP 369627	Antiarrhythmic	Arrhythmia, general
Nifenalol		7413-36-7			
Niflumic Acid		4394-00-7			
Nifuratel		4936-47-4			
Nifurfoline		3363-58-4			
Nifuroxazide		965-52-6			
Nifuroxime		6236051			
Nifurpirinol		13411-16-0			
Nifurpirazine		1614-20-6			
Nifurtimox		23256-30-6			
Nifurtinol		1088-92-2			

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
nifurzide	2-Thiophenecarboxylic acid, 5-nitro-, [3-(5-nitro-2-furanyl)-2-propenylidene]hydrazide [CAS]	39978-42-2	US 3847911	Antidiarrhoeal	Infection, GI tract
NIK-254	Gentamicin, sulfate (salt) [CAS]	1405-41-0		Formulation, other	Infection, general
Nikethamide		59-26-7			
nilutamide	2,4-Imidazolidinedione, 5,5-dimethyl-3-[4-nitro-3-(trifluoromethyl)phenyl]-[CAS]	63612-50-0	US 4472382	Anticancer, hormonal	Cancer, prostate
nilvadipine	3,5-Pyridinedicarboxylic acid, 2-cyano-1,4-dihydro-6-methyl-4-(3-nitrophenyl)-, 3-methyl 5-(1-methylethyl) ester [CAS]	75530-68-6	US 4338322	Antihypertensive, other	Hypertension, general
nimesulide	Methanesulfonamide, N-(4-nitro-2-phenoxyphenyl)- [CAS]	51803-78-2	US 3840597	Anti-inflammatory	Pain, general
Nimetazepam		2011-67-8			
nimodipine	3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-, 2-methoxyethyl 1-methylethyl ester [CAS]	66085-69-4	EP 533014	Neuroprotective	
Nimorazole		6506-37-2			
ninustine	Urea, N-[(4-amino-2-methyl-5-pyrimidinyl)methyl]-N-(2-chloroethyl)-N-nitroso-[CAS]	103745-00-2 42471-28-3 55661-38-6	GB 1374344	Anticancer, alkylating	Cancer, brain
Ninopterin		2179-16-0			
NIP-142	N-[4(S)-(Cyclopropylamino)-3-(R)-hydroxy-2,2-dimethyl-7-nitro-3,4-dihydro-2H-1-benzopyran-6-yl]-4-methoxybenzeneacetamide		WO 9804542	Antiarrhythmic	Fibrillation, atrial
NIP-531	N-[3,5-Bis(trifluoromethyl)benzyl]-N-[3-[N-[(1-(4-fluorobenzyl)benzimidazol-2-yl)-amino]propyl-N-methylurea hydrochloride			Antipruritic/inflamm, allergic	Eczema, atopic
niperolidine	N-[2-[[5-[[dimethylamino)methyl]furfuryl]thio]ethyl]-2-nitro-N'-piperonyl-1,1-ethenediamine	84845-75-0	GB 2104071	Antitumor	Ulcer, GI, general

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
nipradilol	2H-1-Benzopyran-3-ol, 3,4-dihydro-8-[2-hydroxy-3-[(1-methylethyl)amino]propoxy]-, 3-nitrate [CAS]	81486-22-8 86247-86-1	EP 42299	Formulation, mucosal, topical	Glaucoma
Niridazole	3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(2-nitrophenyl)-, methyl 2-methylpropyl ester- [CAS]	61-57-4			
nisdolipine	Benzamide, 2-(acetyloxy)-N-(5-nitro-2-thiazolyl)- [CAS]	63675-72-9	GB 1516793	Antihypertensive, other	Hypertension, general
nitazoxanide	1,3-Cyclohexanedione, 2-[2-nitro-4-(trifluoromethyl)benzoyl]- [CAS]	55981-09-4	US 5387598	Protozoacide	Infection, GI tract
nitisinone	1,3-Propanediamine, N,N-dimethyl-N-(1-nitro-9-acridinyl)- [CAS]	104206-65-7 4533-39-5	EP 186118	Metabolic and enzyme disorders	Cirrhosis, hepatic
nitracrine		6514-85-8	FR 1458183	Anticancer, other	Cancer, ovarian
Nitrazepam	3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-, ethyl methyl ester- [CAS]	146-22-5			
nitrendipine	(1,1'-Biphenyl)-4-acetic acid, 2-fluoro-Alpha-methyl-, 4-(nitrooxy)butyl ester [CAS]	39562-70-4	GB 1358951	Antihypertensive, other	Hypertension, general
nitroflurbiprofen		158836-71-6	EP 670825	Urological	Incontinence
Nitrofurantoin		67-20-9			
Nitrofurazone		59-87-0			
nitroglycerin	1,2,3-Propanetriol, trinitrate [CAS]	55-63-0		Formulation, transdermal, patch	Angina, general
Nitromersol		133-58-4			
nitronaproxen	2-Naphthaleneacetic acid, 6-methoxy-Alpha-methyl 4-(nitrooxy)butyl ester (AlphaS)- [CAS]	163133-43-5	WO 9509831	Analgesic, NSAID	Pain, post-operative
nitroxazepine	Dibenz[b,f][1,4]oxazepin-11(10H)-one, 10-[3-(dimethylamino)propyl]-2-nitro-, monohydrochloride [CAS]	16398-39-3	NL 6608671	Antidepressant	
Nitroxoline		4008-48-4			
nizatidine	1,1-Ethenediamine, N-[2-[[[2-[(dimethylamino)methyl]-4-thiazolyl]methyl]thio]ethyl]-N'-methyl-2-nitro- [CAS]	76963-41-2	EP 49618	Antilulcer	Ulcer, duodenal

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
Nifedipine	3-(2-methylcarboxymethyl)-6-methoxy-8-hydroxy-isocoumarin	54533-85-6			
NIM-3			JP 08176138	Anticancer, other	Cancer, general
NIM-702	4-Bromo-5-(3-pyridylmethylamino)-6-[3-(4-chlorophenyl)propoxy]-3(2H)pyridazinone hydrochloride			Antithrombotic	Peripheral vascular disease
N-Methylephedrine		552-79-4			
N-Methylepinephrine		554-99-4			
N-Methylglucamine		6284-40-8			
NN-414	6-chloro-3-(1-methylcyclopropylamino)-4H-thieno[3,2-e]-[1,2,4]thiadiazine-1,1-dioxide			Antidiabetic	Diabetes, Type II
NNC-05-1869	(R)-1-(3-(10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-1-propyl)-3-piperidine carboxylic acid			Symptomatic antidiabetic	Neuropathy, diabetic
Nogalamycin		1404-15-5			
nolatrexed	4-(1H)-Quinazolinone, 2-amino-6-methyl-5-(4-pyridinylthio), [CAS]	152945-68-4 147149-76-6	WO 9320055	Anticancer, antimetabolite	Cancer, liver
nolomirole	Propanoic acid, 2-methyl-, 5,6,7,8-tetrahydro-6-(methylamino)-1,2-naphthalenediyl ester, hydrochloride, (+/-)-[CAS]	138531-51-8	WO 9529147	Cardio stimulant	Heart failure
nolpitanium	1-Azoniabicyclo[2.2.2]octane, 1-[2-[3-(4-dichlorophenyl)-1-[3-(1-methylethoxy)phenyl]acetyl]-3-piperidinyl]ethyl]-4-phenyl-, chloride, (S)-[CAS]	153050-21-6	EP 591040	GI inflammatory/bowel disorders	Inflammatory bowel disease
nomegestrol	19-Norpregna-4,6-diene-3,20-dione, 17-(acetoxy)-6-methyl-, [CAS]	58652-20-3	DE 2522533	Menstruation disorders	Menstrual disorder, general
Nomifensine		24526-64-5			
Noprylsulfamide		576-97-6			
Norbolethone		1235-15-0			

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
Nordazepam		1088-11-5			
Nordefrin		6539-57-7 (unspecified); 74812-63-8 (R*, S*)-(±)- form			
Nordihydroguaiaretic Acid		27686-84-6 (meso-form); 500-38-9 (unspecified)			
Norelgestromin, Ethinyl Estradiol					
Norepinephrine		51-41-2			
Norethandrolone		52-78-8			
Norethindrone		68-22-4			
Norethynodrel		68-23-5			
Norfenefrine		536-21-0			
norfloxacin	3-Quinolincarboxylic acid, 1-ethyl-6-fluoro- 1,4-dihydro-4-oxo-7-(1-piperazinyl)- [CAS]	68077-27-0 70458-96-7	US 4146719	Quinolone antibacterial	Infection, general
Norgesterone		13663-60-5			
Norgestimate		35189-28-7			
Norgestrel		6533-00-2			
Norgestrienone		848-21-5			
Norlevorphanol		1531-12-0			
Normethadone		467-85-6			
Normethandrone		514-61-4			
Normorphine		466-97-7			
Norphenazone		89-25-8			
Norpipanone		561-48-8			
Norpseudoephedrine		492-39-7			
Nortriptyline		72-69-5			
Norvinisterone		6795-60-4			

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
Noscapine		128-62-1			
Novembichin		1936-40-9			
Novobiocin		303-81-1			
Noxiptilin		3362-45-6			
Noxythiolin		15599-39-0			
NS-1209	Butanoic acid, 2-[[[5-[4-((dimethylamino)sulfonyl)phenyl]-1,2,6,7,8,9-hexahydro-8-methyl-2-oxo-3H-pyrrolo[3,2-h]isoquinolin-3-ylidene]amino]oxy]-3-hydroxy- [CAS]	254751-28-5	WO 9426747	Antiepileptic	Epilepsy, general
NS-1231	5-(4-chlorophenyl)-6,7,8,9-tetrahydro-1H-pyrrolo-(3,2-h)naphthalene-2,3-dione-3-oxime				
NS-126			US 5063222	Neuroprotective Antiallergic, non-asthma	Ischaemia, cerebral Rhinitis, allergic, general
NS-220	2-Methyl-c-5-[4-[5-methyl-2-(4-methylphenyl)-4-oxazoly]butyl]-1,3-dioxane-r-2-carboxylic acid				
NS-2330	NS 2330 [CAS]	402856-42-2		Hypolipaeimic/Antiatherosclerosis Cognition enhancer	Atherosclerosis Alzheimer's disease
NS5A inhibitors			US 6030785	Antiviral, other	Infection, hepatitis-C virus
NS-7	Pyrimidine, 4-(4-fluorophenyl)-2-methyl-6-[[5-(1-piperidinyl)pentyl]oxy]-, monohydrochloride [CAS]	178429-67-9	WO 9607641	Neuroprotective	Ischaemia, cerebral
NS-8	2-Amino-5-(2-fluorophenyl)-4-methyl-1H-pyrrole-3-carbonitrile				
NSC-330507	17-Allylaminogeldanamycin			Urological	Incontinence
NSC-619534	2-chloroethyl phenyl selenone			Anticancer, antibiotic	Cancer, general
NSC-697726	2,5-diazimidinyl-3-[hydroxymethyl]6-methyl-1,4-benzoquinone			Anticancer, alkylating	Cancer, general
N-Sulfanilyl-3,4-xylamide		120-34-3		Anticancer, antibiotic	Cancer, general

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
NU-6027	2,4-Pyrimidinadiazine, 6-(cyclohexylmethoxy)-5-nitroso- [CAS]	220036-08-8		Anticancer, other	Cancer, general
NV-07	2,4,6-(1H,3H,5H)-Pyrimidinetrione, 5-ethyl-5-sec-pentyl-, 2-oxime [CAS]	53745-16-7	US	Antipruritic/inflam, non-allergic	Keratosis
NVP-SRA880	[(3R,4aR,10aR)-1,2,3,4,4a,5,10,10a-Octahydro-6-methoxy-1-methyl-benz[9]quinoline-3-carboxylic acid-4-(4-nitrophenyl)piperazine amide, hydrogen maleate				
NW-1029	(S)-(+)-2-[4-(2-fluorobenzyloxy)benzylamino]propanamide methanesulfonate			Neurological	Unspecified
NYX-059	CPI 22 [CAS]	168021-79-2	US	Analgesic, other	Pain, general
Nyldrin		447-41-6		Neuroprotective	Ischaemia, cerebral
NZ-314	1-Imidazolidineacetic acid, 3-[(3-nitrophenyl)methyl]-2,4,5-trioxo- [CAS]	128043-99-2	EP	Symptomatic antidiabetic	Neuropathy, diabetic
NZ-419	5-hydroxy-1-methylimidazolidine-2,4-dione		EP	Urological	Renal failure
Obidoxime Chloride		114-90-9			
OC-108	OC 108 [CAS]	162602-62-2		Vasoprotective, topical	Venous insufficiency
ocinaplon	Methanone, 2-pyridinyl[7-(4-pyridinyl)pyrazolo[1,5-a]pyrimidin-3-yl]- [CAS]				
Octabenzonone		96604-21-6	EP	Anxiolytic	Generalized anxiety disorder
Octacaine		1843-05-6			
Octamoxin		13912-77-1			
Octaverine		4684-87-1			
		549-68-8			
		70775-75-6			
octenidine	1-Octanamine, N,N'-(1,10-decanediylidene-1,4H)-pyridinyl-4-ylidene)bis- [CAS]	71251-02-0			
Octodrine		86767-75-1	WO	Stomatological	Periodontitis
Octopamine		543-82-8			
Octotamine		104-14-3			
		137-86-0			

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
octreotide	L-Cysteinamide, D-phenylalanyl-L-cysteinyl-L-phenylalanyl-D-typtophyl-L-lysyl-L-threonyl-N-[2-hydroxy-1-(hydroxymethyl)propyl]-, cyclic (2-7)-disulfide, [R-(R*, R*)]- [CAS]	83150-76-9		Formulation, fixed-dose combinations	Cancer, general
Octyl		5466-77-3			
Methoxycinnamate					
ofloxacin	7H-Pyrido[1,2,3-de]-1,4-benzoxazine-6-carboxylic acid, 9-fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-, (H)- [CAS]	82419-36-1	EP 47005	Quinolone antibacterial	
o-Iodohippurate		133-17-5			
olanzapine	10H-Thieno(2,3-b)(1,5)benzodiazepine, 2-methyl-4-(4-methyl-1-piperazinyl)- [CAS]	132539-06-1	EP 454436	Neuroleptic	Schizophrenia
Oleandrin		465-16-7			
Oleic Acid		112-80-1			
olmesartan medoxomil	1H-Imidazole-5-carboxylic acid, 4-(1-hydroxy-1-methylethyl)-2-propyl-1-((2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl)methyl)-, (5-methyl-2-oxo-1,3-dioxol-4-yl) methyl ester [CAS]	144689-63-4	EP 503785	Antihypertensive, renin system	Hypertension, general
olopatadine	11-[(Z)-3-(Dimethylamino)propylidene]-6,11-dihydrodibenz[b,e]oxepin-2-acetic acid, monohydrochloride	113806-05-6 140462-76-6	EP 235796	Ophthalmological	Conjunctivitis
olpadronic acid	Monosodium 3-dimethylamino-1-(hydroxypropylidene)-1,1-bisphosphonate	63132-39-8	WO 961998	Osteoporosis treatment	Osteoporosis
olsalazine	Benzoic acid, 3,3'-azobis[6-hydroxy- [CAS]	15722-48-2 53200-51-4	US 4559330	GI inflammatory/bowel disorders	Colitis, ulcerative
olipraz	3H-1,2-Dithiole-3-thione, 4-methyl-5-pyrazinyl- [CAS]	64224-21-1	DE 2705641	Anticancer, other	Cancer, general

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
OM-294DP	2-[3(R)-(Dodecanoyloxy)tetradecanamido]-N-[4-[3(R)-hydroxytetradecanamido]-5-(phosphonoxy)pentyl]-4-(phosphonoxy)butyramide				
Omacor	ethyl (5Z,8Z,11Z,14Z,17Z)-eicosa-5,8,11,14,17-pentaenoate + ethyl (4Z,7Z,10Z,13Z,16Z,19Z)-docosa-4,7,10,13,16,19-hexaenoate	81926-94-5 86227-47-6		Anticancer, immunological	Unspecified
onapatrilat	7H-Pyrido(2,1-b)(1,3)thiazepine-7-carboxylic acid, octahydro-4-((2-mercapto-1-oxo-3-phenylpropyl)amino)-5-oxo, (4S-(4Alpha(R*),7Alpha,10aB))- [CAS]	167305-00-2	US 5508272	Antihypertensive, renin system	Hypertension, general
omeprazole	1H-Benzimidazole, 5-methoxy-2-[[4-methoxy-3,5-dimethyl-2-pyridyl)methyl]sulfinyl]- [CAS]	73590-58-6	US 4255431	Anticancer	Ulcer, GI, general
omiloxetine	Ethanone, 2-[(3R,4S)-3-[(1,3-benzodioxol-5-yloxy)methyl]-4-(4-fluorophenyl)-1-piperidinyl]-1-(4-fluorophenyl)-, rel- [CAS]	176894-09-0		Antidepressant	Depression, general
omoconazole	1H-Imidazole, 1-[2-[2-(4-chlorophenoxy)ethoxy]-2-(2,4-dichlorophenyl)-1-methylethenyl]-, (Z)- [CAS]	74512-12-2	EP 8804	Antifungal	Infection, dermatological
Onapristone	4H-Carbazol-4-one, 1,2,3,9-tetrahydro-9-methyl-3-[(2-methyl-1H-imidazol-1-yl)methyl]- [CAS]	96346-61-1			
ondansetron	Benzoic acid, 4-[(1E)-3-[(2-ethoxy-2-oxoethyl)-2-propenyl]amino]-2-methyl-3-oxo-1-propenyl]-, 4-(aminomethyl)phenyl ester, monomethanesulfonate [CAS]	99614-01-4 99614-02-5	US 4847281	Antiemetic	Chemotherapy-induced nausea and vomiting
ONO-3403		181586-07-2		GI inflammatory/bowel disorders	Unspecified

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
ONO-4128	1,4,9-Triazaspiro[5.5]undecane-2,5-dione, 1-butyl-3-(cyclohexylmethyl)-9-((2,3-dihydro-1,4-benzodioxin-6-yl)methyl)-[CAS]	342394-93-8		Antiviral, anti-HIV	Infection, HIV/AIDS
ONO-8815 Ly	L-lysine (Z)-7-[(1R,2R,3R,5R)-5-chloro-3-hydroxy-2-[(E)-(S)-4-(1-ethylcyclobutyl)-4-hydroxy-1-butenyl]cyclopentyl]-5-heptenoate				
ONT-093			US 5756527	Labour inhibitor	Labour, preterm
OPC-14523	2(1H)-Quinolone, 1-[3-[4-(3-chlorophenyl)-1-piperazinyl]propyl]-3,4-dihydro-5-methoxy- [CAS]	145969-30-8	EP 512525	Radio/chemosensitizer	Cancer, general
OPC-31260	Benzamide, N-[4-[[5-(dimethylamino)-2,3,4,5-tetrahydro-1H-1-benzazepin-1-yl]carbonyl]phenyl]-2-methyl-	137975-06-5	WO 9105549	Antidepressant	Depression, general
OPC-51803	(5R)-2-[1-(2-chloro-4-(1-pyridinyl)benzoyl)-2,3,4,5-tetrahydro-1H-1-benzazepin-5-yl]-N-isopropylacetamide			Urological	Unspecified
OPC-6535	2-Pyridinecarboxylic acid, 6-[2-(3,4-dithoxyphenyl)-4-thiazolyl]- [CAS]	145739-56-6	WO 9209586	Antidiabetic	Diabetes, insipidus
Opiniazide		2779-55-7		GI inflammatory/bowel disorders	Inflammatory bowel disease
opioid analgesics	2-(4-trifluoromethylphenyl)-N-methyl-1-phenyl-2-(1-pyridinyl)ethylacetamide				
Opipramol		315-72-0		Analgesic, other	Pain, general
Orazamide		2574-78-9			
orazipone	2,4-Pentanedione, 3-((4-methylsulfonyl)phenyl)methylene)- [CAS]	137109-78-5	EP 440324	Antiasthma	Unspecified
Org-12962	Piperazine, 1-[6-chloro-5-(trifluoromethyl)-2-pyridinyl]-, monohydrochloride [CAS]	210821-63-9		Antidepressant	Depression, general
Org-24448			US 6166008	Neuroleptic	Schizophrenia

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
oritavancin	Vancomycin, 22-O-(3-amino-2,3,6-trideoxy-3-C-methyl-Alpha-L-arabino-hexopyranosyl)-N3"-[(4'-chloro[1,1'-biphenyl]-4-yl)methyl]-, (4'R)- [CAS]	171099-57-3	US 5840684	Peptide antibiotic	Infection, dermatological
orlistat	L-Leucine, N-formyl-, 1-[(3-hexyl-4-oxo-2-oxetanyl)methyl]dodecyl ester, [2S-[2Alpha(R*),3beta]- [CAS]	96829-58-2	EP 129748	Anorectic/Antiobesity	Obesity
ormeloxifene	Pyrrolidine, 1-[2-(p-(7-methoxy-2,2-dimethyl-3-phenyl-4-chromanyl)phenoxy)ethyl]-, trans- [CAS]	31477-60-8	DE 2329201	Female contraceptive	Contraceptive, female
Ornidazole		16773-42-5			
Ornipressin		3397-23-7			
Ornithine		70-26-8			
ornoprostil	Prost-13-en-1-oic acid, 11,15-dihydroxy-17,20-dimethyl-6,9-dioxo-, methyl ester, (11Alpha,13E,15S,17S)- [CAS]	70667-26-4	US 4278688	Prostaglandin	Ulcer, gastric
Orotic Acid		65-86-1			
Orphenadrine		83-98-7			
Orthocaine		536-25-4			
Osalmid		526-18-1			
osanetant	Acetamide, N-[1-[3-[(3R)-1-benzoyl-3-(3,4-dichlorophenyl)-3-piperidinyl]propyl]-4-phenyl-4-piperidinyl]-N-methyl- [CAS]	160492-56-8	EP 673928	Neuroleptic	Schizophrenia
osaterone	2-Oxapregna-4,6-diene-3,20-dione, 17-(acetyloxy)-6-chloro- [CAS]	105149-00-6	EP 193871	Prostate disorders	Benign prostatic hyperplasia
oseltamivir	1-Cyclohexene-1-carboxylic acid, 4-(acetylamino)5-amino-3-(1-ethylpropoxy)-, ethyl ester, (3R-(3Alpha,(4beta,5Alpha))- [CAS]	196618-13-0	WO 9626933	Antiviral, other	Infection, influenza virus
OSI-7836	4'-Thio-beta-D-arabinofuranosylcytosine			Anticancer, antimetabolite	Cancer, general

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
OSI-7904	Pentanedioic acid, 2-[5-[(1,2-dihydro-3-methyl-1-oxobenzof[quinazolin-9-yl)methyl]amino]-1,3-dihydro-1-oxo-2H-isindol-2-yl]-, (S)- [CAS]	139987-54-5	WO 9119700	Formulation, optimized, liposomes	Cancer, general
ospemifene	Ethanol, 2-[4-[(1Z)-4-chloro-1,2-diphenyl-1-butenyl]phenoxy]- [CAS]	128607-22-7	WO 9607402	Menopausal disorders	Osteoporosis
otilonium bromide	Ethanaminium, N,N-diethyl-N-methyl-2-[[4-[[2-(octyloxy)benzoyl]amino]benzoyl]oxy]-bromide [CAS]	26095-59-0	GB 1181406	Antispasmodic	Irritable bowel syndrome
Quabain		630-60-4			
Oxaceprol		33996-33-7			
Oxacillin		66-79-5			
Oxaflozane		25629-87-8			
oxaliplatin	Platinum, (1,2-cyclohexanediamine-N,N')[ethanedioato(2-)-O,O']-, [SP 4-2-(1R-trans)]-, [CAS]	61825-94-3	EP 393575	Anticancer, alkylating	Cancer, colorectal
Oxalyt-C	1,2,3-Propanetricarboxylic acid, 2-hydroxy-, potassium sodium salt [CAS]	28060-67-5	DE 2249274	Urological	
Oxamarin		15301-80-1			
Oxametacine		27035-30-9			
Oxamniquine		21738-42-1			
oxandrolone	2-Oxaandrostane-3-one, 17-hydroxy-17-methyl-, (5 α), (17 β)- [CAS]	53-39-4	US 3128283	Reproductive/gonadal, general	Sex-chromosome abnormality, Turner's syndrome
Oxantel		36531-26-7			
Oxapropanium		541-66-2			
oxaprozin	2-Oxazolepropanoic acid, 4,5-diphenyl- [CAS]	21256-18-8	GB 1206403	Antiarthritic, other	Arthritis, osteo
oxatormide	2H-Benzimidazol-2-one, 1-[3-[4-(diphenylmethyl)-1-piperazinyl]propyl]-1,3-dihydro- [CAS]	60607-34-3	GB 1579365	Antiallergic, non-asthma	Rhinitis, allergic, general
oxazepam	7-Chloro-1,3-dihydro-3-hydroxy-5-phenyl-2H-1,4-benzodiazepin-2-one	604-75-1		Formulation, oral, orally-disintegrating	Anxiety, general

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
oxazolam	Oxazol[3,2-d][1,4]benzodiazepin-6(5H)-one, 10-chloro-2,3,7,11b-tetrahydro-2-methyl-11b-phenyl- [CAS]	27167-30-2	US 3772371	Anxiolytic	
oxcarbazepine	5H-Dibenz[5,6]azepine-5-carboxamide, 10,11-dihydro-10-oxo- [CAS]	28721-07-5 29331-92-8	DE 2011087	Antiepileptic	Epilepsy, general
Oxeladin		468-61-1			
Oxendolone		33765-68-3			
Oxethazaine		126-27-2			
Oxetorone		26020-55-3			
oxiconazole	Ethanone, 1-(2,4-dichlorophenyl)-2-(1H-imidazol-1-yl)-, O-[(2,4-dichlorophenyl)methyl]oxime, (Z)- [CAS]	64211-45-6	GB 1514870	Antifungal	Infection, fungal, general
Oxidronic Acid		15468-10-7			
Oxiniacetic Acid		2398-81-4			
Oxiracetam		62613-82-5			
oxitropium	3-Oxa-9-azoniatricyclo[3.3.1.0 ^{2,3} .1.0 ^{2,4}]nonane, 9-ethyl-7-(3-hydroxy-1-oxo-2-phenylpropoxy)-9-methyl-, bromide, [7(S)-(1 α ,2 β ,4 α ,5 α)- [CAS]	30286-75-0	GB 1178305	Antiasthma	
Oxolamine		959-14-8			
Oxolinic Acid		14698-29-4			
Oxophenarsine		538-03-4			
Oxprenolol		6452-71-7			
Oxybenzone		131-57-7			
oxybutynin	Benzeneacetic acid, Alpha-cyclohexyl-Alpha-hydroxy-, 4-(diethylamino)-2-butynyl ester- [CAS]	5633-20-5 485-89-2		Formulation, modified-release, other	Incontinence
Oxycinchophen					
oxycodone	Morphinan-6-one, 4,5-epoxy-14-hydroxy-3-methoxy-17-methyl-, (5 α)-	76-42-6		Formulation, transmucosal, nasal	Pain, general

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
Oxyfedrine		15687-41-9			
Oxygent	Octane, 1-bromo-1,1,2,2,3,3,4,4,5,5,6,6,7,7,8,8,8-heptadecafluoro- [CAS]	423-55-2		Haematological	Surgery adjunct
Oxymesterone		145-12-0			
Oxymetazoline		1491-59-4			
oxymetholone	Androstan-3-one, 17-hydroxy-2-(hydroxymethylene)-17-methyl-, (5 α), 17 β)- [CAS]	434-07-1		Hormone	Anaemia, general
Oxymethurea		140-95-4			
oxymorphone	(5 α), 4,5-Epoxy-3,14-dihydroxy-17-methylmorphinan-6-one [CAS]	76-41-5		Formulation, modified-release, immediate	Pain, general
Oxypendyl		5585-93-3			
Oxypertine		153-87-7			
Oxyphenbutazone		129-20-4			
Oxyphenacylimine		125-53-1			
Oxyphenisatin		115-33-3			
Oxyphenonium		50-10-2			
Oxypinocamphone		10136-65-9			
oxypurinol	1H-Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione [CAS]	2465-59-0		Antigout	Hyperuricaemia
Oxytetracycline		79-57-2			
ozagrel	2-Propenoic acid, 3-[4-(1H-imidazol-1-ylmethyl)phenyl]-, (E)- [CAS]	78712-43-3			
		82571-53-7	GB 2025946	Antithrombotic	Vasospasm, cerebral
p-(Benzylsulfonamido)benzoic Acid		536-95-8			
P-100					
P-1202	Pentanoic acid, 5-amino-4-oxo, methyl ester, hydrochloride [CAS]		US 6313177	Antiviral, anti-HIV	Infection, HIV/AIDS
		79416-27-6	US 6034267	Dermatological	Keratosis
P32/98	Di-(3N-(2S,3S)-2-amino-3-methyl-pentanoyl)-1,3-thiazolidine/fumarate				
PA-824			WO 9701562	Antidiabetic	Diabetes, Type II
				Antimycobacterial	Infection, tuberculosis

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
PACAP 38	Plutitary adenylylate cyclase-activating peptide-38 [CAS]	128606-20-2	US 5128242	Neuroprotective	Nerve injury, general
pacilitaxel	5 β ,20-Epoxy-1,2Alpha,4,7 β ,10 β ,13Alpha-hexahydroxytax-11-en-9-one-4,10-diacetate-2-benzoate-13-(Alpha-phenylhippurate)	33069-62-4		Formulation, optimized, nanoparticles	Cancer, breast
PADRE	1H-Isoidol-1-one, 2-(7-chloro-1,8-naphthyridin-2-yl)-2,3-dihydro-3-(5-methyl-2-oxohexyl)- (R)- [CAS]		US 6413935	Immunosimulant, other	Vaccine adjunct
pagoclone		133737-32-3	US 4960779	Anxiolytic	Panic disorder
PAI inhbs			WO 9404512	Antithrombotic	Thrombosis, venous
palindore	8H-1,4-dioxino[2,3-e]indol-8-one,2,3,7,9-tetrahydro-2-[(phenylmethyl)amino]methyl]-2(S)-, (2E)-2-butendioate (1:1)	189681-71-8		Neuroleptic	Schizophrenia
Palivizumab		188039-54-5			
palonosetron	3aS-2-[(S)-1-Azabicyclo[2.2.2]oct-3-yl]-2,3,3a,4,5,6-hexahydro-1-oxo-1H-benz[de]isoquinoline hydrochloride	135729-62-3	US 5202333	Antiemetic	Chemotherapy-induced nausea and vomiting
Pamabrom		606-04-2			
Pamaquine		491-92-9			
pamicrogel	1H-Pyrrole-1-acetic acid, 2-[4,5-bis(4-methoxyphenyl)-2-thiazolyl]-, ethyl ester [CAS]	101001-34-7	EP 159677	Antithrombotic	Thrombosis, cerebral
pamidronate	(3-Amino-1-hydroxypropylidene)diphosphonic acid-[CAS]	40391-99-9		Formulation, implant	Hypercalcaemia of malignancy
p-Aminobenzoic Acid		150-13-0			
p-Aminohippuric Acid		61-78-9			
p-Aminopropiophenone		70-69-9			
p-Aminosalicilic Acid		65-49-6			

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
Paravir	4,4'-isopropylidenedithiobis-2,6-di- <i>t</i> -butylphenol			Neuroprotective	Vasospasm, cerebral
Pancuronium		15500-66-0			
Panipenem		87726-17-8			
Pantethine		16816-67-4			
pantoprazole	1H-Benzimidazole, 5-(difluoromethoxy)-2-[[[3,4-dimethoxy-2-pyridinyl)methyl]sulfonyl]- [CAS]	102625-70-7	EP 166287	Antilulcer	Ulcer, duodenal
Pantothenic Acid		79-83-4			
Papain					
Papaverine		58-74-2			
paracetamol	Acetamide, N-(4-hydroxyphenyl)- [CAS]	103-90-2		Formulation, oral, other, modified-release	Pain, general
Parafutizide		1580-83-2			
Paraldehyde		123-63-7			
Paramethadione		115-67-3			
Paramethasone		53-33-8			
Paranyline		1729-61-9			
Parathyroid Hormone		9002-64-6			
parecoxib	Propanamide, N-[(4-(5-methyl-3-phenyl-4-isoxazolyl)phenyl)sulfonyl]-, sodium salt [CAS]	198470-85-8	WO 9738986	Analgesic, NSAID	Pain, post-operative
Parethoxycaine		94-23-5			
Pargyline		555-57-7			
paricalcitol	19-Nor-9,10-secoergosta-5,7,22-triene-1,3,25-triol, (1 α ,3 β ,7 α ,22 E)- [CAS]	131918-61-1	EP 387077	Hormone	Hyperparathyroidism
paromomycin	O-2-Amino-2-deoxy- α -D-glucopyranosyl-(1-4)-O-[O-2,6-diamino-2,6-dideoxy- β -L-idopyranosyl-(1-3)- β -D-ribofuranosyl-(1-5)]-2-deoxy-D-streptamine	7542-37-2		Protozoacide	Infection, leishmaniasis
paroxetine	Piperidine, 3-[[[1,3-benzodioxol-5-yloxy)methyl]-4-(4-fluorophenyl)-, (3S-trans)- [CAS]	61869-08-7	EP 223403	Antidepressant, formulation, oral, orally-disintegrating	Depression, general

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
Paroxypropione		70-70-2			
Parsalmide		30653-83-9			
PaTriin-2	4-Bromothénylguanine			Radio/chemosensitizer	Cancer, melanoma
Pazinacilone					
	7H-Pyrido[1,2,3-de]-1,4-benzoxazine-6-carboxylic acid, 10-(1-aminocyclopropyl)-9-fluoro-2,3-dihydro-3-methyl-7-oxo-, (S)-[CAS]	103255-66-9			
pazufloxacin		127045-41-4 127046-45-1 136905-87-8	DE 3913245	Quinolone antibacterial	Infection, general
p-Bromoacetanilide PC-NSAIDs		103-88-8	US 4918063	Formulation, other	Arthritis, general
	6-(2,6-Dichlorophenyl)-2-[4-(diethylaminoethoxy)-phenylamino]-8-pyrido[2,3-D]pyrimidine-7-one			Anticancer, other	Cancer, general
PD-0166285					
Pecilocin		19504-77-9			
pelofloxacin	3-Quinolonecarboxylic acid, 1-ethyl-6-fluoro-1,4-dihydro-7-(4-methyl-1-piperazinyl)-4-oxo- [CAS]	70458-92-3	GB 1598915	Quinolone antibacterial	Infection, urinary tract
pegvisomant	Somatotropin (18-aspartic acid, 21-asparagine, 120-lysine, 167-asparagine, 168-alanine, 171-serine, 172-arginine, 174-serine, 179-threonine (human), pegylated [CAS]	218620-50-9		Somatostatin	Acromegaly
Pelletierine		4396-1-4			
pemetrexed	L-Glutamic acid, N-[4-(2-amino-4,7-dihydro-4-oxo-1H-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl]-, disodium salt [CAS]	137281-23-3 150399-23-8	US 5248775	Anticancer, antimetabolite	Cancer, mesothelioma
pemtrilast	4H-Pyrido[1,2-a]pyrimidin-4-one, 9-methyl-3-(1H-tetrazol-5-yl)- [CAS]	100299-08-9 69372-19-6	US 4457932	Antiasthma	Asthma
Pemoline		2152-34-3			
Pempidine		79-55-0			
PEN-203			US 5955446	Antiviral, other	Infection, human papilloma virus
Penamcillin		983-85-7			

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
penbutolol	2-Propanol, 1-(2-cyclopentylphenoxy)-3-[[1-(1-dimethylethyl)amino]-(S)-, sulfate (2:1) (salt) [CAS]	38363-32-5 38363-40-5	GB 1215751	Antihypertensive, adrenergic	
peniclovir	6H-Purin-6-one, 2-amino-1,9-dihydro-9-[4-hydroxy-3-(hydroxymethyl)butyl]- [CAS]	39809-25-1	JP 60058982	Antiviral, other	Infection, herpes simplex virus
Penethamate		808-71-9			
penfluridol	4-Piperidinol, 1-[4,4-bis(4-fluorophenyl)butyl]-4-[4-chloro-3-(trifluoromethyl)phenyl]- [CAS]	28864-56-2	DE 2040231	Neuroleptic	
Penicillamine		52-67-5			
Penicillin G		61-33-6			
Penicillin G Benzathine		1538-09-6			
Penicillin G Procaine		6130-64-9			
Penicillin N		525-94-0			
Penicillin O		87-09-2			
Penicillin V		87-08-1			
Penimepicycline		4599-60-4			
Pennituss			US 4221778	Formulation, modified-release, other	Rhinitis, allergic, general
Pentaerythritol Chloral		78-12-6			
Pentaerythritol		2209-86-1			
Dichlorohydrin					
Pentaerythritol		597-71-7			
Pentagastrin		5534-95-2			
Pentagestrone		7001-56-1			
Pentalyle	Starch, 2-hydroxyethyl ether [CAS]	9005-27-0	US 5407428	Plasma substitute	Surgery adjunct
Pentamethonium		541-20-8			
pentamidine	Benzenecarboximidamide, 4,4'-[1,5-pentanediy]bis(oxy)]bis- [CAS]	100-33-4		Formulation, inhalable, systemic	Infection, Pneumocystis jiroveci prophylaxis
Pentazocine		359-83-1			
Pentetate		12111-24-9			
Pentetic Acid		67-43-6			
Pentetreotide		138661-02-6			

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
Penthienate		60-44-6			
Pentifylline		1028-33-7			
Pentigetide		62087-72-3			
Pentisomide		78833-03-1			
Pentobarbital		76-74-4			
Pentolinium		52-62-0			
Pentorex		434-43-5			
pentosan	Xylan, [CAS]	37319-17-8	US 5180715	Urological	Inflammation, urinary tract
pentostatin	Imidazo[4,5-d][1,3]diazepin-8-ol, 3-(2-deoxy-4,5-D-erythro-pentofuranosyl)-3,6,7,8-tetrahydro-, (R)- [CAS]	53910-25-1	US 3923785	Anticancer, antimetabolite	Cancer, leukaemia, hairy cell
pentoxifylline	1H-Purine-2,6-dione, 3,7-dihydro-3,7-dimethyl-1-(5-oxohexyl)- [CAS]			Neuroprotective	Amyotrophic lateral sclerosis
Pentoxyl		147-61-5			
Pentritinol		1607-17-6			
Pentylene tetrazole		54-95-5			
peplomycin	Bleomycinamide, N1-[3-[(1-phenylethyl)amino]propyl]-, (S)- [CAS]	68247-85-8	US 4195018	Anticancer, antibiotic	
Perazine		84-97-9			
Perflubron		423-55-2			
Perfosfamide		62435-42-1; 39800-16-3 (unspecified)			
pergolide	Ergoline, 8-[(methylthio)methyl]-6-propyl-, (8S)-, monomethanesulfonate- [CAS]	66104-22-1 66104-23-2	US 4797405	Antiparkinsonian	Parkinson's disease
Perhexiline		6621-47-2			
Pericyazine		2622-26-6			
perifosine	Piperidinium, 4-[[[hydroxy(octadecyloxy)phosphinyl]oxy]-1,1-dimethyl-, inner salt [CAS]	157716-52-4	EP 594999	Anticancer, other	Cancer, prostate
perillyl alcohol	1-Cyclohexene-1-methanol, 4-(1-methylethenyl)- [CAS]	536-59-4	US 5110832	Anticancer, other	Cancer, breast
Perimethazine		13093-88-4			

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
perindopril	1H-Indole-2-carboxylic acid, 1-[2-[[1-(ethoxycarbonyl)butyl]amino]-1-oxopropyl]octahydro-, [2S-[1R*(R*)], 2Alpha,3aβ,7aβ]], compd. with 2-methyl-2-propanamine (1:1) [CAS]	107133-36-8 82834-16-0 95153-31-4	EP 49658	Antihypertensive, renin system	Hypertension, general
Peritodyl	1-Piperidineethanol, Alpha-(5-phenyl-3-isoxazolyl)-, 2-hydroxy-1,2,3-propanetricarboxylate (2:1) (salt) [CAS]	53586-99-5 2139-25-5 2055-44-9	JP 04217925	Anti-inflammatory	
perisoxal		1977-11-3			
Perlapipe		52645-53-1			
Permethrin					
perospirone	1H-Isoindole-1,3(2H)-dione, 2-[4-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]butyl]hexahydro-, dis- [CAS]	129273-38-7 150915-41-6	CA 2167004	Neuroleptic	Schizophrenia
Perphenazine		58-39-9			
Petroleum Benzin		8030-30-6	US 6331286	Antipsoriasis	Psoriasis
PH-10		84-12-8			
Phanquinone			WO 9638482	Immunological	Unspecified
Pharmaprojects No. 4994			WO 9703986	Neuroleptic	Schizophrenia
Pharmaprojects No. 5325			WO 0204426	Antiasthma	Asthma
Pharmaprojects No. 5972			US 6057346	Antiviral, anti-HIV	Infection, HIV/AIDS
Pharmaprojects No. 6362	(R)-N-[4-[2-[[2-Hydroxy-2-(3-pyridinyl)ethyl]amino]ethyl]phenyl]-4-[4-(trifluoromethyl)phenyl]thiazol-2-yl]benzenesulfonamide				
Pharmaprojects No. 6446				Anorectic/Antiobesity	Obesity
Pharmaprojects No. 6590			WO 0206223	Psychostimulant	Attention deficit disorder
Pharmaprojects No. 6656			US 6455026	Genomics-based drug discovery	Cancer, brain
Pharmaprojects No. 6691			US 6299900	Formulation, other	Pain, general
Pharmaprojects No. 6743	3-(6-Aminopyridin-3-yl)-N-methyl-N-[(1-methyl-1H-indol-2-yl)methyl]acrylamide			Antibacterial, other	Infection, general

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
Pharmaprojects No. 6748	1,2,3,4,10,14b-Hexahydro-6-methoxy-2-methylidibenzo[c,f]pyrazino[1,2-a]azepin				
Phenacaine		620-99-5		Antidepressant	Depression, general
Phenacetamide		63-98-9			
Phenacetin		62-44-2			
Phenadoxone		467-84-5			
Phenallymal		115-43-5			
Phenamet		3819-34-9			
Phenazocine		127-35-5			
Phenazopyridine		136-40-3			
Phenbutamide		3149-00-6			
Phencyclidine		77-10-1			
Phendimetrazine		634-03-7			
Phenelzine		51-71-8			
Phenesterine		3546-10-9			
Phenetharbital		357-67-5			
Phenethicillin		132-93-4			
Pheneturide		90-49-3			
Phenformin		114-86-3			
Phenylglutaramide		1156-05-4			
Phenindamine		82-88-2			
Phenindione		83-12-5			
Pheniprazine		55-52-7			
Pheniramine		86-21-5			
Phenmetrazine		134-49-6			
Phenobarbital		50-06-6			
Phenobutiodil		554-24-5			
Phenocoll		103-97-9			
Phenoclide		78-05-7			
Phenolphthalein		77-09-8			
Phenolphthalol		81-92-5			

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
Phenolsulfonphthalein		143-74-8			
Phenoltetrachlorophthal		639-44-1			
ein					
Phenoperidine		562-26-5			
Phenosulfazole		515-54-8			
Phenoxybenzamine		59-96-1			
Phenoxypropazine		3818-37-9			
Phenprobamate		673-31-4			
Phenprocoumon		435-97-2			
phenserine	Pyrrolo(2,3-b)indol-5-ol, 1,2,3,3a,8,8a-hexahydro-1',3a,8-trimethyl-, phenylcarbamate (ester), (3aS-cis)- [CAS]	101246-66-6		Cognition enhancer	Alzheimer's disease
Phensuximide		86-34-0			
Phentermine		122-09-8			
Phentetiothalein		18265-54-8			
phenylamine	Phenol, 3-(((4,5-dihydro-1H-imidazol-2-yl)methyl)(4-methylphenyl)amino)-, monomethanesulfonate (salt) [CAS]	65-28-1 50-60-2		Formulation, oral, other	Impotence
Phenyl Acetylsalicylate		134-55-4			
Phenyl Aminosalicylate		133-11-9			
Phenyl Salicylate		118-55-8			
Phenylbutazone		50-33-9			
Phenylephrine		61-76-7			
Phenylethanolamine		7568-93-6			
Phenylmercury		102-98-7			
Phenylmethylbarbituric Acid		76-94-8			
phenylpropanolamine	Benzenemethanol, Alpha-(1-aminoethyl)-, (R',S')-(+/-)- [CAS]	14838-15-4		Anorectic/Antiobesity, formulation, optimized, microparticles	
Phenylpropylmethylamine		93-88-9			

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
Phenyltoloxamine		92-12-6			
Phenylramidol		553-69-5			
phenytoin	2,4-imidazolidinedione, 5,5-diphenyl- [CAS]	57-41-0		Formulation, oral, other	Epilepsy, general
Phethenylate		510-34-9			
Phloroglucinol		108-73-6			
Pholcodine		509-67-1			
Pholedrine		370-14-9			
Phosphocreatine		67-07-2			
Phosphocysteamine		5746-40-7			
Phosphorylcholine		107-73-3			
Phthalylsulfacetamide		131-69-1			
Phthalylsulfathiazole		85-73-4			
p-Hydroxyephedrine		365-26-4			
Phylloquinone		84-80-0			
Physostigmine		57-47-6			
Phytic Acid		83-86-3			
PI-88	D-Mannose, O-6-O-phosphono-Alpha-D-mannopyranosyl-(1-3)-O-Alpha-D-mannopyranosyl-(1-3)-O-Alpha-D-mannopyranosyl-(1-3)-O-Alpha-D-mannopyranosyl-(1-2)-hydrogen sulphate [CAS]	185077-23-0		Anticancer, other	Cancer, melanoma
Piberaline		39640-15-8			
piboserod	2H-(1,3)Oxazino(3,2-a)indole-10-carboxamide, N-((1-butyl-4-piperidinyl)methyl)-3,4-dihydro- [CAS]	152811-62-6	WO 9318036	Antiarrhythmic	Fibrillation, atrial
Piciflores		62510-56-9			
Picloxydine		5636-92-0			
Picoperine		21755-66-8			
Picosulfate		10040-45-6			
Picotamide		32828-81-2			
Picumast		39577-19-0			

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
pidotimod	4-Thiazolidinecarboxylic acid, 3-[(5-oxo-2-pyrrolidinyl)carbonyl]- [CAS]	121808-62-6	EP 276752	Immunomodulator, anti-infective	Infection, respiratory tract, lower
Pifamine		56208-01-6			
piketoprofen	Benzeneacetamide, 3-benzoyl- α -methyl-N-(4-methyl-2-pyridinyl)- [CAS]	60576-13-8	GB 1436502	Anti-inflammatory, topical	
Pildralazine		64000-73-3			
pilocarpine	2(3H)-Furanone, 3-ethylidihydro-4-[(1-methyl-1H-imidazol-5-yl)methyl]-, (3S-cis)- [CAS]	92-13-7		Formulation, implant, Stomatological	
	2-Propenoic acid, 2-methyl-, dodecyl ester, polymer with 2-propenoic acid, compd. with (3S-cis)-3-ethylidihydro-4-[(1-methyl-1H-imidazol-5-yl)methyl]-2(3H)-furanone [CAS]	62783-28-2	DE 2636559	Formulation, mucosal, topical	Glaucoma
Pilopex	1H-Pyrrolizine-7a(5H)-acetamide, N-(2,6-dimethylphenyl)tetrahydro-, monohydrochloride [CAS]	88069-49-2 88069-67-4	US 4564624	Antiarrhythmic	Arrhythmia, general
Pimeclonone		534-84-9			
	15,19-Epoxy-3H-pyrido(2,1-o)(1,4)oxazaoclotricosine-1,7,20,21(4H,23H)-tetrone, 3-(2-(4-chloro-3-methoxycyclohexyl)-1-methylethenyl)-8-ethyl-5,6,8,11,12,13,14,15,16,17,18,19,24,25,26,26a-hexadecahydro-5,19-dihydroxy-14,16-dimethoxy-4,10,12,18-tetramethyl-(3S-(3R*E(1S*,3S*,4R*)), 4S*,5R* 8S*,9E*,12R*,14R*,5S*,16R*,18S 8,19S*,26aR*)) [CAS]	137071-32-0	EP 626385	Antipruritic/inflamm, allergic	Eczema, atopic
Pimefylline		10001-43-1			
	Acetic acid, [2-(octahydro-5-hydroxy-6-(3-hydroxy-5-methyl-1-nonyl)-2-pentalenyl]ethoxy]-, methyl ester, [2R-[2 α Pha.3 α Pha.4 α Pha(1E,3S*,5S*),5 β ,6 α Alpa]]- [CAS]	139403-31-9 13495-09-5 74150-27-9		Dermatological	Ulcer, general
pimilprost					
Piminodine					
Pimobendan					

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
pimozide	2H-Benzimidazol-2-one, 1-[1-[4,4-bis(4-fluorophenyl)butyl]-4-piperidinyl]-1,3-dihydro- [CAS]	2062-78-4	FR M3695	Neuroleptic	
Pinacidil		85371-64-8			
	Morpholinium, 4-[(2-bromo-4,5-dimethoxyphenyl)methyl]-4-[2-[2-(6,6-dimethylbicyclo[3.1.1]hept-2-yl)ethoxy]ethyl]-, [CAS]	53251-94-8 59995-65-2			
pinaverium			EP 406743	Antispasmodic	Irritable bowel syndrome
pinazepam	2H-1,4-Benzodiazepin-2-one, 7-chloro-1,3-dihydro-5-phenyl-1-(2-propynyl)-[CAS]	52463-83-9	DE 2339790	Anxiolytic	
Pindolol		13523-86-9			
pioglitazone	2,4-Thiazolidinedione, 5-[[4-[2-(5-ethyl-2-pyridinyl)ethoxy]phenyl]methyl]-, monohydrochloride (+/-), [CAS]	111025-46-8 112529-15-4	EP 193256	Antidiabetic	Diabetes, Type II
Pipacycline		1110-80-1			
Pipamazine		84-04-8			
Pipamperone		1893-33-0			
Pipazethate		2167-85-3			
Pipebuzone		27315-91-9			
Pipecurium		52212-02-9			
	Pipecurinium, 4,4'-[[[(2S,3Alpha,5Alpha,16S,17S)-3,17-bis(acetyloxy)androstane-2,16-diol]bis[1,1,1-dimethyl-, [CAS]	52212-02-9 68399-57-5	GB 1398050	Muscle relaxant	Anaesthesia, adjunct
pipecuronium	Pyrido[2,3-d]pyrimidine-6-carboxylic acid, 8-ethyl-5,8-dihydro-5-oxo-2-(1-piperazinyl)-[CAS]	51940-44-4 125-51-9			
pipemidic acid		3819-00-9	GB 1451911	Antibacterial, other	Infection, urinary tract
Pipenzolate Bromide					
Piperacetazine					
	4-Thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, 6-[[[(4-ethyl-2,3-dioxo-1-piperazinyl)carbonyl]amino]phenylacetyl]amino]-3,3-dimethyl-7-oxo-, [2S-[2Alpha,5Alpha,6(S*)]]-, [CAS]	59703-84-3 61477-96-1	GB 1508062	Penicillin, injectable	Infection, general
pipecillin					

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
Piperazine Adipate		142-88-1			
Piperidione		77-03-2			
Piperidolate		82-98-4			
Piperilate		4546-39-8			
piperine analogues			WO 002544	Dermatological	Vitiligo
Piperocaine		136-82-3			
Piperonal		120-57-0			
Piperoxan		59-39-2			
Piperylone		25 31-4-6			
Pipobroman		54-91-1			
Piposulfan		2608-24-4			
pipotiazine	Hexadecanoic acid, 2-[1-[3-[2-[(dimethylamino)sulfonyl]-10H-phenothiazin-10-yl]propyl]-4-piperidinyl]ethyl ester [CAS]	37517-26-3 39860-99-6	US 4782077	Neuroleptic	
Pipoxolan		18174-58-8			
Pipradrol		467-60-7			
piprozolin	Acetic acid, [3-ethyl-4-oxo-5-(1-piperidinyl)-2-thiazolidinylidene] ⁺ , ethyl ester [CAS]	17243-64-0	US 3971794	GI inflammatory/bowel disorders	Motility dysfunction, GI, general
Piracetam		7491-74-9			
pirarubicin	5,12-Naphthacenedione, 10-[3-amino-2,3,6-trideoxy-4-O-(tetrahydro-2H-pyran-2-yl)-Alpha-L-lyxo-hexopyranosyl]oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, [8S-[8Alpha, 10Alpha(S*)]]- [CAS]	72496-41-4	US 4303785	Anticancer, antibiotic	Cancer, breast
Pirazolac	2,6-Pyridinedimethanol, Alpha6-[[[(1,1-dimethylethyl)amino]methyl]-3-hydroxy-, monoacetate (salt) [CAS]	71002-09-0 38029-10-6 38677-81-5 65652-44-0			
Pirbuterol			US 3786160	Antiasthma	Asthma
Pirenoxine		1043-21-6			

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
pirenzepine	6H-Pyrido[2,3-b][1,4]benzodiazepin-6-one, 5,11-dihydro-11-[(4-methyl-1-piperazinyl)acetyl]- [CAS]	28797-61-7 29868-97-1	FR 1505795	Anticancer	
piretanide	Benzoic acid, 3-(aminosulfonyl)-4-phenoxy-5-(1-pyrrolidinyl)- [CAS]	55837-27-9	US 4010273	Antihypertensive, diuretic	Hypertension, general
pirfenidone	2(1H)-Pyridinone, 5-methyl-1-phenyl- [CAS]	53179-13-8		Respiratory	Fibrosis, pulmonary
piribedil	Pyrimidine, 2-[4-(1,3-benzodioxol-5-ylmethyl)-1-piperazinyl]- [CAS]	3605-01-4	US 3299067	Vasodilator, peripheral	Parkinson's disease
Piridocaine		87-21-8			
Pirifibrate		55285-45-5			
Piritramide		302-41-0			
Piritrexim		72732-56-0			
pirindole	1H-Pyrazino[3,2,1-k]carbazole, 2,3,3a,4,5,6-hexahydro-8-methyl- [CAS]	16154-78-2 60762-57-4	SU 276060	Antidepressant	Depression, general
pirmenol	(2-Pyridinemethanol, Alpha-[3-(2,6-dimethyl-1-piperidinyl)propyl]-Alpha phenyl-, cis-(+)- [CAS]	61477-94-9 69252-19-7	US 4112103	Antiarrhythmic	Tachycardia, supraventricular
Piroctone		50650-76-5			
Piroheptine		16378-21-5			
Piromidic Acid		19562-30-2			
piroxicam	2H-1,2-Benzothiazine-3-carboxamide, 4-hydroxy-2-methyl-N-2-pyridinyl-, 1,1-dioxide [CAS]	36322-90-4	US 3862319	Anti-inflammatory	
piroxicam betadex	β-Cyclodextrin, compd. with 4-hydroxy-2-methyl-N-2-pyridinyl-2H-1,2-benzothiazine-3-carboxamide 1,1-dioxide- [CAS]	121696-62-6 96684-39-8	EP 153998	Formulation, other	Pain, musculoskeletal
piroxicam cinnamate	2-Propenoic acid, 3-phenyl-, 2-methyl-3-[(2-pyridinylamino)carbonyl]-2H-1,2-benzothiazin-4-yl ester, S,S-dioxide [CAS]	87234-24-0	EP 79639	Antiarrhythmic, other	Inflammation, general
Pirozadil		54110-25-7			
Pirprofen		31793-07-4			

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
pitavastatin	6-Heptenoic acid, 7-[2-cyclopropyl-4-(4-fluorophenyl)-3-quinolyl]-3,5-dihydroxy-, calcium salt (2:1), [S-[R*,S*-(E)]]- [CAS]	147526-32-7	EP 304063	Hypolipaeamic/Antiatherosclerosis	Hyperlipidaemia, general
pivagabine	N-trimethylacetyl-4-aminobutyric acid	69542-93-4		Neurological	Anxiety, general
pivaloyloxymethyl	Butanoic acid, (2,2-dimethyl-1-oxopropoxy)methyl ester [CAS]	122110-53-6	EP 302349	Anticancer, other	Cancer, lung, non-small cell
Pivalylbenzhydrazine		306-19-4			
Pivampicillin		33817-20-8			
pivampicillin/pivmecillinam		98445-47-7		Penicillin, oral	Infection, general
Pivcefalexin		63836-75-9			
pivmecillinam	4-Thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, 6-[[[hexahydro-1H-azepin-1-yl)methylene]amino]-3,3-dimethyl-7-oxo-, (2,2-dimethyl-1-oxopropoxy)methyl ester, [2S-(2Alpha,5Alpha,6S)]- [CAS]	32886-97-8	GB 1293590	Penicillin, oral	Infection, general
pixantrone	Benz[<i>g</i>]isoquinoline-5,10-dione, 6,9-bis[(2-aminoethyl)amino]-, (2Z)-butenedioate(1:2) [CAS]	144675-97-8	EP 503537	Anticancer, other	Cancer, lymphoma, non-Hodgkin's
pizotifen	4-[9,10-dihydro-4H-benzo[4,5]cyclohepta[1,2-b]thien-4-ylidene]-1-methylpiperidine	15574-96-6	DE 2346747	Antimigraine	
Pizotyline		15574-96-6			
PKI-166	Phenol, 4-(4-(((1R)-1-phenylethyl)amino)-1H-pyrrolo[2,3-d]pyrimidin-6-yl)- [CAS]	187724-61-4		Anticancer, other	Cancer, general
p-Lactophenetide		539-08-2			
Plafibride		63394-05-8			
plasminogen activator	Plasminogen activator [CAS]	105913-11-9	EP 151996	Fibrinolytic	Infarction, myocardial
Plasmocid		551-01-9			
Platonin		3571-88-8			
Plaunotol		64218-02-6			
PLD-118	Cyclopentanecarboxylic acid, 2-amino-4-methylene-, (1R,2S)- [CAS]	198022-65-0	EP 805145	Antifungal	Infection, Candida, general

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
PLD-147	(OC-6-43)-Bis(acetato)(1-adamantylamine)ammine-dichloro-platinum (IV)				
pleconaril	1,2,4-Oxadiazole, 3-(3,5-dimethyl-4-(3-(3-methyl-5-isoxazolyl)propoxy)phenyl)-5-(trifluoromethyl)- [CAS]	153168-05-9	US 5464848	Anticancer, alkylating	Cancer, general
Plicamycin		18378-89-7			
p-Methyldiphenhydramine		19804-27-4		Antiviral, other	Infection, respiratory tract, general
PMS-601			WO 0001677	Antiviral, anti-HIV	Infection, HIV/AIDS
<i>Pneumococcal Vaccine, Diphtheria Conjugate</i>					
<i>Pneumococcal Vaccine, Polyvalent</i>					
PNU-288034	N-[[[(5s)-3{4[(1,1-dioxido-4-thiomorpholinyl)3,5-difluorophenyl]-2-oxo-5-oxazolidinyl)methyl]acetamide]			Antibiotic, other	Infection, general
Podophyllotoxin		518-28-5			
polaprezinc	Zinc, bis(N-β-alanyl-L-histidinato-N3, OAlpha)-, (T-4)- [CAS]	107667-60-7	EP 303380	Antilulcer	Ulcer, duodenal
Poldine Methylsulfate		545-80-2			
Poliresulen		9011-2-3			
Polidexide		9064-92-0			
polidocanol	Polyethylene glycol monododecyl ether	3055-99-0			
		9002-92-0		Vasoprotective, systemic	Venous insufficiency
<i>Poliovirus Vaccine Inactivated</i>					

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
poly-ADPRT inhibitors			WO 9845263	Anticancer, other	Cancer, general
Polyestradiol Phosphate		28014-46-2			
Polyphenon E	Polyphenon E [CAS]	188265-33-0		Antiviral, other	Infection, human papilloma virus
Polythiazide		346-18-9			
porfimer	Photofrin [CAS]	87806-31-3	US 4882234	Anticancer, other	Cancer, lung, non-small cell
Porfiromycin		801-52-5			
posaconazole	D-threo-Pentitol, 2,5-anhydro-1,3,4-trideoxy-2-C-(2,4-difluorophenyl)-4-((4-(4-(1'(1S,2S)-1-ethyl-2-hydroxypropyl)-1,5-dihydro-5-oxo-4H-1,2,4-triazol-4-yl)phenyl)-1-piperazinyl)phenoxy)methyl)-1-((1H-1,2,4-triazol-1-yl)- [CAS]	171228-49-2	US 5714490	Antifungal	Infection, fungal, general
Posatirelin		78664-73-0			
potassium chloride	Potassium chloride (KCl) [CAS]	7447-40-7		Formulation, oral, enteric-coated	
Potassium Gluconate		299-27-4			
Potassium		1321-14-8			
Guaiacolsulfonate					
Potassium p-Aminobenzoate		138-84-1			
Potassium		7722-64-7			
Permanganate					
Povidone		9003-39-8			
Povidone-Iodine		25655-41-8			
PP-117	3-Pyridinemethanol, hydrofluoride [CAS]	62756-44-9	DE 2633028	Formulation, oral, other	Unspecified
PR-2699	(-)-(E)-4-(2,4-dichlorophenyl)-1,3-dithiolan-2-ylidene]-1-imidazolylacetone nitrile			Antifungal	Infection, fungal, general

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
PR-608	(S)-(-)-1-[4,4-bis(4-fluorophenyl)butyl]-4-(2-hydroxy-3-phenylaminopropyl)piperazine trihydrochloride			Antiparkinsonian	Parkinson's disease
Practolol		6673-35-4			
Prasinaline		35080-11-6			
Pralidoxime		51-15-0			
pralnacasan	6H-Pyridazino(1,2-a)(1,2-diazepine-1-carboxamide, N-((2R,3S)-2-ethoxytetrahydro-5-oxo-3-furanyl)octahydro-9-((1-isoquinolinylcarbonyl)amino)-6,10-dioxo-, (1S,9S)- [CAS]	192755-52-5		Antiarthritic, immunological	Arthritis, rheumatoid
pramipexole	2,6-Benzothiazolediamine, 4,5,6,7-tetrahydro-N6-propyl-, (S)- [CAS]	104632-26-0	EP 186087	Antiparkinsonian	Parkinson's disease
pramiracetam	1-Pyrrolidineacetamide, N-[2-bis(1-methylethyl)aminoethyl]-2-oxo-, monohydrochloride [CAS]	68497-62-1 72869-16-0 75733-50-5	US 4145347	Cognition enhancer	Amnesia
Pramiverin		14334-40-8			
pramlintide	1,2-Dithia-5,8,11,14,17-pentaazacycloicosane, cyclic peptide deriv. [CAS]	151126-32-8	US 5124314	Antidiabetic	Diabetes, Type I
Pramoxine		140-65-8			
pranidipine	3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-, methyl 3-phenyl-2-propenyl ester, (E)- [CAS]	99522-79-9	EP 173126	Antihypertensive, other	Hypertension, general
Pranlukast	5H-[1]Benzopyrano[2,3-b]pyridine-7-acetic acid, Alpha-methyl- [CAS]	103177-37-3			
pranoprofen	Androst-5-en-17-one, 3-hydroxy-, (3S)- [CAS]	52549-17-4		Formulation, mucosal, topical	Ocular disorder, general
prasterone	4(3H)-Cycloheptimidazolone, 5,6,7,8-tetrahydro-2-propyl-3-[[2-(1H-tetrazol-5-yl)][1,1'-biphenyl]-4-yl]methyl]- [CAS]	53-43-0		Labour inducer	
prazosin		153804-05-8	US 5409947	Antihypertensive, renin system	Hypertension, general

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
pravastatin	1-Naphthalenepentanoic acid, 1,2,6,7,8,8a-hexahydro- β , delta, 6-trihydroxy-2-methyl-8-(2-methyl-1-oxobutoxy)-, monosodium salt, [1S-], 8a[alpha]- [CAS]	81093-37-0 81131-70-6	US 4346227	Hypolipemic/Antiatherosclerosis	Atherosclerosis
Pravapam		2955-38-6			
praziquantel	4H-Pyrazino[2,1-a]isoquinolin-4-one, 2-(cyclohexylcarbonyl)-1,2,3,6,7,11b-hexahydro- [CAS]	55268-74-1	US 4001411	Schistosomicide	
prazosin	Piperazine, 1-(4-amino-6,7-dimethoxy-2-quinazolinyl)-4-(2-furanylcarbonyl)-[CAS]	19216-56-9 19237-84-4 73771-04-7	US 4092315	Antihypertensive, adrenergic	Hypertension, general
Prednicarbate					
prednimustine	Pregna-1,4-diene-3,20-dione, 21-[4-[bis(2-chloroethylamino)phenyl]-1-oxobutoxy]-11,17-dihydroxy-, (11S)- [CAS]	29069-24-7	GB 1272841	Anticancer, alkylating	
Prednisolone		50-24-8			
Prednisolone 21-Diethylaminoacetate		5626-34-6			
prednisolone farnesil	Pregna-1,4-diene-3,20-dione, 11,17-dihydroxy-21-[(3,7,11-trimethyl-1-oxo-2,6,10-dodecatrienyl)oxy]-, [11S,21(2E,6E)]- [CAS]	118244-44-3	EP 332143	Antiarthritic, other	Arthritis, rheumatoid
Prednisolone Sodium Phosphate		125-02-0			
Prednisone		53-03-2			
Prednival		15180-00-4			
Prednylidene		599-33-7			
pregabalin	Hexanoic acid, 3-(aminomethyl)-5-methyl, (S)- [CAS]	148553-50-8		Antiepileptic	Epilepsy, general
Pregnan-3α-ol-20-one		128-20-1			
Premarin + trimegestone	Estra-4,9-dien-3-one, 17-(2-hydroxy-1-oxopropyl)-17-methyl-, [17B (S)]- [CAS]	74513-62-5		Menopausal disorders	Hormone replacement therapy

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
prenalterol	Phenol, 4-[2-hydroxy-3-[(1-methylethylamino)propoxy]-hydrochloride, (S)-[CAS]	57526-81-5 61260-05-7	GB 1470039	Cardio stimulant	
Prenoxdiazine		982-43-4			
Prenylamine		390-64-7			
prezatide	Cuprate(1-), (N2-(N-glycyl-L-histidyl)-L-lysinate)(N2-(N-glycyl-L-histidyl)-L-lysinate(2-))-, hydrogen, [CAS]	130120-57-9		Vulnery	Wound healing
Pridinol		511-45-5			
Prifinium		4630-95-9			
Prilocaine		721-50-6			
Primaquine		90-34-6			
Primidone		125-33-7			
Prinomastat		192329-42-3			
PRO-2000			US 5614599	Antiviral anti-HIV	Infection, HIV prophylaxis
Probenecid		57-66-9			
Probutol		23288-49-5			
procainamide	Benzamide, 4-amino-N-[2-(diethylamino)ethyl]- [CAS]	51-06-9 614-39-1		Formulation, other	Arrhythmia, general
Procaine		59-46-1			
Procarbazine		671-16-9			
procatol	2-(1H)-Quinolone, 8-hydroxy-5-[1'-hydroxy-5'-oxo-2'-butyl]-, 2-[(1-methylethylamino)butyl]-, monohydrochloride [CAS]	53828-07-8 60443-17-6 72332-33-3	GB 1496766	Antiasthma	
prochlorperazine	10H-Phenothiazine, 2-chloro-10-[3-(4-methyl-1-piperazinyl)propyl]-, (Z)-2-butenedioate	58-38-8 84-02-6		Formulation, oral, other	Nausea and vomiting, general
procodazol	1H-Benzimidazole-2-propanoic acid [CAS]	23249-97-0	ES 407882	Anticancer, immunological	Cancer, general
Procyclidine		77-37-2			
Procymate		13931-64-1			
Prodipine		31314-38-2			
Proflavine		92-62-6			
Progabide		62666-20-0			

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
progesterone	Pregn-4-ene-3,20-dione [CAS]	57-83-0		Formulation, transmucosal, systemic	Amenorrhoea
proglumetacin	1H-Indole-3-acetic acid, 1-(4-chlorobenzoyl)-5-methoxy-2-methyl-, 2-(4-(3-((4-(benzoylamino)-5-(dipropylamino)-1,5-dioxopentyl)oxy)propyl)-1-piperazinyl)ethyl ester, (+/-)- [CAS]	57132-53-3 59209-40-4	GB 1467568	Anti-inflammatory	Inflammation, general
proglumide	Pentanoic acid, 4-(benzoylamino)-5-(dipropylamino)-5-oxo-, (+/-)- [CAS]	6620-60-6	DE 1518125	Antiulcer	Ulcer, gastric
Proheptazine		77-14-5			
Prolactin		9002-62-4			
Prolintane		493-92-5			
Prolonium		123-47-7			
Promazine		58-40-2			
Promedol		64-39-1			
Promegestone		34184-77-5			
promestriene	Estra-1,3,5(10)-triene, 17-methoxy-3-propoxy-, (17 β)- [CAS]	39219-28-8	GB 1337198	Reproductive/gonadal, general	Acne
Promethazine		60-87-7			
Pronethalol		54-80-8			
propacetamol	Glycine, N,N-diethyl-, 4-(acetyl amino)phenyl ester [CAS]	66532-85-2 66532-86-3	US 4127671	Formulation, parenteral, other	
propafenone	1-Propanone, 1-[2-[2-hydroxy-3-(propylamino)propoxy]phenyl]-3-phenyl- [CAS]	54063-53-5	GB 1307455	Antiarrhythmic	Fibrillation, ventricular
Propagermanium		12758-40-6			
Propallylonal		545-93-7			
Propamidine		104-32-5			
propane-1,2-diol	1,2-propanediol	57-55-6		Formulation, dermal, topical	Infection, fungal, general
Propanidid		1421-14-3			
Propantheline		50-34-0			
Proparacaine		499-67-2			
PropatyI		2921-92-8			
propenidazole	ethyl trans-Alpha-acetyl-1-methyl-5-nitroimidazole-2-acrylate	76448-31-2		Antifungal	Infection, trichomoniasis

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
propentofylline	1H-Purine-2,6-dione, 3,7-dihydro-3-methyl-1-(5-oxohexyl)-7-propyl- [CAS]	55242-55-2	GB 1470220	Neuroprotective	Ischaemia, cerebral
Propicillin		551-27-9			
Propiomazine		362-29-8			
Propionic Acid		79-09-4			
propionyl L-carnitine	1-Propanaminium, 3-carboxy-N,N,N-trimethyl-2-(1-oxopropoxy)-, chloride, (R)- [CAS]	119793-66-7 20084-19-1	GB 2008578	Vasodilator, peripheral	Peripheral vascular disease
Propipocaine		3670-68-6			
Propiram		15686-91-6			
propiverine	2,2-diphenyl-2-(1-propoxy)acetic acid (1-methylpiperid-4-yl) ester hydrochloride	54556-98-8 60569-19-9		Urological	Incontinence
Propizepine		10321-12-7			
propofol	Phenol, 2,6-bis(1-methylethyl)- [CAS]	2078-54-8	US 4056635	Anaesthetic, injectable	Anaesthesia
Propoxycaine		550-83-4			
Propoxyphene		469-62-5			
proporanolol	2-Propanol, 1-[(1-methylethyl)amino]-3-(1-naphthalenyloxy)- [CAS]	318-98-9 525-66-6		Formulation, modified-release, <=24hr	Hypertension, general
Propylhexedrine		101-40-6			
Propylodone		587-61-1			
Propylthiouracil		51-52-5			
Propyphenazone		479-92-5			
Proquazone		22760-18-5			
Proscillaridin		466-06-8			
Prostacyclin		35121-78-9			
Prostaglandin E₁		745-65-3			
Prostaglandin E₂		363-24-6			
Prostaglandin F_{2α}		551-11-1			
Proslutamine		59-58-5			
Protein C		60202-16-6			
Protheobromine		50-39-5			
Prothipendyl		303-69-5			

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
Protiofate		58416-00-5			
Protionamide		14222-60-7			
protizinc acid	10H-Phenothiazine-2-acetic acid, 7-methoxy-Alpha, 10-dimethyl-, (+/-)- [CAS]	13799-03-6	US 3450698	Anti-inflammatory	
Protoanemonin		108-28-1			
Protokylol		136-70-9			
Protoporphylin IX		553-12-8			
Protriptyline		438-60-8			
Pro-Urokinase		82657-92-9			
Proxazole		5696-9-3			
Proxibarbal		2537-29-3			
proxigermanium	Propanoic acid, 3,3'-(1,3-dioxo-1,3-digermoxanedyl)bis- [CAS]	12758-40-6	FR 2005110	Antiviral, other	Infection, hepatitis-B virus
Proxiphylline		503-00-9			
Prozapine		3426-8-2			
Prucalopride		179474-81-8			
prulifloxacin	1H,4H-[1,3]Thiazeto[3,2-a]quinoline-3-carboxylic acid, 6-fluoro-1-methyl-7-[4-[(5-methyl-2-oxo-1,3-dioxol-4-yl)methyl]-1-piperazinyl]-4-oxo- [CAS]	123447-62-1	EP 315828	Quinolone antibacterial	Infection, respiratory tract, general
Pseudococaine		478-73-9			
pseudoephedrine + triprolidine	Benzenemethanol, Alpha-[1-(methylamino)ethyl]-, hydrochloride, [S-(R*, R*)]-, mixt. with (E)-2-[1-(4-methylphenyl)-3-(1-pyrrolidinyl)-1-propenyl]pyridine monohydrochloride [CAS]				
pseudoephedrine	Benzenemethanol, Alpha-[1-(methylamino)ethyl]-, [S-(R*, R*)]- [CAS]	90-82-4, 8054-27-1, 345-78-8		Formulation, modified-release, other	Rhinitis, allergic, general
Psilocybin		520-52-5		Formulation, oral, other	Infection, respiratory tract, general
PSK-3841	Benzonitrile, 4-[3-(4-hydroxybutyl)-4,4-dimethyl-2,5-dioxo-1-imidazolidinyl]-2-(trifluoromethyl)- [CAS]	154992-24-2		Dermatological	Alopecia, general

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
p-Sulfanilylbenzylamine		4393-19-5			
PT-141			US 6051555	Male sexual dysfunction	Impotence
Pteropterin		89-38-3			
Puromycin		53-79-2			
PX-12	1-Methylpropyl 2-mercaptimidazolyl disulfide			Anticancer, other	Cancer, general
Pyrantel		15686-83-6			
Pyrazinamide		98-96-4			
Pyridinol Carbamate		1882-26-4			
Pyridostigmine Bromide		101-26-8			
Pyridoxal 5-Phosphate		54-47-7			
Pyridoxine		58-56-0			
Pyrilamine		91-84-9			
Pyrimethamine		58-14-0			
Pyrinoline		1740-22-3			
Pyrisuccideanol		33605-94-6			
Pyrithione		1121-30-8			
Pyrithyldione		77-04-3			
Pyritinol		1098-97-1			
Pyrocatechol		120-80-9			
Pyrogallol		87-66-1			
Pyronaridine		74847-35-1			
Pyrovalerone		3563-49-3			
Pyroxylin		9004-70-0			
Pyrobutamine		91-82-7			
Pyrrocaine		2210-77-7			
Pyrrolnitrin		1018-71-9			
Pyrvinium Pamoate		3546-41-6			

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
quazepam	2H-1,4-Benzodiazepine-2-thione, 7-chloro-5-(2-fluorophenyl)-1,3-dihydro-1-(2,2,2-trifluoroethyl)- [CAS]	36735-22-5	US 3845039	Hypnotic/Sedative	Insomnia
Quercetin		117-39-5			
quetiapine	Ethanol, 2-[2-(4-dibenzo[b,f][1,4]thiazepin-11-yl-1-piperazinyl)ethoxy]-, (E)-2-butenedioate (2:1) (salt) [CAS]	111974-69-7 111974-72-2	EP 240228	Neuroleptic	Schizophrenia
Quinacillin		1596-63-0			
	N-(6-Chloro-2-methoxy-9-acridinyl)-N,N-diethyl-1,4-pentanedi-amine + 10H-Phenothiazine-10-propanamine, 2-chloro-N,N-dimethyl	83-89-6			
quinacrine				Neurological	Creutzfeldt-Jakob disease
quinagolide	Sulfamide, N,N-diethyl-N'-(1,2,3,4,4a,5,10,10a-octahydro-6-hydroxy-1-propylbenzo[g]quinolin-3-yl)-, (3A)pha,4aAlpha,10aB)- (+/-) [CAS]	87056-78-8 94424-50-7 97805-49-7	EP 77754	Antiprolactin	Hyperprolactinaemia
quinapril	3-Isoquinolinecarboxylic acid, 2-[2-[(1-(ethoxycarbonyl)-3-phenylpropyl)amino]-1-oxopropyl]-1,2,3,4-tetrahydro-, [3S-[2[R'*(R*)],3R'*)]- [CAS]	82586-55-8 85441-61-8 90243-99-5	EP 49605	Antihypertensive, renin system	Hypertension, general
quinaprilat	3-Isoquinolinecarboxylic acid, 2-[2-[(1-carboxy-3-phenylpropyl)amino]-1-oxopropyl]-1,2,3,4-tetrahydro-, [3S-[2[R'*(R*)],3R'*)]- [CAS]				
Quinapryramine		82768-85-2	EP 46953	Antihypertensive, renin system	Hypertension, general
Quinbolone		20493-41-8			
Quinestradiol		2487-63-0			
Quinestrol		1169-79-5			
Quinethazone		152-43-2			
		73-49-4			
quinfamide	2-Furancarboxylic acid, 1-(dichloroacetyl)-1,2,3,4-tetrahydro-6-quinolinyl ester [CAS]	62265-68-3	US 3997542	Amoebicide	
quinidine	Gincfonan-9-ol, 6'-methoxy-, (9S)-, sulfate (1:1) (salt) [CAS]	147-45-5 56-54-2		Formulation, modified-release, other	Arrhythmia, general

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
Quinine		130-95-0			
Quinocidine		525-61-1			
Quinupramine		31721-17-2			
Quinupristin		120138-50-3			
R-107500	dis-2,3,3a,8-tetrahydro-N,N-dimethyl-2-benz[c,f]isoxazolo[2,3-a]azepine-2-methanamine		WO 9614320	Anxiolytic	Anxiety, general
R-667			WO 0204439	COPD treatment	Emphysema, general
rabeprazole	1H-Benzimidazole, 2-[[4-(3-methoxypropoxy)-3-methyl-2-pyridinyl]methyl]sulfinyl-, sodium salt- [CAS]	117976-89-3 117976-90-6	EP 268956	Antulcer	Ulcer, gastric
racecadotril	Glycine, N-[2-[(acetylthio)methyl]-1-oxo-3-phenylpropyl]-, phenylmethyl ester, (+/-)- [CAS]	112573-72-5 81110-73-8	EP 38758	Antidiarrhoeal	Diarrhoea, general
Racemethorphan	Methanone, [6-hydroxy-2-(4-hydroxyphenyl)benzo[b]thien-3-yl][4-[2-(1-piperidinyl)ethoxy]phenyl]-, hydrochloride [CAS]	510-53-2			
raloxifene	L-glutamic acid, N-[[5-[[1,4-dihydro-2-methyl-4-oxo-6-quinazolinyl)methyl]methylamino]-2-thienyl]carbonyl]- [CAS]	82640-04-8 84449-90-1	EP 62503	Osteoporosis treatment	Osteoporosis
ralitrexed	9H-Carbazole-9-propanoic acid, 3-[[[(4-fluorophenyl)sulfonyl]amino]-1,2,3,4-tetrahydro-, (R)- [CAS]	112887-68-0	EP 239362	Anticancer, antimetabolite	Cancer, colorectal
ramatroban		116649-85-5	EP 242518	Antiallergic, non-asthma	Rhinitis, allergic, perennial
Ramifenazone	Cyclopenta[b]pyrrole-2-carboxylic acid, 1-[2-[[1-(ethoxycarbonyl)-3-phenylpropyl]amino]-1-oxopropyl]octahydro-, [2S-[1(R*,R*)],2Alpha,3aβ,6aβ]]- [CAS]	3615-24-5			
ramipril	Methanone, (1-methyl-1H-indol-3-yl)(4,5,6,7-tetrahydro-1H-benzimidazol-5-yl)-, monohydrochloride, (R)- [CAS]	87269-97-4 87333-19-5	EP 79022	Antihypertensive, renin system	Heart failure
ramosetron		132907-72-3 132036-88-5	EP 381422	Antiemetic	Nausea and vomiting, general

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
Ramot project No. 1097			US 5730992	Dermatological	Unspecified
Ranimustine		58994-96-0			
ranitidine	1,1-Ethenediamine, N-[2-[[[5-[(dimethylamino)methyl]-2-furanyl]methyl]thio]ethyl]-N'-methyl-2-nitro- [CAS]				
	1,2,3-Propanetricarboxylic acid, 2-hydroxy-bismuth(3+) salt (1:1), compd. with N-(2-[[[5-[(dimethylamino)methyl]-2-furanyl]methyl]thio]ethyl)-N'-methyl-2-nitro-ethenediamine (1:1)- [CAS]	66357-35-5	US 4128658	Antitumor	Ulcer, duodenal
ranitidine bismuth citrate		128345-62-0	EP 533281	Antitumor	Ulcer, duodenal
ranolazine	1-Piperazineacetamide, N-(2,6-dimethylphenyl)-4-[2-hydroxy-3-(2-methoxyphenoxy)propyl]-, (+/-)- [CAS]	95635-55-5 95635-56-6	EP 126449	Antianginal	Angina, general
Ranipirase		133737-96-9			
Rapacuronium		156137-99-4			
rasagiline	1H-Inden-1-amine, 2,3-dihydro-N-2-propenyl-, (R)-, [CAS]	161735-79-1	US 5457133	Antiparkinsonian	Parkinson's disease
Raubasine		483-04-5			
ravuconazole	Benzonitrile, 4-[2-[(1R,2R)-2-(2,4-difluorophenyl)-2-hydroxy-1-methyl-3-(1H-1,2,4-triazol-1-yl)propyl]-4-thiazolyl]- [CAS]	182760-06-1		Antifungal	Infection, meningitis, general
raxofelast	2-Benzofuranacetic acid, 5-(acetoxy)-2,3-dihydro-4,6,7-trimethyl-, (+)- [CAS]	128232-14-4	US 4999350	Symptomatic antidiabetic	Nephropathy, diabetic
razoxane	2,6-Piperazinedione, 4,4'-(1-methyl-1,2-ethanediylo)bis- [CAS]	21416-67-1, 21416-87-5	GB 1234935	Anticancer, other	Cancer, general
RC-529	Tetradecanoic acid (1R)-1-(2-((2-(2-deoxy-3-O-((3R)-1-oxo-3-((1-oxotetradecyl)oxy)tetradecyl)amino-4-O-phosphono-β-D-glucopyranosyl)oxy)ethyl)amino)-2-oxoethyl)dodecyl ester, compd. with N,N-diethylethanamine (1:1) [CAS]	216014-46-9		Immunostimulant, other	Vaccine adjunct
rebamipide	4-Quinolonepropanoic acid, Alpha-[(4-chlorobenzoyl)amino]-1,2-dihydro-2-oxo- [CAS]	90098-04-7	DE 3324034	Antitumor	

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
rebimastat	L-Valinamide, N-((2S)-2-mercapto-1-oxo-4-(3,4,4-trimethyl-2,5-dioxo-1-imidazolidinyl)butyl)-L-leucyl-N,3-dimethyl- [CAS]	259188-38-0		Anticancer, other	Cancer, lung, non-small cell
reboxetine	Morpholine, 2-[(2-ethoxyphenoxy)phenylmethyl]-, (R*, S*)- [CAS]	71620-89-8, 98769-81-4	US 4229449	Antidepressant	Depression, general
Remacemide		128298-28-2			
remifentanyl	1-Piperidinepropanoic acid, 4-(methoxycarbonyl)-4-((1-oxopropyl)phenylamino)-methyl ester- [CAS]	132539-07-2, 132875-61-7	EP 383579	Analgesic, other	Pain, general
remindertant	Tricyclo[3.3.1.1 ^{3,7}]decane-2-carboxylic acid, 2-[[1-(7-chloro-4-quinolyl)-5-(2,6-dimethoxyphenyl)-1H-pyrazol-3-yl]carbonyl]amino]- [CAS]	146362-70-1	EP 699438	Neuroleptic	Schizophrenia
Remoxipride		80125-14-0			
renzapride	Benzamide, 4-amino-N-1-azabicyclo[3.3.1]non-4-yl-5-chloro-2-methoxy- [CAS]	109872-41-5, 88721-77-1	JP 58188885	Gastroprokinetic	Irritable bowel syndrome
repaglinide	Benzoic acid, 2-ethoxy-4-[2-[[3-methyl-1-[2-(1-piperidinyl)phenyl]butyl]amino]-2-oxoethyl]-, (S)- [CAS]	135062-02-1	WO 9300337	Antidiabetic	Diabetes, Type II
repertaxin L-lysine salt	2(R)-4-Isobutylphenylpropionyl methanesulfonamide L-lysine salt		WO 0024710	Cardiovascular	Reperfusion injury
repinotan	1,2-Benzisothiazol-3(2H)-one, 2-(4-(((3,4-dihydro-2H-1-benzopyran-2-yl)methyl)amino)butyl)-, 1,1-dioxide, monohydrochloride [CAS]	144980-29-0, 144980-77-8	US 5137901	Neuroprotective	Ischaemia, cerebral
repirinast	4H-Pyran[3,2-c]quinoline-2-carboxylic acid, 5,6-dihydro-7,8-dimethyl-4,5-dioxo-, 3-methylbutyl ester [CAS]	73080-51-0	US 4298610	Antiasthma	
Reposal		3625-25-0			

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
reproterol	1H-Purine-2,6-dione, 7-[3-[[2-(3,5-dihydroxyphenyl)-2-hydroxyethyl]amino]propyl]-3,7-dihydro-1,3-dimethyl- [CAS]	13055-82-8 54063-54-6	FR M5969	Antiasthma	Asthma
Rescimetol		73573-42-9			
Rescinnamine		24815-24-5			
Reserpiline		131-02-2			
Reserpine		50-55-5			
Resibufogenin		465-39-4			
resiquimod	1H-Imidazo(4,5-c)quinoline-1-ethanol(ethoxymethyl)-Alpha, Alpha-dimethyl- [CAS]	144875-48-9	US 5389640	Antiviral, other	Infection, hepatitis-C virus
Resorcinol		108-46-3			
Reteplase		133652-38-7			
retigabine	Carbamic acid, (2-amino-4-(((4-fluorophenyl)methyl)amino)phenyl)-, ethyl ester [CAS]	150812-12-7	DE 4200259	Antiepileptic	Epilepsy, general Cancer, leukaemia, acute myelogenous
retinoic acid	Retinoic acid [CAS]	302-79-4		Formulation, parenteral, other	
Revimid	[1,1'-Biphenyl]-4-acetic acid, 2-fluoro-Alpha-methyl	5104-49-4	US 6281230	Anticancer, other	Cancer, myeloma
R-flurbiprofen				Anticancer, other	Cancer, prostate
<i>Rho (D) Immune Globulin (Human)</i>					
Rho-kinase inhibitors			WO 0156988	Antiasthma	Unspecified
ribavirin	1H-1,2,4-Triazole-3-carboxamide, 1-β-D-ribofuranosyl- [CAS]	36791-04-5	US 4211771	Antiviral, other	Infection, haemorrhagic fever
Riboflavin		146-17-8			
ribostamycin	D-Streptamine, O-2,6-diamino-2,6-dideoxy-Alpha-D-glucopyranosyl-(1-4)-O-β-D-ribofuranosyl-(1-5)]-2-deoxy- [CAS]	25546-65-0	GB 1254883	Aminoglycoside antibiotic	Infection, general
Ricinoleic Acid		141-22-0			
Ridogrel		110140-89-1			

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
rifabutin	Rifamycin XIV, 1',4-didehydro-1-deoxy-1,4-dihydro-5-(2-methylpropyl)-1-oxo-[CAS]	72559-06-9	US 4219478	Antimycobacterial	Infection, Mycobacterium avium complex
rifalazil	Rifamycin VIII, 1',4-didehydro-1-deoxy-1,4-dihydro-3'-hydroxy-5-[4-(2-methylpropyl)-1-piperazinyl]-1-oxo-[CAS]	129791-92-0 129791-94-2 133633-12-2	EP 366914	Antimycobacterial	Infection, tuberculosis
rifametane	Rifamycin, 3-[[[1-(diethylamino)ethylidene]hydrazono]methyl]-[CAS]	94188-98-6	EP 119571	Antimycobacterial	Infection, general
Rifamide		2750-76-7			
rifampicin + trimethoprim	Rifamycin, 3-[[[4-methyl-1-piperazinyl]imino]methyl]-, mixt. with 5-[[3,4,5-trimethoxyphenyl]methyl]-2,4-pyrimidinediamine [CAS]	61498-94-0		Formulation, fixed-dose combinations	Infection, general
Rifampin		13292-46-1			
Rifamycin SV		6998-60-3			
rifapentine	Rifamycin, 3-[[[4-cyclopentyl-1-piperazinyl]imino]methyl]-[CAS]	61379-65-5	DE 2608218	Antibiotic, other	Infection, tuberculosis
rifaximin	Epoxypentadeca[1,11,13]trienino)benzofuro[4,5-e]pyrido[1,2-a]benzimidazole-1,15(2H)-dione, 25-(acetyloxy)-5,6,21,23-tetrahydroxy-27-methoxy-2,4,11,16,20,22,24,26-octamethyl-, [2S-(2R*,16Z,18E,20R*,22S*,23S*,24S*,25R*,26S*,27R*,28E)]	80621-81-4	GB 2079270	Antibiotic, other	Infection, GI tract
rifaximine cream	4-deoxy-4'-methylpyrido[1',2'-1,2']imidazo[5,4-c]rifamycin SV	80621-81-4	BE 888895	Formulation, dermal, topical	Infection, dermatological
Rilmazafone		99593-25-6			
rimenidine	2-Oxazolamine, N-(dicyclopropylmethyl)-4,5-dihydro-[CAS]	54187-04-1 54249-57-9	DE 2362754	Antihypertensive, adrenergic	Hypertension, general
riluzole	2-Benzothiazolamine, 6-(trifluoromethoxy)-[CAS]	1744-22-5	EP 50551	Neuroprotective	Amyotrophic lateral sclerosis
Rimantadine		13392-28-4			

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
rimazolium	4H-Pyrido[1,2-a]pyrimidin-3-(ethoxycarbonyl)-6,7,8,9-tetrahydro-1,6-dimethyl-4-oxo-, [CAS]	28610-84-6 35615-72-6	DE 2461349	Anaesthetic, NSAID	
rimexolone	Androsta-1,4-dien-3-one, 11-hydroxy-16,17-dimethyl-17-(1-oxopropyl)-, (11 β , 16 α), [CAS]	49697-38-3	DE 2301317	Ophthalmological	Inflammation, ocular
Rimiferol		32953-89-2			
rimonabant	1H-Pyrazole-3-carboxamide, 5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-N-1-piperidinyl-, monohydrochloride [CAS]	158681-13-1	US 5624941	Anorectic/Antiobesity	Obesity
ritodolol	1,3-Benzenediol, 2,4,6-triiodo- [CAS]	19403-92-0	US 3755251	Antiviral, other	
Rioprostil		77287-05-9			
risedronate	Phosphonic acid, (1-hydroxy-2-(3-pyridinyl)ethylidene)bis-, monosodium salt	115436-72-1	EP 304961	Osteoporosis treatment	Page's disease
Risedronic Acid		105462-24-6			
risperidone	4H-Pyrido[1,2-a]pyrimidin-4-one, 3-[2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]ethyl]-6,7,8,9-tetrahydro-2-methyl-, [CAS]	106266-06-2	EP 196132	Neuroleptic, formulation, optimized, microencapsulate	Schizophrenia
Ritanerlin		87051-43-2			
Ritipenem		84845-57-8			
ritodrine	Benzenemethanol, 4-hydroxy-Alpha-[1-[2-(4-hydroxyphenyl)ethyl]amino]ethyl-, (R*, S*), [CAS]	23239-51-2 26652-09-5	US 3410944	Labour inhibitor	Labour, preterm
ritonavir	2,4,7,12-Tetraazatridecan-13-ol-ic acid, 10-hydroxy-2-methyl-5-(1-methylethyl)-1-(2-(1-methylethyl)-4-thiazolyl)-3,6-dioxo-8,11-bis(phenylmethyl)-, 5-thiazolyl-methyl ester, (5S-(5R*, 8R*, 10R*, 11R*))-, [CAS]	155213-67-5	WO 9414436	Antiviral, anti-HIV	Infection, HIV/AIDS
Rituximab		174722-31-7			
rivastigmine	Carbamic acid, ethylmethyl-, 3-[1-(dimethylamino)ethyl]phenyl ester, (S)- [CAS]	123441-03-2 129101-54-8	DE 3805744	Cognition enhancer	Alzheimer's disease

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
rizatriptan	1H-Indole-3-ethanamine, N,N-dimethyl-5-((1H-1,2,4-triazol-1-yl)methyl)-, [CAS]	145202-66-0 159776-67-7 144034-80-0	EP 497512	Antimigraine	Migraine
RJR-2403	3-Buten-1-amine, N-methyl-4-(3-pyridinyl)-, (3E)-, (2E)-2-butenedioate (1:1) [CAS]	183288-99-5		Cognition enhancer	Alzheimer's disease
RNA Stealth Nucleosides	5-Formyluridine			Antiviral, other	Infection, hepatitis-C virus
Ro-0094889	2',3'-Di-O-acetyl-5'-vinylcytidine			Anticancer, antimetabolite	Cancer, general
Ro-61-1790	2-Pyridinesulfonamide, N-[6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)-2-[2-(1H-tetrazol-5-yl)-4-pyridinyl]-4-pyrimidinyl]-5-methyl-, [CAS]	180384-56-9	WO 9619459	Cardiovascular	Haemorrhage, subarachnoid
Rociverine	Pyrolidinium, 1-[[2(3,3Alpha,5Alpha,16S,17S)-17-(acetyloxy)-3-hydroxy-2-(4-morpholinyl)androstan-16-yl]-1-(2-propenyl)-, bromide-, [CAS]	53716-44-2			
rocuronium	Pyrolidinium, 1-[[2(3,3Alpha,5Alpha,16S,17S)-17-(acetyloxy)-3-hydroxy-2-(4-morpholinyl)androstan-16-yl]-1-(2-propenyl)-, bromide-, [CAS]	104855-17-6 104884-91-5 119302-91-9 143558-00-3	EP 287150	Muscle relaxant	Muscle spasm, general
rofecoxib	2(5H)-Furanone, 4-(4-(methylsulfonyl)phenyl)-3-phenyl-, [CAS]	162011-90-7	US 5474995	Analgesic, NSAID	Arthritis, osteo
roflumilast	Benzamide, 3-(cyclopropylmethoxy)-N-(3,5-dichloro-4-pyridinyl)-4-(difluoromethoxy)-, [CAS]	162401-32-3	WO 9501338	COPD treatment	Chronic obstructive pulmonary disease
rokitamycin	Leucomycin V, 4B-butanolate 3B-propanoate [CAS]	74014-51-0	US 4242504	Macrolide antibiotic	Infection, general
Rolipram		51413-54-5			
Rolitetracycline		751-97-3			
Romurtide		78113-36-7			
Ronifibrate		42597-57-9			
ropinirole	2H-Indol-2-one, 4-[2-(dipropylamino)ethyl]-1,3-dihydro-, monohydrochloride-, [CAS]	91374-20-8 91374-21-9	EP 266033	Antiparkinsonian	Parkinson's disease

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
ropivacaine	2-Piperidinecarboxamide, N-(2,6-dimethylphenyl)-1-propyl-, (S)- [CAS]	84057-96-4 98717-15-8	EP 239710	Anaesthetic, local	Anaesthesia
Roquinimex		84088-42-6			
rosaprostol	Cyclopentanepentanoic acid, 2-hexyl-5-hydroxy- [CAS]	56695-65-9	GB 1523355	Prostaglandin	
Rosaramicin		35834-26-5			
Rose Bengal		632-68-8			
rosiglitazone	2,4-Thiazolidinedione, 5-((4-(2-(methyl-2-pyridinylamino)ethoxy)phenyl)methyl)-, (Z)-2-butenedioate (1:1) [CAS]	122320-73-4 155141-29-0	US 5002953	Antidiabetic	Diabetes, Type II
rosoxacin	3-Quinolonecarboxylic acid, 1-ethyl-1,4-dihydro-4-oxo-7-(4-pyridinyl)- [CAS]	40034-42-2	US 3753993	Quinolone antibacterial	Infection, gonorrhoea
rostaporphin	Tin, dichloroethyl 3,4,20,21-tetrahydro-4,9,14,19-tetraethyl-18,19-dihydro-3,8,13,18-tetramethyl-20-phorbinecarboxylato(2-)-kappaN23,kappaN24,kappaN25,kappaN26]-, (OC-6-13)- [CAS]	114494-17-6		Ophthalmological	Macular degeneration
rosuvastatin	6-Heptenoic acid, 7-(4-(4-fluorophenyl)-6-(1-methylethyl)-2-(methyl(methylsulfonyl)amino)-5-pyrimidinyl)-3,5-dihydroxy- (S-(R*, S*-(E))) [CAS]	147098-20-2	JP 2648897	Hypoipaeamic/Antiatherosclerosis	Hyperlipidaemia, general
rotigotine	1-Naphthalenol, 5,6,7,8-tetrahydro-6-[propyl[2-(2-thienyl)ethyl]amino]-, (S)- [CAS]	99755-59-6	US 4564628	Antiparkinsonian	Parkinson's disease
Rotraxate		92071-51-7			
Roxarsone		121-19-7			
roxatidine	Acetamide, 2-(acetoxy)-N-[3-{3-(1-piperidinylmethyl)phenoxy}propyl]-, [CAS]	78628-28-1 93793-83-0	EP 24510	Antulcer	Ulcer, gastric
roxifiban	L-Alanine, 3-(((3-(4-(aminoiminomethyl)phenyl)-4,5-dihydro-5-isoxazolyl)acetyl)amino)-N-(butoxycarbonyl)-, methyl ester, (R)-, [CAS]	176022-59-6	US 5849736	Antithrombotic	Thrombosis, general
Roxindole		112192-04-8			

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
roxithromycin	Erythromycin, 9-[O-[(2-methoxyethoxy)methyl]oxime] [CAS]	80214-83-1 80214-86-4	EP 33255	Macrolide antibiotic	Infection, general
RPR-109881A	Benzenepropanoic acid, β -((1,1-dimethylethoxy)carbonyl)amino)-Alpha-hydroxy- (1S,2S,4S,7R,8aR,9aS,10aR,12aS,12bR)-7,12a-bis(acetyloxy)-1-(benzoyloxy)-1,3,4,7,8,9,9a,10,10a,12,12a,12b-dodecahydro-2-hydroxy-5,13,13-trimethyl-8-oxo-2,6-methano-2H-cyclodeca(3,4)cyclopropano (4,5) benz (1,2-b) oxet-4-yl ester, dihydrate Alpha R, beta S [CAS]	192573-38-9		Anticancer, other	Cancer, lung, general
RPR-130401	4,9-Ethano-3aH-benz[flisoindole-3a-carboxylic acid, 1,2,3,4,9,9a-hexahydro-2-[2-(2-methoxyphenyl)-1-oxo-2-propenyl]-9-(4-methylphenyl)-, (3aR,4S,9S,9aR)-rel- [CAS]	210282-69-2	WO 9829390 US 6316456	Anticancer, other Anticancer, other	Cancer, general Cancer, lung, non-small cell
R-roscovitine	N,N'-bis(3-hydroxyphenyl)pyridazine-3,6-diamine			Neuroprotective	Alzheimer's disease
RS-0406					
RSR-13					
Rubijervine		131179-95-8 79-58-3			
rubitecan	1H-Pyrano[3',4':6,7]indolizino(1,2-b)quinoline-3,14(4H,12H)-dione, 4-ethyl-4-hydroxy-10-nitro-, (S)- [CAS]	91421-42-0	US 6485514	Anticancer, other	Cancer, pancreatic
ruboxistaurin	9H,18H-5,21:12,17-Dimethenodibenzo(e,k)pyrrolo(3,4-h)(1,4,13)oxadiazacyclohexadecene-18,20(19H)-dione, 9-(((dimethylamino)methyl)-6,7,10,11-tetrahydro-, (S)- [CAS]	169939-94-0		Symptomatic antidiabetic	Retinopathy, diabetic
Rufinamide		106308-44-5			

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
rifloxacin	7H-Pyrido[1,2,3-de]-1,4-benzothiazine-6-carboxylic acid, 9-fluoro-2,3-dihydro-10-(4-methyl-1-piperazinyl)-7-oxo- [CAS]	101363-10-4 102052-47-1 106017-08-7	EP 165375	Quinolone antibacterial	Infection, general
rupatadine	5H-Benzof[5,6]cyclohepta[1,2-b]pyridine, 8-chloro-6,11-dihydro-1,1'-[1'-(5-methyl-3-pyridinyl)methyl]-4-piperidinylidene]-, trihydrochloride- [CAS]	156611-76-6 153-18-4	EP 0577957	Antiallergic, non-asthma	Rhinitis, allergic, seasonal
Rutin					
RWJ-54428	5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid, 7-(((2Z)-(2-amino-5-chloro-4-thiazolyl)(hydroxymino)acetyl)amino)-3-[[3-[(2-aminoethyl)thio]methyl]-4-pyridinyl]thio]-8-oxo-, (6R,7R)- [CAS]	189448-35-9	WO 9713772	Cephalosporin, injectable	Infection, beta-lactamase resistant
S-0139	Olean-12-en-28-olic acid, 27-[[3-[5-hydroxy-2-[(4-methoxy-1,4-dioxo-2-butenyl)amino]phenyl]-1-oxo-2-propenyl]oxy]-3-oxo- [CAS]			Cardiovascular	Ischaemia, cerebral
S-15535	Piperazine, 1-(2,3-dihydro-1,4-benzodioxin-5-yl)-4-(2,3-dihydro-1H-inden-2-yl)- [CAS]	146998-34-7		Cognition enhancer	Cognitive disorder, general
S-18886	1-Naphthalenepropanoic acid, 6-(((4-chlorophenyl)sulfonyl)amino)-5,6,7,8-tetrahydro-2-methyl [CAS]	165537-73-5		Antithrombotic	Thrombosis, general
S-34730	7-chloro-6-sulfamoyl-2-(1H)-quinoline-3-phosphonic acid			Neuroprotective	Unspecified
S-3578	7[[2-(5-amino-1,2,4-thiadiazol-3-yl)-2(Z)-ethoxyminoacetamido]-3-(1-(N-methylaminopropyl)-1H-imidazo[4,5-b]pyridin-4-yl)-4-methyl-3-cephem-4-carboxylate monosulfate			Cephalosporin, injectable	Infection, general

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
S-36496	2-[N-[4-(4-Chlorophenyl)sulfonylamino]butyl]-N-[3-[(4-isopropylthiazol-2-yl)methoxy]benzyl]sulfamoyl]benzoic acid			Antiasthma	Asthma
S-36527	2-[N-[4-(4-Chlorophenyl)sulfonylamino]butyl]-N-[3-[2-(4-cyclobutylthiazol-2-yl)ethyl]benzyl]sulfamoyl]benzoic acid			Antiasthma	Asthma
S-5751	(1R,2R,3S,5S)-7-[2-(5-Hydroxybenzothiophen-3-ylcarboxamido)-6,6-dimethylbicyclo[3.1.1]hept-3-yl]-5(Z)-heptenoic acid			Antiallergic, non-asthma	Allergy, general
S-8510	Imidazo[4,5-d]pyrano[4,3-b]pyridine, 1,6,7,9-tetrahydro-2-(3-isoxazolyl)-, phosphate (1:1) [CAS]	151466-23-8	EP	Cognition enhancer	Alzheimer's disease
S-8921	2-Naphthalenecarboxylic acid, 1-(3,4-dimethoxyphenyl)-3-(3-ethyl-1-oxopentyl)-4-hydroxy-6,7,8-trimethoxy-, methyl ester [CAS]				
Sabcomeline		151165-96-7	WO	Hypolipaeic/Antiatherosclerosis	Hypercholesterolaemia
Sabeluzole		159912-53-5			
S-Adenosylmethionine		104383-17-7			
		29908-03-0			
saflnamide	(S)-(+)-2-[4-(3-fluorobenzoyloxy)benzylamino]propanamide methanesulfonate	133865-89-1	AU	Antiepileptic	Epilepsy, general
Salacetamide		487-48-9			
Salazosulfadimidine		2315-8-4			
salbutamol	1,3-Benzenedimethanol, Alpha 1-[[[1,1-dimethylethyl]amino]methyl]-4-hydroxy-[CAS]	18559-94-9	EP	Formulation, inhalable, topical, dry powder	Asthma
Salicin		138-52-3			
Salicyl Alcohol		90-01-7			

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
Salicylamide		65-45-2			
Salicylamide O-Acetic Acid		25395-22-6			
Salicylanilide		87-17-2			
Salicylic Acid		69-72-7			
Salicylsulfuric Acid		89-45-2			
Salinazid		495-84-1			
salmeterol	1,3-Benzenedimethanol, 4-hydroxy-Alpha1+ [[[6-(4-phenylbutoxy)hexylamino]methyl]- (4)- 1-hydroxy-2-naphthalenecarboxylate [CAS]	89365-50-4 94749-08-3	WO 9006775	Antiasthma	Asthma
Salsalate		552-94-3			
Salverine		6376-26-7			
Samarium ¹⁵³ Sm Lexidronam		154427-83-5			
sampatriptat	L-Tyrosine, N2-(methylsulfonyl)-L-lysyl-1- [(2S)-3-amino-2- carboxypropyl]cyclopentanecarbonyl- [CAS]	129981-36-8	EP 358398	Antihypertensive, renin system	Hypertension, general
Sancycline		808-26-4			
Saperconazole		110588-57-3			
sapropterin	4(1H)-Pteridinone, 2-amino-6-(1,2- dihydroxypropyl)-5,6,7,8-tetrahydro- dihydrochloride, [6R-[6R*(1R*,2S*)]]- [CAS]	69056-38-8 62989- 33-7	EP 191335	Antidepressant	Hyperphenylalaninaemia
saquinavir	Butanediamide, N1-[3-[3-[[[(1,1- dimethyl)ethyl]amino]carbonyl]octahydro- 2(1H)-isquinolinyl]-2-hydroxy-1- (phenyl)methyl]propyl]-2-[(2- quinolinylcarbonyl)amino]-, [3S- [2(1R*(R*),2S*),3Alpha,4aβ,8aβ]]-, [CAS]	127779-20-8	EP 432695	Antiviral, anti-HIV	Infection, HIV/AIDS
Saralasin		34273-10-4			

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
sarebutant	Benzamide, N-[4-[4-(acetylamino)-4-phenyl-1-piperidinyl]-2-(3,4-dichlorophenyl)butyl]-N-methyl-, (S)- [CAS]	142001-63-6	EP 474561	Antiasthma	Asthma
sarizolan	3-Pyridinemethanamine, N-[(3,4-dihydro-2H-1-benzopyran-2-yl)methyl]-5-(4-fluorophenyl)- [CAS]	177975-08-5		Antiparkinsonian	Parkinson's disease
sarpogrelate	Butanedioic acid, mono[2-(dimethylamino)-1-[2-[2-(3-methoxyphenyl)ethyl]phenoxy]methyl]ethyl ester [CAS]	125926-17-2	EP 398326	Antithrombotic	
Satigrel		111753-73-2			
satraplatin	Platinum, bis(acetato-O)amminedichloro(cyclohexanamine)-, (OC-6-43)- [CAS]	129580-63-8	EP 328274	Anticancer, alkylating	Cancer, prostate
Satumomab		144058-40-2			
SB-237376	N-[3-[2-(3,4-dimethoxyphenyl)ethyl]amino]propyl-4-nitrobenzamide, HCl			Antiarrhythmic	Fibrillation, atrial
SB-238039	(5-(2-phenylamino-4-pyrimidinyl)-4-(4-fluorophenyl)-1-(4-piperidinyl)imidazole			Anticancer, other	Cancer, general
SB-277011	trans-N-[4-[2-(6-Cyano-1,2,3,4-tetrahydroisoquinolin-2-yl)ethyl]cyclohexyl]-4-quinolinecarboxamide			Neuroleptic	Schizophrenia
Scarlet Red		85-83-6			
SCH-00013	Benzonitrile, 4-[2-[3,6-dihydro-4-(1,4,5,6-tetrahydro-6-oxo-3-pyridazinyl)-1(2H)-pyridinyl]-1-hydroxyethyl]- [CAS]	217963-18-3	EP 618204	Cardio stimulant	Heart failure
Sch-23863	(2-[10,11-Dihydro-5-ethoxy-5H-dibenzo[a,d] cyclohepten-S-yl]-N, N-dimethylethanamine			Immunosuppressant	Inflammation, general

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
Sch-57790	1-Piperazineacetoneitrile, 4-cyclohexyl-alpha-[4-((S)-4-methoxyphenyl)sulfinyl]phenyl- [CAS]	221660-80-6		Cognition enhancer	Alzheimer's disease
Sch-63390	7H-Pyrazolo[4,3-e][1,2,4]triazolo[1,5-c]pyrimidin-5-amine, 2-(2-furanyl)-7-(3-phenylpropyl)- [CAS]	174648-45-4		Antiparkinsonian	Parkinson's disease
Scillarenin		465-22-5			
Scopolamine		51-34-3			
Scopolamine N-Oxide		97-75-6			
scopolamine	Benzeneacetic acid, Alpha-(hydroxymethyl)-, 9-methyl-3-oxa-9-azatricyclo[3.3.1.0 ^{2,4}]non-7-yl ester, [7(S)- (1Alpha,2β,4β,5Alpha,7β)]- [CAS]	51-34-3	US 4262003	Formulation, transdermal, other	Nausea and vomiting, general
SCS technology			US 6046188	Antialthma	Unspecified
secalciferol	9,10-Secocholesta-5,7,10(19)-triene-3,24,25-triol, (3β,5Z,7E,24R)- [CAS]	55721-11-4	EP 301167	Osteoporosis treatment	Osteodystrophy
secnidazole	1H-Imidazole-1-ethanol, Alpha,2-dimethyl-5-nitro- [CAS]	3366-95-8	FR M3270	Protozoacide	Infection, trichomoniasis
Secobarbital		309-43-3			
selegiline	Benzeneethanamine, N,Alpha-dimethyl-N-2-propynyl-, (R)- [CAS]	14611-51-9	GB 1153578	Antiparkinsonian	
Selenomethionine		1464-42-2			
Sematilide		101526-83-4			
Semotiadil		116476-13-2			
seocalcitol	1,3-Cyclohexanediol, 5-((1-(6-ethyl-6-hydroxy-1-methyl-2,4-octadienyl)octahydro-7a-methyl-4H-inden-4-ylidene)ethylidene)-4-methylene-, (1R- (1Alpha(1R*,2E,4E),3aβ,4E(1R*,3S*,5Z),7aAlpha))- [CAS]	134404-52-7	WO 9100855	Anticancer, other	Cancer, liver
Sepimostat		103926-64-3			
seratrodast	Benzeneheptanoic acid, zeta-(2,4,5-trimethyl-3,6-dioxo-1,4-cyclohexadien-1-yl)-, (+/-)- [CAS]	103187-07-1 112665-43-7	EP 232089	Antialthma	Asthma

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
sertaconazole	1H-Imidazole, 1-[2-[(7-chlorobenzol[blnien-3-yl)methoxy]-2-(2,4-dichlorophenyl)ethyl]-[CAS]	99592-32-2	EP 151477	Antifungal	Infection, dermatological
sertindole	2-Imidazolidinone, 1-[2-[4-[5-chloro-1-(4-fluorophenyl)-1H-indol-3-yl]-1-piperidinyl]ethyl]-[CAS]	106516-24-9	EP 392959	Neuroleptic	Schizophrenia
serttraline	1-Naphthalenamine, 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-N-methyl-, (1S-cis)-[CAS]	79559-97-0 79617-96-2 79617-97-3	EP 30081	Antidepressant	Depression, general
Setastine		64294-95-7			
sevelamer	2-Propen-1-amine polymer with (chloromethyl)oxirane, hydrochloride [CAS]	152751-57-0 52757-95-6	US 5496545	Urological	Renal failure
sevoflurane	Propane, 1,1,1,3,3,3-hexafluoro-2-(fluoromethoxy)-[CAS]	28523-86-6	DE 1954268	Anaesthetic, inhalation	Anaesthesia
SG-210	2H-1,4-Benzothiazine-2-acetic acid, 3,4-dihydro-3-oxo-4-[(4,5,7-trifluoro-2-benzothiazolyl)methyl]-[CAS]	143162-65-6		Symptomatic antidiabetic	Neuropathy, diabetic
sibutramine	Cyclobutanemethanamine, 1-(4-chlorophenyl)-N,N-dimethyl-Alpha-(2-methylpropyl)-[CAS]	106650-56-0 84485-00-7	GB 2098602	Anorectic/Antiobesity	Obesity
siccanin	(4aS-(4aAlpha,6aAlpha,11bAlpha,13aR*,13bAlp ha))-1,2,3,4,4a,5,6a,11b,13b-decahydro-4,4,6a,9-tetramethyl-13H-benzof[a]furo[2,3,4-mn]xanthen-11-ol	22733-60-4	JP 37003548	Antifungal	
sildenafil	Piperazine, 1-[(3-(4,7-dihydro-1-methyl-7-oxo-3-propyl-1H-pyrazolo[4,3-d]pyrimidin-5-yl)-4-ethoxyphenyl)sulfonyl]-4-methyl, 2-hydroxy-1,2,3-propanetricarboxylate- (1:1) [CAS]	171599-83-0 139755-83-2	WO 9428902	Male sexual dysfunction	Impotence
sildenafil	1H-Indole-7-carboxamide, 2,3-dihydro-1-(3-hydroxypropyl)-5-[(2R)-2-[[2-(2,2,2-trifluoroethoxy)phenoxy]ethyl]amino]propyl]-[CAS]	160970-54-7 128-00-7	EP 600675	Urological	Dysuria
Silver Lactate					

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
Silver Picrate	N'-2-pyrimidinylsulfanilamide monosilver salt	146-84-9 22199-08-2 68-35-9			
silver sulfadiazine				Anti-infective, other	Infection, general
Simetride		154-82-5			
Simfibrate		14929-11-4			
simvastatin	Butanoic acid, 2,2-dimethyl-, 1,2,3,7,8a-hexahydro-3,7-dimethyl-8-[2-(tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl)ethyl]-1-naphthalenyl ester, [1S-[1 α ,3 α ,7 β ,8 β (2S*,4S*),8a β]]-[CAS]	79902-63-9	US 4444784	Hypolipaeamic/Antiatherosclerosis	Hyperlipidaemia, general
Sincalide		25126-32-3			
Sintropium Bromide		79467-19-9			
Sisomicin		32385-11-8			
sitafloxacin	3-Quinolincarboxylic acid, 7-(7-amino-5-azaspiro[2.4]hept-5-yl)-8-chloro-6-fluoro-1-(2-fluorocyclopropyl)-1,4-dihydro-4-oxo-, [1R-[1 α pha(S*),2 α pha]]-, hydrate	127254-12-0	EP 341493	Quinolone antibacterial	Infection, general
sifamiquine	1,6-Hexanediamine, N,N-diethyl-N'-(6-methoxy-4-methyl-8-quinolyl)- [CAS]	5330-29-0 57695-04-2		Protozoacide	Infection, leishmaniasis
silaxsentan	N-(4-Chloro-3-methyl-5-isoxazolyl)-2-[[4,5-(methylenedioxy)-o-tolyl]acetyl]-3-thiophenesulfonamide	184036-34-8	US 5464853	Antihypertensive, other	Hypertension, pulmonary
sivelestat	Glycine, N-[2-[[[4-(2,2-dimethyl-1-oxopropoxy)phenyl]sulfonyl]amino]benzoyl]- [CAS]	127373-66-4	EP 347168	Respiratory	Systemic inflammatory response syndrome
SJA-6017	Butanamide, 2-[[[4-(fluorophenyl)sulfonyl]amino]-N-[(1S)-1-formyl-3-methylbutyl]-3-methyl-, (2S)-[CAS]	190274-53-4	EP 771565	Ophthalmological	Cataract
SL-65-1498	6-Fluoro-9-methyl-2-phenyl-4-pyrrolidin-1-ylcarbonyl)-2,9-dihydro-1H-pyrido[3,4-b]indole-1-one		EP 607076	Anxiolytic	Anxiety, general

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
SLV-306	(3S,2R)-3-[1-[2'-(Ethoxycarbonyl)-4'-phenyl-butyl]-cyclopentan-1-carbonylamino]-2,3,4,5-tetrahydro-2-oxo-1H-benzapin-1-acetic acid			Antihypertensive, diuretic	Hypertension, general
SLV-308	2-(3H)-Benzoxazolone, 7-(4-methyl-1-piperazinyl)-, monohydrochloride	269718-83-4		Antiparkinsonian	Parkinson's disease
Sm153 leixidronam	Samarate(5-)-153Sm, (((1,2-ethanedithiolbis(nitriobis(methylene)))tetraakis(phosphonato)))(8-)-N,N',OP',OP'',OP''', pentasodium, (OC-6-21)- [CAS]	160369-78-8		Analgesic, other	Pain, cancer
S-Methylmethionine		4727-40-6			
SMP-300	N-(Aminoinomethyl)-1,1-chloro-5,6,7,8-tetrahydro-8-oxo-4H-pyrrolo[3,2,1-kl][1]benzazocine-2-carboxamide monomethanesulfonate monohydrate			Antianginal	Angina, general
SN-38	(4S)-4,7,11-triethyl-3,4,12,14-tetrahydro-4,10-dihydroxy-3,14-dioxo-1H-pyrano[3',4':6,7]indolizino[1,2-b]quindin-9-yl	100286-90-6		Formulation, optimized, liposomes	Cancer, colorectal
SNAP-7941	((+)-methyl (4S)-3-[(3-{4-[3-(acetylamino)phenyl]-1-piperidinyl}propyl)amino] carbonyl]-4-(3,4-difluorophenyl)-6-(methoxymethyl)-2-oxo-1,2,3,4-tetrahydro-5-pyrimidinecarboxylate hydrochloride)			Anxiolytic	Anxiety, general
SOA-132	2-Naphthalenecarboxamide, N-[2-[4-(diphenylmethoxy)-1-piperidinyl]ethyl]-3-hydroxy-5-(3-pyridinylmethoxy)- [CAS]	143964-80-1		Formulation, inhalable, topical	Asthma

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
soblidotin	L-valinamide, N,N-dimethyl-L-valyl-N-[2-methoxy-4-[2-[1-methoxy-2-methyl-3-oxo-3-[(2-phenylethyl)amino]propyl]-1-pyrrolidinyl]-1-(2-methylpropyl)-4-oxobutyl]-N-methyl-, [2S-[1[1R*(R*),2S*],2R*(1S*,2S*)]]- [CAS]	149606-27-9	WO 9303054	Anticancer, other	Cancer, lung, non-small cell
Sobrerol		498-71-5			
sobuzoxane	Carbonic acid, 1,2-ethanedithybis(2,6-dioxo-4,1-piperazinediyl)methylenebis(2-methylpropyl) ester [CAS]	98631-95-9	EP 140327	Anticancer, other	Cancer, lymphoma, T-cell
Sodium Arsanilate		127-85-5			
Sodium Arspenamine		1936-28-3			
<i>Sodium Chloride</i>					
Sodium Dibunate		14992-59-7			
Sodium Folate		6484-89-5			
Sodium Formaldehydesulfoxylate		149-44-0			
Sodium Glycerophosphate		1334-74-3			
<i>Sodium Hyaluronate</i>					
Sodium Iodomethamate		519-26-6			
Sodium Nitrite		7632-00-0			
Sodium Nitroprusside		14402-89-2			
sodium oxybate	Butyric acid, 4-hydroxy monosodium salt [CAS]	502-85-2		Psychostimulant	Narcolepsy
Sodium Phenolsulfonate		1300-51-2			
sodium phenylbutyrate	Butyric acid, 4-phenyl-, sodium salt [CAS]	1716-12-7		Formulation, other	Hyperammonaemia

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
sodium phosphate	Sodium phosphate monobasic anhydrous		US 6162464	Formulation, oral, other	Surgery adjunct
sodium prasterone sulfate	3β-hydroxy-5-androsten-17-one(sodium sulfate dihydrate)		EP 380036	Formulation, mucosal, topical	Labour, induction
Sodium Propionate		137-40-6			
sodium salicylate	Benzoic acid, 2-hydroxy-, monosodium salt [CAS]	54-21-7		Formulation, oral, solubility-enhanced	Pain, general
Sodium Tetradecyl Sulfate		139-88-8			
sofalcone	Acetic acid, [5-[(3-methyl-2-butenyloxy]-2-[3-[4-[(3-methyl-2-butenyloxy)phenyl]-1-oxo-2-propenyl]phenoxy]- [CAS]	64506-49-6	GB 1523241	Antitumor	
Solasulfone		133-65-3			
	Butanedioic acid compd with (1S)-(3R)-1-azabicyclo(2.2.2)oct-3-yl 3,4-dihydro-1-phenyl-2(1H)-isoquinolinecarboxylate (1:1) [CAS]	242478-38-2		Urological	Overactive bladder
solifenacin	D-Glucitol, hexa-3-pyridinecarboxylate [CAS]	6184-06-1	BE 883352	Hypolipemic/Antiatherosclerosis	
Sorbinic acid		50-70-4			
Sorbitol		77181-69-2			
Sorivudine					
sotalol	Methanesulfonamide, N-[4-[1-hydroxy-2-[(1-methylethyl)amino]ethyl]phenyl]- [CAS]	3930-20-9 959-24-0		Antiarrhythmic	
Soterinol		13642-52-9			
Sozoiodolic Acid		554-71-2			
sparglumic acid	L-Glutamic acid, N-(N-acetyl-L-Alpha-aspartyl)- [CAS]	3106-85-2 80619-64-3		Formulation, mucosal, topical	Conjunctivitis
sparfloxacin	3-Quinolonecarboxylic acid, 5-amino-1-cyclopropyl-7-(3,5-dimethyl-1-piperazinyl)-6,8-difluoro-1,4-dihydro-4-oxo-, cis- [CAS]	110871-86-8	EP 221463	Quinolone antibacterial	Infection, respiratory tract, general
Sparteine		90-39-1			

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
SR-146131	1H-Indole-1-acetic acid, 2-[[[4-(4-chloro-2,5-dimethoxyphenyl)-5-(2-cyclohexylethyl)-2-thiazolyl]amino]carbonyl]-5,7-dimethyl- [CAS]	221671-61-0	WO 9915525	Anorectic/Antiobesity	Obesity
SR-271425	N-[1-[2-(diethylamino)ethylamino]-7-methoxy-9-oxo-9H-thioxanthene-4-ylmethyl]formamide			Anticancer, alkylating	Cancer, general
SR-27897	1H-Indole-1-acetic acid, 2-[[[4-(2-chlorophenyl)-2-thiazolyl]amino]carbonyl]- [CAS]	136381-85-6	EP 432040	Anticancer, other	Cancer, pancreatic
SR-31747	Cyclohexanamine, N-(3-(3-chloro-4-cyclohexylphenyl)-2-propenyl)-N-ethyl-, hydrochloride, (Z)- [CAS]	132173-07-0	EP 376850	Anticancer, other	Cancer, myeloma
SR-58611	Acetic acid, [[(7S)-7-[(2R)-2-(3-chlorophenyl)-2-hydroxyethyl]amino]-5,6,7,8-tetrahydro-2-naphthalenyl]oxy]-, ethyl ester, hydrochloride [CAS]	121524-09-2	EP 303546	GI inflammatory/bowel disorders	Irritable bowel syndrome
SS732	(R)-(-)-2-(2,4-difluorophenyl)-1-(ethylsulfonyl)-1,1-difluoro-3-(1H-1,2,4-triazol-1-yl)-2-propanol		US 5385900	Formulation, mucosal, topical	Infection, ocular
SS-750	Propanamide, N, N'(difluoro-2,1-ethanediy)bis(3-amino)- [CAS]		US 6083968	Antifungal	Infection, fungal, general
β -alethine	(2S,4R)-1-[5-chloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-3-(2-methoxyphenyl)-2-oxo-2,3-dihydro-1H-indol-3-yl]-4-hydroxy-N,N-dimethyl-2-pyrrolidine carboxamide	646-08-2		Anticancer, immunological	Cancer, myeloma
SSR-149415	2-(7-chloro-5-methyl-4-oxo-3-phenyl-4,5-dihydro-3H-pyridazinol[4,5-b]indol-1-yl)-N,N-dimethylacetamide		WO 0155130	Antidepressant	Depression, general
SSR-180575				Neuroprotective	Unspecified

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
SSR-181507	(3-Exo)-8-benzoyl-N-[(2S)-7-chloro-2,3-dihydro-1,4-benzodioxin-2-yl]methyl]-8-azabicyclo[3.2.1]octane-3-methanamine HCl		US 6221879	Neuroleptic	Schizophrenia
SSR-591813	(5aS,8S,10aR)-5a,6,9,10-tetrahydro,7H,11H-8,10a-methanopyrido[2',3':5,6]pyrano[2,3-d]azepine			Dependence treatment	Addiction, nicotine
SST-101	D-Glucitol, 1,4:3,6-dianhydro-, dinitrate [CAS]	87-33-2		Formulation, transdermal, other	Angina, general
SSY-726	(-)-(R)-3-Methyl-3-(methylsulfonyl)-1-(1,2,4-triazol-1-yl)-2-[4-(trifluoromethyl)phenyl]-2-butanol		US 5147886	Antifungal	Infection, fungal, general
ST-200	1-Propanaminium, 2-(acetyloxy)-3-carboxy-N,N,N-trimethyl-, chloride, (R)- [CAS]	5080-50-2	DE 3015635	Cognition enhancer	Dementia, senile, general
stachyfin			WO 9711947	Antiviral, other	Infection, influenza virus
Stallimycin		636-47-5			
Stampidine			US 6350736	Antiviral, anti-HIV	Infection, HIV/AIDS
Stannous Pyrophosphate		15578-26-4			
stannosporfin	(OC-6-13)-Dihydrogen dichloro[7,12-diethyl-3,8,13,17-tetramethyl-21H,23H-porphine-2,18-dipropionate(4-)-N21,N22,N23,N24]stannate(2-)	106344-20-1		Hepatoprotective	Hyperbilirubinaemia
Stanolone		521-18-6			
Stanozolol		10418-03-8 (2'H form); 302-96-5 (1'H form)			
Staph aureus ther			US 6376652	Genomics-based drug discovery	Infection, MRSA
STAT4 inhibitors			WO 9629341	Immunosuppressant	Unspecified

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
stavudine	Thymidine, 2',3'-dideoxy-3'-deoxy- [CAS]	3056-17-5	EP 501511	Antiviral, anti-HIV	Infection, HIV/AIDS
Stenbolone		5197-58-0			
stepronin	Glycine, N-[1-oxo-2-[(2-thienylcarbonyl)thio]propyl]- [CAS]	72324-18-6	US 4242354	Antitussive	Cough
Stibocaptate		27279-76-1			
Stibophen		15489-16-4			
Stilbamidine		122-06-5			
stiripentol	1-Penten-3-ol, 1-(1,3-benzodioxol-5-yl)-4,4-dimethyl- [CAS]	49763-96-4		Antiepileptic	Epilepsy, general
Streptodornase		37340-82-2			
Streptomycin		57-92-1			
Streptonicozid		5667-71-0			
Streptonigrin		3930-19-6			
Streptozocin		18883-66-4			
strontium ranelate	3-Thiopheneacetic acid, 5-[bis(carboxymethyl)amino]-2-carboxy-4-cyano-, strontium salt (1:2)- [CAS]	135459-87-9	EP 415850	Osteoporosis treatment	Osteoporosis
strontium-89 chloride	Strontium chloride (89SrCl ₂) [CAS]	38270-90-5		Analgesic, other	Pain, cancer
Succimer		304-55-2			
Succinimide		123-56-8			
Succinylcholine		55-94-7			
Succinylcholine		71-27-2			
Succinylsulfathiazole		116-43-8			
Succisulfone		5934-14-5			
Suclofenide		30279-49-3			
	Aluminium, hexadeca-μ-hydroxytetraacosahydroxy(μ ₈ -[1,3,4,6-tetra-O-sulfo-β-D-fructofuranosyl]-Alpha-D-glucopyranoside tetrakis(hydrogen sulfato)(8-)))hexadeca- [CAS]				
suclafate	Propanamide, N-[4-(methoxymethyl)-1-[2-(2-thienyl)ethyl]-4-piperidinyl]-N-phenyl- [CAS]	54182-58-0	JP 58208233	Antilucer, Formulation, oral, other	Ulcer, general
sufentanil		56030-54-7	US 3998834	Analgesic, other, formulation implant	Pain, general

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
sulbactam	4-Thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, 3,3-dimethyl-7-oxo-, 4,4-dioxide, (2S-cis)- [CAS]	68373-14-8	GB 2000138	Antibiotic, other	Infection, general
sulbactam + ampicillin		117060-71-6	US 4234579	Antibiotic, other	Infection, general
sulbenicillin	4-Thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, 3,3-dimethyl-7-oxo-6-[(phenylsulfoacetyl)amino]-, [2S-[2Alpha,5Alpha,6S(S*)]]- [CAS]	28002-18-8 41744-40-5			
Sulbentine		350-12-9	GB 1289358	Penicillin, injectable	Infection, pseudomonal
	Propanoic acid, 2-methyl-, dithiobis[3-[1-[[[4-amino-2-methyl-5-pyrimidinyl)methyl]formylamino]ethylidene]-3,1-propanediyl] ester [CAS]	3286-46-2 67-16-3			
sulbutamine				Neurological	Unspecified
sulconazole	1H-imidazole, 1-[2-[[[4-chlorophenyl)methyl]thio]-2-(2,4-dichlorophenyl)ethyl]-, (+/-)- [CAS]	61318-90-9 61318-91-0	US 4055652	Antifungal	Infection, fungal, general
Sulesomab		167747-19-5			
Sulfabenzamide		127-71-9			
Sulfacetamide		144-80-9			
Sulfachlorpyridazine		80-32-0			
Sulfachrysoidine		485-41-6			
Sulfacytine		17784-12-2			
Sulfadiazine		68-35-9			
Sulfadiazinamide		115-68-4			
Sulfadimethoxine		122-11-2			
Sulfadoxine		2447-57-6			
Sulfaethidole		94-19-9			
Sulfaguanidine		57-67-0			
Sulfaguanole		27031-08-9			
Sulfalene		152-47-6			
Sulfaloxic Acid		14376-16-0			
Sulfamerazine		127-79-7			
Sulfamer		651-06-9			
Sulfamethazine		57-68-1			

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
Sulfamethizole		144-82-1			
Sulfamethomidine		3772-76-7			
Sulfamethoxazole		723-46-6			
Sulfamethoxypyridazine		80-35-3			
Sulfametrole		32909-92-5			
Sulfamidochrysoidine		103-12-8			
Sulfamoxole		729-99-7			
Sulfanilamide		63-74-1			
Sulfanilic Acid		121-57-3			
Sulfanilylurea		547-44-4			
Sulfaperine		599-88-2			
Sulfaphenazole		526-08-9			
Sulfaproxyline		116-42-7			
Sulfapyrazine		116-44-9			
Sulfapyridine		144-83-2			
Sulfarside		1134-98-1			
Sulfarsphenamine		618-82-6			
sulfasalazine	Benzoic acid, 2-hydroxy-5-[4-[(2-pyridinylamino)sulfonyl]phenyl]azoyl- [CAS]	599-79-1		Formulation, oral, enteric-coated	Arthritis, rheumatoid
Sulfasomizole		632-00-8			
Sulfasymazine		1984-94-7			
Sulfathiazole		72-14-0			
Sulfathiourea		515-49-1			
Sulfinalol		66264-77-5			
Sulfinpyrazone		57-96-5			
Sulfiram		95-05-6			
Sulfisomidine		515-64-0			
Sulfisoxazole		127-69-5			
Sulfobromophthalein		71-67-0			
Sulfonethylmethane		76-20-0			

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
Sulfoniazide		3691-81-4			
Sulfonmethane		115-24-2			
Sulfuridazine		14759-06-9			
Sulfoxone		144-75-2			
sulindac	cis-5-fluoro-2-methyl-1-[(p-methylsulfinyl)benzylidene]indene-3-acetic acid	38194-50-2	US 3725548	Anti-inflammatory	Inflammation, general
Sulisatin		54935-03-4			
Sulisobenzonone		4065-45-6			
Sulmarin		29334-07-4			
Sulmazole		73384-60-8			
Suloctidil		54063-56-8			
Sulphan Blue		129-17-9			
sulpiride	Benzamide, 5-(aminosulfonyl)-N-[(1-ethyl-2-pyrrolidinyl)methyl]-2-methoxy-[CAS]	15676-16-1		Alimentary/Metabolic, other	
subprostone	5-Heptenamide, 7-[3-hydroxy-2-(3-hydroxy-4-phenoxy-1-butenyl)-5-oxocyclopentyl]-N-(methylsulfonyl)-, [1R-[1Alpha(Z),2R(1E,3R*),3Alpha]]- [CAS]	60325-46-4	US 4024179	Prostaglandin	Abortion
sultamicillin	4-Thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid, 6-((aminophenylacetyl)amino)-3,3-dimethyl-7-oxo-, (((3,3-dimethyl-7-oxo-4-thia-1-azabicyclo(3.2.0)hept-2-yl)carbonyloxy)methyl ester, S, S-dioxide, (2S-(2.alpha.(2R*,5S*),5.alpha.,6.beta.(S*))-[CAS]	117060-71-6 76497-13-7	GB 2044255	Penicillin, oral	Infection, general
Sulthiame		61-56-3			
sultopride	Benzamide, N-[(1-ethyl-2-pyrrolidinyl)methyl]-5-(ethylsulfonyl)-2-methoxy-[CAS]	53583-79-2	FR M5916	Neuroleptic	Psychosis, general
Sultosilic Acid		57775-26-5			

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
sumanirole	4H-Imidazo[4,5,1-ij]quinolin-2(1H)-one, 5,6-dihydro-5-(methylamino)-, (5R)-, (2Z)-2-butanedioate (1:1) [CAS]	179386-44-8	WO 9514020	Antiparkinsonian	Parkinson's disease
sumatriptan	1H-Indole-5-methanesulfonamide, 3-[2-(dimethylamino)ethyl]-N-methyl-, butanedioate (1:1)- [CAS]	103628-46-2 103628-48-4	EP 147107	Antimigraine	Migraine
SUN-N8075	1-(4-amino-2,3,5-trimethylphenoxy)-3-[4-{(4-fluorobenzyl)phenyl}piperazin-1-yl]propan-2(s)-ol dimethanesulfonate			Neuroprotective	Infarction, cerebral
suplatast	Sulfonium, [3-[[4-(3-ethoxy-2-hydroxypropoxy)phenyl]amino]-3-oxopropyl]dimethyl-, [CAS]	94055-76-2	JP 59167564	Antiasthma	Asthma
Suprofen		40828-46-4			
Suramin		129-46-4			
surfactant TA	Beractant [CAS]	108778-82-1	WO 9117766	Lung Surfactant	Respiratory distress syndrome, general
Suriclone		53813-83-5			
Suxibuzone		27470-51-5			
SYM-1010					
SYM-2081	L-Glutamic acid, 4-methyl-, (4R)- [CAS]	31137-74-3	US 5830998	Antiepileptic	Epilepsy, general
	4-(Aminophenyl)-1-methyl-6,7-(methylenedioxy)-N-butyl-1,2-dihydrophthalazine-2-carboxamide			Analgesic, other	Pain, general
SYM-2207				Neuroprotective	Ischaemia, cerebral
Synclosene		87-90-1			
Syn-1253	1-cyclopropyl-6-fluoro-8-methoxy-7-[3-(4-methyl-1,2,3-triazol-1-yl)pyrrolidin-1-yl]-4-oxo-1,4-dihydroquinoline 3-carboxylic acid			Quinolone antibacterial	Infection, peritoneum
Syn-2190	1-Azetidinesulfonic acid, 3-[[[2E)-1,4-dihydro-1,5-dihydroxy-4-oxo-2-pyridinyl]methoxy]imino]-2-thienylacetyl]amino]-2-methyl-4-oxo-, (2S,3S)- [CAS]	214963-75-4	WO 9847895	Antibacterial, other	Infection, general

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
Syn-2869	3H-1,2,4-Triazol-3-one, 4-(4-((1R,2R)-2-(2,4-difluorophenyl)-2-hydroxy-1-methyl-3-(1H-1,2,4-triazol-1-yl)propyl)-1-piperazinyl)phenyl)-2,4-dihydro-2((4-(trifluoromethoxy)phenyl)methyl)- [CAS]	210562-98-4	US 6153616	Antifungal	Infection, Aspergillus
Synephrine		94-07-5			
Syrosingopine		84-36-6			
T-1095	1-Propanone, 3-(5-benzofuran-1-yl)-2-hydroxy-6-((6-O-methoxycarbonyl)-β-D-glucopyranosyl)oxy)-4-methylphenyl- [CAS]	209746-59-8	EP 850948	Antidiabetic	Diabetes, general
T-1249	L-Phenylalaninamide, N-acetyl-L-tryptophyl-L-glutamyl-L-Alpha-glutamyl-L-tryptophyl-L-Alpha-glutamyl-L-glutamyl-L-lysyl-L-isoleucyl-L-threonyl-L-alanyl-L-leucyl-L-leucyl-L-Alpha-glutamyl-L-glutamyl-L-alanyl-L-glutamyl-L-isoleucyl-L-glutamyl-L-glutamyl-L-Alpha-glutamyl-L-tyrosyl-L-Alpha-glutamyl-L-asparagyl-L-tyrosyl-L-Alpha-glutamyl-L-leucyl-L-glutamyl-L-lysyl-L-leucyl-L-Alpha-aspartyl-L-lysyl-L-tryptophyl-L-ananyl-L-seryl-L-leucyl-L-tryptophyl-L-Alpha-glutamyl-L-tryptophyl- [CAS]	251562-00-2	WO 9959615	Antiviral, anti-HIV	Infection, HIV/AIDS
T-3912	1-cyclopropyl-8-methyl-7-[5-methyl-6-(methylamino)-3-pyridinyl]-4-oxo-1,4-dihydro-3-quinolinecarboxylic acid			Quinolone antibacterial	Infection, dermatological
T-588	Benzo(b)thiophene-5-methanol, Alpha-((2-(diethylamino)ethoxy)methyl)-, hydrochloride, (R)- [CAS]	142935-03-3	EP 565965	Cognition enhancer	Alzheimer's disease
T-57	Benzene-sulfonamide, 2,3,4,5,6-pentafluoro-N-(3-fluoro-4-methoxyphenyl)- [CAS]	195533-53-0		Anticancer, other	Cancer, liver
T-82			US 5190951	Cognition enhancer	Alzheimer's disease

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
TA-2005	2-(1H)-Quinolone, 8-hydroxy-5-[1-(hydroxy-2-[[2-(4-methoxyphenyl)-1-methylethyl]amino]ethyl)-, monohydrochloride, [R-(R*, R*)]- [CAS]	137888-11-0	US 4579854	Antiasthma	Asthma
TA-2005	2-(1H)-Quinolone, 8-hydroxy-5-[1-(hydroxy-2-[[2-(4-methoxyphenyl)-1-methylethyl]amino]ethyl)-, monohydrochloride, [R-(R*, R*)]- [CAS]		WO 189480	Formulation, inhalable, solution	Asthma
TA-993	1,5-Benzothiazepin-4(5H)-one, 3-(acetyloxy)-5-[2-(dimethylamino)ethyl]-2,3-dihydro-8-methyl-2-(4-methylphenyl)-, (2R,3R)-rel-(+), (2Z)-2-butenedioate [CAS]	122024-98-0	JP 01045376	Antithrombotic	Peripheral vascular disease
tabimorelin	(R)-Alpha-[(E)-5-Amino-N,5-dimethyl-2-hexenamido]-N-methyl-N-[(R)-Alpha-(methylcarbamoyl)phenethyl]-2-naphthalenepropanamide	170851-70-4 193079-59-5		Releasing hormones	Growth hormone deficiency
tacalcitol	9,10-Secosterolesta-5,7,10(19)-triene-1,3,24-triol, (1Alpha,3S,5Z,7E,24R)- [CAS]	57333-96-7 93129-94-3	EP 129003	Antipsoriasis	Keratosis
tacedinaline	Benzamide, 4-(acetylamino)-N-(2-aminophenyl)- [CAS]	112522-64-2 1884-40-8	DE 3613571	Anticancer, other	Cancer, pancreatic
tacrine	9-Acridinamine, 1,2,3,4-tetrahydro- [CAS]	321-64-2	EP 332147	Cognition enhancer	Alzheimer's disease
Tacrolimus	Pyrazino(1',2':1,6)pyrido(3,4-b)indole 1,4-dione, 6-(1,3-benzodioxol-5-yl)-2,3,6,7,12,12a-hexahydro-2-methyl-, (6R-trans) [CAS]	104987-11-3			
tadalafil	1,4-Pentanediamine, N4-[2,6-dimethoxy-4-methyl-5-[3-(trifluoromethyl)phenoxy]-8-quinolinyl]- [CAS]	171596-29-5 106635-80-7 106635-81-8 80065-55-0	US 6143746	Male sexual dysfunction	Impotence
tafenoquine	(S)-N-[2-(1,6,7,8-Tetrahydro-2H-indeno-[5,4-b]furan-8-yl)]propionamide	179067-42-6	US 4617394	Antimalarial	Infection, malaria
tafluposide			WO 9612727	Anticancer, other	Cancer, general
TAK-375				Hypnotic/Sedative	Insomnia

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
TAK-427	2-[6-[[3-[4-(Diphenylmethoxy)-piperidin-1-yl]-2-benzimidazol-2-yl]-2-methylpropionic acid dihydrate			Antipruritic/anti-inflammatory, allergic	Eczema, atopic
TAK-559	(E)-4-[4-[5-Methyl-2-phenyl-1,3-oxazol-4-yl)methoxy]benzoyloxyimino]-4-phenylbutyric acid			Antidiabetic	Diabetes, general
Taka-Diastase		9001-19-8			
talampanel	7H-1,3-Dioxolo[4,5-h][2,3]benzodiazepine, 7-acetyl-5-(4-aminophenyl)-8,9-dihydro-8-methyl-, (8R)- [CAS]	161832-65-1	US 5639751	Antiepileptic	Epilepsy, general
Talampicillin		47747-56-8			
talaporfin	N-[(2S,3S)-18-Carboxy-2-(2-carboxyethyl)-13-ethyl-2,3-dihydro-3,7,12,17-tetramethyl-8-vinyl porphyrin-20-yl]acetyl-L-aspartic acid	220201-34-3		Radio/chemosensitizer	Cancer, lung, general
Talastine		16188-61-7			
Talbutal		115-44-6			
Talinolol		57460-41-0			
talipexole	4H-Thiazolo[4,5-d]azepin-2-amine, 5,6,7,8-tetrahydro-6-(2-propenyl)- [CAS]	101626-70-4 36085-73-1	DE 3503963	Antiparkinsonian	Schizophrenia
talnetant	4-Quinolincarboxamide, 3-hydroxy-2-phenyl-N-[(1S)-1-phenylpropyl]- [CAS]	174636-32-9	WO 9532948	GI inflammatory/bowel disorders	Irritable bowel syndrome
talniflumate	3-Pyridinecarboxylic acid, 2-[[3-(trifluoromethyl)phenylamino]-, 1,3-dihydro-3-oxo-1-isobenzofuran-1-yl ester] [CAS]	66898-62-2	BE 858864	Anti-inflammatory	Inflammation, ocular
talirelin	L-Prolinamide, N-[(hexahydro-1-methyl-2,6-dioxo-4-pyrimidinyl)carbonyl]-L-histidyl-, (S)- [CAS]	103300-74-9	JP 61033197	Neurological	Dyskinesia, general
tamoxifen	Ethanolamine, 2-[4-(1,2-diphenyl-1-butenyl)phenoxy]-N,N-dimethyl-, (Z)- [CAS]	10540-29-1	US 4536516	Anticancer, hormonal	

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
tamsulosin	Benzenesulfonamide, 5-[2-[[2-(2-ethoxyphenoxy)ethyl]amino]propyl]-2-methoxy-, (R)- [CAS]	106133-20-4 80223-99-0	EP 34432	Prostate disorders	Benign prostatic hyperplasia
tandospirone	4,7-Methano-1H-isoindole-1,3(2H)-dione, hexahydro-2-[4-[4-(2-pyrimidinyl)-1-piperazinyl]butyl]-, (3aAlpha,4b,7b,7aAlpha)-, 2-hydroxy-1,2,3-propanetricarboxylate (1:1) [CAS]	112457-95-1 87760-53-0	EP 82402	Anxiolytic	Anxiety, general
Tannoform		9010-29-1			
Taprostene		108945-35-3			
tariquidar	3-Quinolincarboxamide, N-[2-[[[4-[2-(3,4-dihydro-6,7-dimethoxy-2(1H)-isoquinolinyl)ethyl]phenyl]amino]carbonyl]-4,5-dimethoxyphenyl]- [CAS]	206873-63-4	WO 9817648	Radiochemosensitizer	Cancer, lung, non-small cell
TAS-103	6-[[2-(Dimethyl-amino)ethyl]amino]-3-hydroxy-7H-indeno[2,1-c]quinolin-7-one dihydrochloride	174634-09-4	WO 9532187	Anticancer, other	Cancer, lung, non-small cell
Tasosartan		145733-36-4			
Taurocholic Acid		81-24-3			
Taurolidine		19388-87-5			
tazanolast	Acetic acid, oxo[[3-(1H-tetrazol-5-yl)phenyl]amino]-, butyl ester [CAS]	82989-25-1	US 4778816	Antisthma	
tazarotene	3-Pyridinecarboxylic acid, 6-[(3,4-dihydro-4,4-dimethyl-2H-1-benzothiopyran-6-yl)ethynyl]-, ethyl ester [CAS]	118292-40-3	EP 284288	Antipsoriasis	Psoriasis
Tazobactam		89786-04-9			
tazobactam + piperacillin			JP 58225091	Antibiotic, other	Infection, general
TBC-3711	N-Methyl-N-propargyl-10-aminomethyl-dibenzo(b,f)oxepin	374680-51-0		Cardiovascular	Heart failure
TCH-346	5-Hexenoic acid, 4-hydroxy-, polymer with 4-ethenyl-1H-imidazole [CAS]			Neuroprotective	Amyotrophic lateral sclerosis
tebipenem		82200-24-6		Beta-lactam antibiotic	Infection, streptococcal

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
tecadenoson	Adenosine, N-[(3R)-tetrahydro-3-furanyl]- [CAS]	204512-90-3	WO 9808855	Antiarrhythmic	Tachycardia, supraventricular
tecastemizole	1H-Benzimidazol-2-amine, 1-[(4-fluorophenyl)methyl]-N-4-piperidinyl- [CAS]	75970-99-9	US 4219559	Antiallergic, non-asthma	Rhinitis, allergic, seasonal
Technetium ^{99m}Tc		121281-41-2			
Bicisate					
Technetium ^{99m}Tc		125224-05-7;			
Mertiatide		104348-91-6			
Technetium ^{99m}Tc		109581-73-9			
Sestamibi					
Technetium ^{99m}Tc		104716-22-5			
Teboroxime					
Teclothiazide		4267-5-4			
Teclozan		5560-78-1			
tedisamil	Spiro[cyclopentane-1,9'- [3,7]diazabicyclo[3.3.1]nonane], 3',7'- bis(cyclopropylmethyl)- [CAS]	90961-53-8	EP 102833	Antiarrhythmic	Fibrillation, atrial
Teflurane		124-72-1			
tegafur	2,4(1H,3H)-Pyrimidinedione, 5-fluoro-1- (tetrahydro-2-furanyl)- [CAS]	17902-23-7	GB 1168391	Anticancer, antimetabolite	Cancer, general
tegafur + uracil	2,4(1H,3H)-Pyrimidinedione, 5-fluoro-1- (tetrahydro-2-furanyl)-, mixt. with 2,4(1H,3H)-pyrimidinedione- [CAS]	74578-38-4	EP 224885	Anticancer, antimetabolite	Cancer, breast
tegaserod	Hydrazinecarboximidamide, 2-[(5-methoxy- 1H-indol-3-yl)methylene]-N-pentyl-, (Z)-2- butenedioate [CAS]	189188-57-6 145158-71-0		GI inflammatory/bowel disorders	Irritable bowel syndrome
Teicoplanin		61036-64-4			
telbivudine	β-L-2'-deoxythymidine	3424-98-4		Antiviral, other	Infection, hepatitis-B virus
Telenzepine		80880-90-6			

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
telithromycin	3-De(2,6-dideoxy-3-C-methyl-3-O-methyl-Alpha-L-ribo-hexopyranosyl)oxy)-11,12-dideoxy-6-O-methyl-3-oxo-12,11-(oxycarbonyl)-((4-(4-(3-pyridinyl)-1H-imidazol-1-yl)butyl)imino))- [CAS]	191114-48-4	EP 680967	Macrolide antibiotic	Infection, respiratory tract, general
telmestaine	3,4-Thiazolidinedicarboxylic acid, 3-ethyl ester, (R)- [CAS]	122946-43-4		COPD treatment	Bronchitis, chronic
telmisartan	(1,1'-Biphenyl)-2-carboxylic acid, 4'-((1,4-dimethyl-2'-propyl(2,6'-bi-1H-benzimidazol)-1'-yl)methyl)- [CAS]	144701-48-4	EP 502314	Antihypertensive, renin system	Hypertension, general
telomerase inhibits			WO 9941261	Anticancer, other	Cancer, general
temazepam	7-chloro-1,3-dihydro-3-hydroxy-1-methyl-5-phenyl-2H-1,4-benzodiazepin-2-one	846-50-4	US 3197467	Hypnotic/Sedative	Insomnia
temiverine	Benzeneacetic acid, Alpha-cyclohexyl-Alpha-hydroxy-, 4-(diethylamino)-1,1-dimethyl-2-butynyl ester, [CAS]	129927-33-9	GB 2222828	Urological	Pollakiuria
temocapril	1,4-Thiazepine-4(5H)-acetic acid, 6-[[1-(ethoxycarbonyl)-3-phenylpropyl]amino]tetrahydro-5-oxo-2-(2-thienyl)-, [2S-[2Alpha,6(R*)]]- [CAS]	102090-90-4 110221-44-8 111902-57-9	US 4495188	Antihypertensive, renin system	Hypertension, general
Temocillin		66148-78-5			
temoporfin	Phenol, 3,3',3''-(2,3-dihydro-21H,23H-porphine-5,10,15,20-tetrayl)tetrakis- [CAS]	122341-38-2	EP 337601	Radio/chemosensitizer	Cancer, head and neck
temozolomide	Imidazol[5,1-c]-1,2,3,5-tetrazine-8-carboxamide, 3,4-dihydro-3-methyl-4-oxo- [CAS]	85622-93-1	DE 3231255	Anticancer, alkylating	Cancer, brain, general
tenatoprazole	1H-Imidazo(4,5-b)pyridine, 5-methoxy-2-(((4-methoxy-3,5-dimethyl-2-pyridinyl)methyl)sulfinyl)- [CAS]	113712-98-4	US 4808596	Antiulcer	Ulcer, gastric
Tenecteplase		191588-94-0			
Tenidap		120210-48-2			

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
teniposide	Furo[3',4':6,7]naphtho[2,3-d]-1,3-dioxol-6(5aH)-one, 5,8,8a,9-tetrahydro-5-(4-hydroxy-3,5-dimethoxyphenyl)-9-[4,6-O-(2-thienylmethylene)-6-D-glucopyranosyl]oxy], [5R-[5 α],5 α S,8 α S,9 α S(R*)]- [CAS] 29767-20-2		US 3524844	Anticancer, other	Cancer, lymphoma, non-Hodgkin's
tenofovir	Phosphonic acid, (((1R)-2-(6-amino-9H-purin-9-yl)-1-methylethoxy)methyl)- [CAS] 147127-20-6			Antiviral, anti-HIV	Infection, HIV/AIDS
tenofovir disoproxil	2,4,6,8-tetraoxa-5-phosphanonanediolic acid, 5-(2-(6-amino-9H-purin-9-yl)-1-methylethoxymethyl) bis(1-methylethylester, 5-oxide (R)-, (E)-2-butenedioate	202138-50-9		Antiviral, anti-HIV	Infection, HIV/AIDS
Tenonitroazole	2H-Thieno[2,3-e]-1,2-thiazine-3-carboxamide, 4-hydroxy-2-methyl-N-2-pyridinyl-, 1,1-dioxide [CAS]	3810-35-3			
tenoxicam		59804-37-4	GB 1519811	Antiarthritic, other	
Tenuazonic Acid		610-88-8			
teprenone	5,9,13,17-Nonadecatetraen-2-one, 6,10,14,18-tetramethyl- [CAS]	3796-63-2		Antitumor	
terazosin	Piperazine, 1-(4-amino-6,7-dimethoxy-2-quinazolinyl)-4-[(tetrahydro-2-furanyl)carbonyl]- [CAS]	63074-08-8 63590-64-7 70024-40-7	US 4112097	Antihypertensive, adrenergic	Hypertension, general
terbinafine	1-Naphthalenemethanamine, N-(6,6-dimethyl-2-hepten-4-ynyl)-N-methyl-, (E)- [CAS]	78628-80-5 91161-71-6	EP 24587	Antifungal	Infection, dermatological
terbutaline	1,3-Benzenediol, 5-[2-[(1,1-dimethylethyl)amino]-1-hydroxyethyl]- [CAS]	23031-25-6		Formulation, mucosal, topical	Dysmenorrhea
terconazole	Piperazine, 1-[4-[2-(2,4-dichlorophenyl)-2-(1H-1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]-4-(1-methylethyl)-, cis- [CAS]	67915-31-5	US 4358449	Antifungal	Vaginitis

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
terfenadine	1-Piperidinebutanol, Alpha-[4-(1,1-dimethylethyl)phenyl]-4-(hydroxydiphenylmethyl)- [CAS]	50679-08-8	US 3878217	Antiallergic, non-asthma	
terguride	Urea, N,N-diethyl-N'-[(8 α)-6-methylergolin-8-yl]- [CAS]	37686-84-3	EP 159522	Antiprolactin	Hyperprolactinaemia
Terlipressin		14636-12-5			
Terodiline		15793-40-5			
Terofenamate		29098-15-5			
Terpin		80-53-5			
	2-Propanol, 1-[(3,4-dihydro-2H-1-benzothio-pyran-8-yl)oxy]-3-[(1,1-dimethylethyl)amino]-, hydrochloride, (+)- [CAS]	33580-30-2 83688-84-0 34784-64-0			
tertatolol			GB 1308191	Antihypertensive, adrenergic	Hypertension, general
tert-Pentyl Alcohol		75-85-4			
tesaglitazar	(2S)-2-ethoxy-3-[4-[2-[4-[(methylsulfonyl)oxy]phenyl]ethoxy]phenyl]propanoic acid				
tesmilifene	Ethanamine, N,N-Diethyl-2-(4-phenylmethyl)phenoxy)- [CAS]	92981-78-7		Antidiabetic	Diabetes, Type II
Testolactone		968-93-4		Radio/chemosensitizer	Cancer, breast
Testosterone	androst-4-en-3-one, 17-hydroxy-, (17 β) - [CAS]	58-22-0 5949-44-0		Formulation, transdermal, systemic	Hormone replacement therapy
tetrabamate		60763-47-5	DE 2748794	Anxiolytic	Addiction, alcohol
Tetrabarbital		76-23-3			
Tetrabenazine		58-46-8			
Tetracaine		136-47-0			
Tetrachloroethylene		127-18-4			
tetracine	Benzoic acid, 4-(butylamino)-, 2-(dimethylamino)ethyl ester [CAS]	94-24-6		Formulation, transdermal, systemic	Pain, general
	2-Naphthacene-carboxamide, 4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,6,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-, [4S-(4 α),4 α ,5 α ,6 α ,12 α)]- [CAS]				
tetracycline		60-54-8		Formulation, oral, other	Infection, oral

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
Tetrahydrozoline		84-22-0			
Tetrandrine		518-34-3			
Tetrantoin		52094-70-9			
Tetrazepam		10379-14-3			
Tetrofosmin		127502-06-1			
tetroxoprim	2,4-Pyrimidinediamine, 5-[[3,5-dimethoxy-4-(2-methoxyethoxy)phenyl]methyl]-[CAS]	53808-87-0 74515-38-1	US 3992379	Trimethoprim and analogues	Infection, general
Tevenel®		4302-95-8			
tezacitabine	Cytidine, 2'-deoxy-2'-(fluoromethylene)-, (2E)- [CAS]	130306-02-4	US 5616702	Anticancer, antimetabolite	Cancer, colorectal
tezosentan	2-Pyridinesulfonamide, N-(6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)-2-(2-(1H-tetrazol-5-yl)-4-pyridinyl)-4-pyrimidinyl)-5-(1-methylethyl)- [CAS]	180384-57-0		Cardio stimulant	Oedema, general
thalidomide	1H-Isindole-1,3(2H)-dione, 2-(2,6-dioxo-3-piperidinyl)- [CAS]	50-35-1		Dermatological	Infection, dermatological
Thenaldine		86-12-4			
Theridiamine		91-79-2			
Theobromine		83-67-0			
Theofibrate		54504-70-0			
theophylline	1H-Purine-2,6-dione, 3,7-dihydro-1,3-dimethyl- [CAS]	58-55-9 5967-84-0		Formulation, modified-release, other	Asthma
Thiabendazole		148-79-8			
Thiacetazone		104-06-3			
thiacymserine	Carbamic acid, [4-(1-methylethyl)phenyl]-, (3aS,8aS)-3,3a,8,8a-tetrahydro-3a,8-dimethyl-2H-thieno[2,3-b]indol-5-yl ester [CAS]	145209-51-4		Cognition enhancer	Alzheimer's disease
Thialbarbital		467-36-7			
Thiamine		59-43-8			
Thiamine		154-87-0			
Thiamine		67-16-3			
Thiamiprine		5581-52-2			

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
Thiamphenicol		15318-45-3			
Thiamylal		77-27-0			
Thiazesim		5845-26-1			
Thiazinamium		58-34-4			
Thiazolinobutazone		54749-86-9			
Thiazolsulfone		473-30-3			
Thibenzazoline		6028-35-9			
Thiethylperazine		1420-55-9			
Thimerfonate		5964-24-9			
Thimerosal		54-64-8			
Thiobarbital		77-32-7			
Thiobutabarbital		2095-57-0			
Thiocarbamizine		91-71-4			
Thiocarbarsone		120-02-5			
Thiocolchicine		2730-71-4			
Thiocresol		26445-03-4			
Thioctic Acid		62-46-4			
Thioglycerol		96-27-5			
Thioguanine		154-42-7			
Thiomreg	L-Thietyrosinyl-glycyl-glycine			Anticancer, immunological	Cancer, general
Thiopental		71-73-8			
Thiopropazate		84-06-0			
Thiopropazine		316-81-4			
Thioridazine		50-52-2			
Thiothixene		5591-45-7			
Thiovir	Thiophosphonoformic acid			Antiviral, anti-HIV	Infection, HIV/AIDS
Thiophenamil		82-99-5			
Thiram		137-26-8			
Thonzylamine		63-56-9			
Thozalinone		655-05-0			
Thromboplastin		9035-58-9			

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
Thurfyl Nicotinate		70-19-9			
thymectacin			US 6245750	Anticancer, other	Cancer, colorectal
Thymol		89-83-8			
Thymopentin		69558-55-0			
Thymyl N-		578-20-1			
Isoamylcarbamate					
Thyropropic Acid		51-26-3			
Thyroxine		51-48-9			
Tiadenol		6964-20-1			
tiagabine	3-Piperidinecarboxylic acid, 1-[4,4-bis(3-methyl-2-thienyl)-3-butenyl]- (R)- [CAS]	115103-54-3	WO 8700171	Antiepileptic	Epilepsy, general
Tiamenidine		31428-61-2			
tianeptine	Heptanoic acid, 7-[(3-chloro-6,11-dihydro-6-methylbenzo[c,f][1,2]thiazepin-11-ylamino)]-, S,S-dioxide [CAS]	72797-41-2 66981-73-5	GB 1269551	Antidepressant	Depression, general
tiapride	Benzamide, N-[2-(diethylamino)ethyl]-2-methoxy-5-(methylsulfonyl)- [CAS]	51012-32-9	GB 1394563	Neuroleptic	
tiaprofenic acid	2-Thiopheneacetic acid, 5-benzoyl-Alpha-methyl- [CAS]	33005-95-7	GB 1331505	Antiarthritic, other	
Tiamide		32527-55-2			
tiazofurin	4-Thiazolecarboxamide, 2-B-D-ribofuranosyl- [CAS]	60084-10-8	EP 54432	Anticancer, antimetabolite	Cancer, leukaemia, chronic myelogenous
Tibezonium		54663-47-7			
tibolone	19-Norpregn-5(10)-en-20-yn-3-one, 17-hydroxy-7-methyl-, (7Alpha, 17Alpha)- [CAS]	5630-53-5	EP 389035	Menopausal disorders	Hormone replacement therapy
Ticarcillin		34787-01-4			
ticlopidine	Thieno[3,2-c]pyridine, 5-[(2-chlorophenyl)methyl]-4,5,6,7-tetrahydro- [CAS]	53885-35-1 55142-85-3	GB 1554424	Antithrombotic	
Ticrynafen		40180-04-9			
tiemonium	4-(3-hydroxy-3-phenyl-3-thien-2-yl-propyl)-4-methylmorpholinium	6252-92-2 144-12-7		Antispasmodic	

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
tigecycline	2-Naphthacene-carboxamide, 4,7-bis(dimethylamino)-9-[[[(1,1-dimethylethyl)amino]acetyl]amino]-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-, (4S,4aS,5aR,12aS)- [CAS]	220620-09-7	EP 582829	Tetracycline	Infection, general
Tigemonam		102507-71-1			
Tigloidine		495-83-0			
Tilidine		20380-58-9			
Tilisolol		85136-71-6			
tilmacoxib	Benzenesulfonamide, 4-(4-cyclohexyl-2-methyl-5-oxazolyl)-2-fluoro- [CAS]	180200-68-4	WO 9619463	Alimentary/Metabolic, other	Polyp
tiludronic acid	Phosphonic acid, [[(4-chlorophenyl)thio]methylene]bis- [CAS]	89987-06-4	EP 100718	Osteoporosis treatment	Paget's disease
Timentin		86482-18-0		Antibiotic, other	Infection, general
timopidum	Piperidinium, 3-[(2-thienylmethylene)-5-methoxy-1,1-dimethyl-, [CAS]	35035-05-3	GB 1358446	Antispasmodic	
Timiperone		57648-21-2			
timolol	(-)-1-(t-butylamino)-3-[(4-morpholino-1,2,5-thiadiazol-3-yl)oxy]-2-propanolmaleate (1:1) salt	26839-75-8 26921-17-5	GB 1253709	Antihypertensive, adrenergic, antiglaucoma	
Timonacic		444-27-9			
Tin Ethyl Etiopurpurin		113471-15-1			
tinazoline	1H-Indole, 3-[(4,5-dihydro-1H-imidazol-2-yl)thio]- [CAS]	62882-99-9	US 3376311	Vasodilator, peripheral	
Tinidazole		19387-91-8			
Tinoridine		24237-54-5			
Tiocarlide		910-86-1			
Tioclomarol		22619-35-8			
tioconazole	1H-Imidazole, 1-[2-[(2-chloro-3-thienyl)methoxy]-2-(2,4-dichlorophenyl)ethyl]-[CAS]	61675-64-7 65899-73-2	US 4062966	Antifungal	Infection, fungal, general
tiopronin	Glycine, N-(2-mercapto-1-oxopropyl)- [CAS]	1953-02-2	US 3246025	Urological	Homocystinuria

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
tiotropium	3-Oxa-9-azoniatricyclo(3.3.1.0 ^{2,4})nonane, 7-((hydroxydi-2-thienylacetyl)oxy)-9-dimethyl-, [CAS]	136310-93-5	EP 418716	COPD treatment	Chronic obstructive pulmonary disease
Tioxolone		4991-65-5			
Tiipeptide		5169-78-8			
tipifarnib	2-(1H)-Quinolone, 6-(amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl)-4-(3-chlorophenyl)-1-methyl [CAS]	192185-68-5 192185-72-1	WO 9716443	Anticancer, other	Cancer, breast
tipranavir	N-[3-1(R)-[4-Hydroxy-2-oxo-6(R)-(2-phenylethyl)-6-propyl-5,6-dihydro-2H-pyran-3-yl]propyl]phenyl]-5-(trifluoromethyl)pyridine-2-sulfonamide	174484-41-4		Antiviral, anti-HIV	Infection, HIV/AIDS
tiqizium	2H-Quinolizinium, 3-(di-2-thienylmethylene)octahydro-5-methyl-, [CAS]	71731-58-3	US 4205074	Antispasmodic	
tiropazamine	1,2,4-Benzotriazin-3-amine, 1,4-dioxide- [CAS]	20028-80-2 27314-97-2 5424-06-6	DE 2204574	Radio/chemosensitizer	Cancer, lung, non-small cell
Tiratricol		51-24-1			
tinilazad	Pregna-1,4,9(11)-triene-3,20-dione, 21-[4-(2,6-di-1-pyrrolidinyl-4-pyrimidinyl)-1-piperazinyl]-16-methyl-, (16Alpha)-, [CAS]	110101-65-0 110101-67-2 110101-66-1	WO 8701706	Neuroprotective	Haemorrhage, subarachnoid
tirofiban	L-Tyrosine, N-(butylsulfonyl)-O-[4-(4-piperidinyl)butyl]-, [CAS]	142373-60-2 144494-65-5	EP 478363	Antithrombotic	Infarction, myocardial
tiropamide	Benzene propanamide, Alpha-(benzoylamino)-4-[2-(diethylamino)ethoxy]-N,N-dipropyl-, (+)-, [CAS]	55837-29-1	DE 2503992	Antispasmodic	Muscle spasm, general
Titanium Sulfate		13825-74-6			
tixocortol	Pregn-4-ene-3,20-dione, 21-[(2,2-dimethyl-1-oxopropyl)thio]-11,17-dihydroxy-, (11S)- [CAS]	55560-96-8 61951-99-3	GB 1475795	Antiallergic, non-asthma, mucosal, topical	Rhinitis, allergic, general

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
tizanidine	2,1,3-Benzothiazol-4-amine, 5-chloro-N-(4,5-dihydro-1H-imidazol-2-yl)-[CAS]	51322-75-9	GB 1429926	Muscle relaxant	Spastic paralysis
TLK-199	Glycine, L-Gamma-glutamyl-S-(phenylmethyl)-L-cysteinyl-2-phenyl-, diethyl ester, (2R)- [CAS]	168682-53-9	US 5679643	Immunostimulant, other	Myelodysplastic syndrome
TLK-286	Glycine, L-Gamma-glutamyl-3-[(2-((bis(2-chloroethyl)amino)phosphinyloxy)ethyl)sulfonyl]-L-alanyl-2-phenyl-, (2R)- [CAS]	158382-37-7	US 5545621	Anticancer, other	Cancer, ovarian
TNF- β analogue			RU 2035185	Anticancer, immunological	Cancer, general
TNP-470		129298-91-5			
TO-186	Pregna-1,4-diene-3,20-dione, 9-fluoro-11 β ,17,21-trihydroxy-16 β ,21-methyl-, 17-butyrate 21-propionate [CAS]	5534-02-1		Antipruritic/inflamm. allergic	
tobramycin	O-3-amino-3-deoxy-Alpha-D-glucopyranosyl-(1,6)-O-(2,6-diamino-2,3,6-trideoxy-Alpha-D-ribo-hexopyranosyl-(1-4))-2-deoxy- [CAS]	32986-56-4		Formulation, inhalable, topical	Infection, respiratory tract, general
tocainide	Propanamide, 2-amino-N-(2,6-dimethylphenyl)- [CAS]	41708-72-9	US 4218477	Antiarrhythmic	Fibrillation, ventricular
Tocamphyl		5634-42-4			
todadesine	8-Chloroadenosine 3'5'-cyclic phosphate	41941-56-4		Anticancer, other	Cancer, colorectal
Tocoretinate		40516-48-1			
Todralazine		14679-73-3			
Tofenacin		15301-93-6			
tofilamilast	5H-Pyrazolo[3,4-c]-1,2,4-triazolo[4,3-a]pyridine,9-cyclopentyl-7-ethyl-6,9-dihydro-3-(2-thienyl)-	185954-27-2		Antiasthma	Asthma
tofisopam	5H-2,3-Benzodiazepine, 1-(3,4-dimethoxyphenyl)-5-ethyl-7,8-dimethoxy-4-methyl-[CAS]	22345-47-7	GB 1334271	Anxiolytic	Anxiety, general
Tolazamide		1156-19-0			

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
Tolazoline		59-98-3			
Tolbutamide		64-77-7			
tolcapone	Methanone, (3,4-dihydroxy-5-nitrophenyl)(4-methylphenyl)- [CAS]	134308-13-7	EP 237929	Antiparkinsonian	Parkinson's disease
tolcidate	Carbamothioic acid, methyl(3-methylphenyl)-, O-(1,2,3,4-tetrahydro-1,4-methanonaphthalen-6-yl) ester [CAS]	50838-36-3	GB 1364407	Antifungal	Infection, dermatological
Tolcyclamide		664-95-9			
tolevamer	Benzenesulfonic acid, 4-ethenyl-, homopolymer,				
tolfenamic acid	Benzoic acid, 2-[(3-chloro-2-methylphenyl)amino]- [CAS]	28038-50-8		Antibacterial, other	Infection, Clostridium, general
Tolindate		13710-19-5	DE 1543295	Anti-inflammatory	Inflammation, general
Toliprolol		27877-51-6			
Toliprolol		2933-94-0			
Tolmetin		26171-23-3			
Tolnafate		2398-96-1			
Tolonidine		4201-22-3			
Tolonium		92-31-9			
toloxatone	2-Oxazolidinone, 5-(hydroxymethyl)-3-(3-methylphenyl)- [CAS]	29218-27-7	GB 1250538	Antidepressant	
Tolperisone		728-88-1			
Tolpropamine		5632-44-0			
Tolrestat		82964-04-3			
tolserine	Carbamic acid, (2-methylphenyl)-, (3aS,8aR)-1,2,3,3a,8,8a-hexahydro-1,3a,8-trimethylpyrrolo[2,3-b]indol-5-yl ester [CAS]	145209-30-9		Cognition enhancer	Alzheimer's disease
tolterodine	Phenol, 2-(3-(bis(1-methylethylamino)-1-phenylpropyl)-4-methyl-, (R)- [CAS]	124937-51-5	EP 325571	Urological	Incontinence
	Benzamide, N-[4-[(7-chloro-2,3,4,5-tetrahydro-5-hydroxy-1H-1-benzazepin-1-yl)carbonyl]-3-methylphenyl]-2-methyl- [CAS]				
tolvaptan		150683-30-0	EP 450097	Cardiovascular	Heart failure

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
Tolycaine	Beta-D-Fructopyranose, 2,3:4,5-bis-O-(1-methylethyldene)-, sulfamate [CAS]	3686-58-6 97240-79-4			
Topiramate			EP 533483	Antiepileptic	Epilepsy, generalized, tonic-clonic
topoisomerase inhibitors			US 5733880	Anticancer, other	Cancer, general
topotecan	1H-Pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione, 9-[(dimethylamino)methyl]-4-ethyl-4,10-dihydroxy-, (S)- [CAS]	123948-87-8	EP 321122	Anticancer, other	Cancer, ovarian
torasemide	3-Pyridinesulfonamide, N-[[1-(methylethyl)amino]carbonyl]-4-[(3-methylphenyl)amino]- [CAS]	56211-40-6	US 4018929	Antihypertensive, diuretic	Hypertension, general
torcetrapib	ethyl (2R,4S)-4-[[3,5-bis(trifluoromethyl)benzyl]([methoxycarbonyl]amino)-2-ethyl-6-(trifluoromethyl)-3,4-dihydroquinoline-1(2H)-carboxylate	262352-17-0			
torcitabine	β-L-2'Deoxyctidine			Hypolipaeic/Antiatherosclerosis	Atherosclerosis
torsemifene	Ethanamine, 2-[4-(4-chloro-1,2-diphenyl-1-butenyl)phenoxy]-N,N-dimethyl-, (Z)-[CAS]	89778-26-7 89778-27-8	EP 95875	Antiviral, other	Infection, hepatitis-B virus
Torsemide		56211-40-6		Anticancer, hormonal	Cancer, breast
Tositumomab		208921-02-2			
tosufloxacin	1,8-Naphthyridine-3-carboxylic acid, 7-(3-amino-1-pyrrolidinyl)-1-(2,4-difluorophenyl)-6-fluoro-1,4-dihydro-4-oxo-, [CAS]	100490-36-6 115964-29-9	US 4704459	Quinolone antibacterial	Infection, urinary tract
tramadol	Cyclohexanol, 2-[(dimethylamino)methyl]-1-(3-methoxyphenyl)-, cis-(+)-[CAS]	27203-92-5 36282-47-0			
Tramadoline		1082-57-1		Analgesic, other	Pain, general
trandolapril	1H-Indole-2-carboxylic acid, 1-[2-[(1-carboxy-3-phenylpropyl)amino]-1-oxopropyl]octahydro-, [2S-[1[R*(R*)],2Alpha,3aAlpha,7aβ]-, [CAS]	87679-71-8 87679-37-6 52-53-9	DE 3151690	Antihypertensive, renin system	Hypertension, general

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
tranexamic acid	Cyclohexanecarboxylic acid, 4-(aminomethyl)-, trans- [CAS]	1197-18-8	US 3950405	Antifibrinolytic	Menstrual disorder, general
tranilast	Benzoic acid, 2-[[3-(3,4-dimethoxyphenyl)-1-oxo-2-propenyl]amino]- [CAS]	53902-12-8	US 3940422	Vulnery	Wound healing
trans-retinoic acid	Retinoic acid [CAS]	302-79-4		Anticancer, other	Cancer, general
Tranylcypromine	[1,2,4]Triazole[1,5-a]pyrimidin-7-amine, N,N-diethyl-5-methyl- [CAS]	155-09-9			
trapidil		15421-84-8	DD 55956	Vasodilator, coronary	
Trastuzumab		180288-69-1			
travoprost	5-Heptenoic acid, 7-(3,5-dihydroxy-2-(3-hydroxy-4-(3-(trifluoromethyl)phenoxy)-1-butenyl)cyclopentyl)-, 1-methylethylester (1R,1Alpha(Z),2S(1E,3R*),3Alpha,5Alpha) [CAS]	157283-68-6		Formulation, mucosal, topical	Glaucoma
Traxanox	1-Piperidineethanol, 4-hydroxy-Alpha-(4-hydroxyphenyl)-beta-methyl-4-phenyl-, (AlphaS, betaS)- [CAS]	58712-69-9			
traxoprodil		134234-12-1 188591-67-5		Analgesic, other	Pain, general
trazodone	1,2,4-Triazole[4,3-a]pyridin-3(2H)-one, 2-[3-[4-(3-chlorophenyl)-1-piperazinyl]propyl]- [CAS]	19794-93-5 23332-39-2	US 4215104	Antidepressant	
Tremacamra		155576-45-7			
Trenbolone		10161-33-8			
Trengestone		5192-84-7			
treosulfan	1,2,3,4-Butanetetrol, 1,4-dimethanesulfonate, [S-(R*,R*)]- [CAS]	299-75-2	WO 8401506	Anticancer, alkylating	
treptibutone	Benzenebutanoic acid, 2,4,5-triethoxy-Gamma-oxo- [CAS]	41826-92-0	GB 1387733	Antispasmodic	
treprostinal	Prosta-5,13-dien-1-oic acid, 6,9-epoxy-11,15-dihydroxy-, [5Z,9Alpha,11Alpha,13E,15S]- [CAS]	35121-78-9 61849-14-7	US 6054486	Formulation, parenteral, other	Hypertension, pulmonary
tretinoin	Retinoic acid [CAS]	302-79-4		Formulation, dermal, topical	Acne

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
tretoquinol	6,7-Isoquinolinediol, 1,2,3,4-tetrahydro-1-[(3,4,5-trimethoxyphenyl)methyl]-, (S)- [CAS]	18559-59-6 30418-38-3 21650-42-0	ZA 6802416	Antiasthma	
TRH		24305-27-9			
TRI-50b	TRI 50b [CAS]	226214-49-9		Antithrombotic	Thrombosis, general
Triacetin		102-76-1			
Triamcinolone Acetonide		76-25-5			
Triamcinolone Benetonide		31002-79-6			
Triamcinolone Hexacetonide		5611-51-8			
triamcinolone	Pregna-1,4-diene-3,20-dione, 9-fluoro-11,21-dihydroxy-16,17-[(1-methylethylidene)bis(oxy)]-, (11 β ,16 α) [CAS]	76-25-5 124-94-7		Formulation, inhalable, topical	Asthma
Triamterene		396-01-0			
Triapine	Triapine [CAS]	236392-56-6	US 6458816	Anticancer, antimetabolite	Cancer, leukaemia, general
Triaziquone		68-76-8			
triazolam	8-chloro-6-(2-chlorophenyl)-1-methyl-4H-[1,2,4]-triazolo[4,3-a][1,4]benzodiazepine	28911-01-5	US 3980790	Hypnotic/Sedative	Insomnia
Tribenoside		10310-32-4			
Trichlorfon		52-68-6			
Trichlormethiazide		133-67-5			
Trichlormethine		555-77-1			
Trichloroethylene		79-01-6			
Triclobisonium		79-90-3			
Triclocarban		101-20-2			
Triclofenol Piperazine		5714-82-9			
Triclofos		306-52-5			
Triclosan		3380-34-5			
Tricromyl		85-90-5			
Tridihexethyl iodide		125-99-5			

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
trientine	1,2-Ethanediamine, N,N-bis(2-aminoethyl)-, [CAS]	38260-01-4 112-24-3		Metabolic and enzyme disorders	Wilson's disease
Triethanolamine		102-71-6			
Triethylenemelamine		51-18-3			
Triethylenephosphoramide		545-55-1			
Triethylenethiophosphoramide		52-24-4			
Trifluoperazine		117-89-5			
Trifluoperidol		749-13-3			
Triflupromazine		146-54-3			
trifluridine	Thymidine, Alpha, Alpha, Alpha-trifluoro- [CAS]	70-00-8	US 3201387	Antiviral, other	Infection, herpes virus, general
triflusal	Benzoic acid, 2-(acetoxy)-4-(trifluoromethyl)- [CAS]	322-79-2	US 4096252	Antithrombotic	Thrombosis, general
Trihexyphenidyl		52-49-3			
trilostane	Androst-2-ene-2-carbonitrile, 4,5-epoxy-3,17-dihydroxy-, (4Alpha,5Alpha,17S)- [CAS]	13647-35-3			
Trimazosin		35795-16-5	US 3296255	Anticancer, hormonal	Cancer, breast
trimebutine	Benzoic acid, 3,4,5-trimethoxy-, 2-(dimethylamino)-2-phenylbutyl ester, (Z)-2-butenedioate (1:1) [CAS]	34140-59-5 39133-31-8	DE 2151716	Antispasmodic	
Trimecaine		616-68-2			
Trimeprazine		84-96-8			
Trimetazidine		5011-34-7			
Trimethadione		127-48-0			
Trimethaphan		68-91-7			
Trimethobenzamide		138-56-7			
Trimethoprim		738-70-5			
Trimetozine		635-41-6			
trimetrexate	2,4-Quinazolinodiamine, 5-methyl-6-[[[(3,4,5-trimethoxyphenyl)amino]methyl]- [CAS]	52128-35-5 82952-64-5	US 4391809	Antifungal	Infection, Pneumocystis jirovecii

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
tripramine	5H-Dibenz[b,f]azepine-5-propanamine, 10,11-dihydro-N,N,8-trimethyl-, (Z)-2-butenedioate (1:1) [CAS]	521-78-8 739-71-9		Antidepressant	
Trimoprostil		69900-72-7			
Trioxsalen		3902-71-4			
tripamide	Benzamide, 3-(aminosulfonyl)-4-chloro-N-(octahydro-4,7-methano-2H-isoindol-2-yl)-, (3aAlpha,4Alpha,7Alpha,7aAlpha)- [CAS]	73803-48-2	JP 7305585	Antihypertensive, diuretic	Hypertension, general
Triparanol		78-41-1			
Tripelennamine		91-81-6			
Tripolidine		486-12-4			
triptorelin	Luteinizing hormone-releasing factor (pig), 6-D-tryptophan- [CAS]	124508-66-3 57773-63-4	US 4010125	Releasing hormones	Cancer, prostate
tritizine	Morpholine, 4-[[thioxo(3,4,5-trimethoxyphenyl)methyl]- [CAS]	35619-65-9	US 3862138	Antulcer	
Tritogualine		14504-73-5			
TRK-530	Phosphonic acid, [[[(4-(methylthio)phenylthio)methylene]bis-, disodium salt [CAS]	151425-92-2	WO 9410181	Antiarthritic, other	Arthritis, rheumatoid
TRK-820	2-Propenamide, N-[(5Alpha,6S)-17-(cyclopropylmethyl)-4,5-epoxy-3,14-dihydroxymorphinan-6-yl]-3-(3-furanyl)-N-methyl-, monohydrochloride, (2E)- [CAS]	152658-17-8	WO 9315081	Antipruritic/inflam, non-allergic	Pruritus
Troclosene		2244-21-5			
trofosamide	3-2-(chloroethyl)-2-[bis(2-chloroethyl)amino]tetrahydro-2H-1,3,2-oxazaphosphorin 2-oxide	22089-22-1	GB 1188159	Anticancer, alkylating	
Troglitazone		97322-87-7			
Troleandomycin		2751-9-9			
Trolnitrate		588-42-1			
tromantidine	N-(1-adamantyl)-2-(2-dimethylaminoethoxy)acetamide	53783-83-8	DE 1941218	Antiviral, other	Infection, herpes simplex virus
Tromethamine		77-86-1			

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
Tuaminoheptane		123-82-0			
Tubercidin		69-33-0			
Tubocurarine Chloride		57-94-3			
tiolbuterol	Benzenemethanol, 2-chloro-Alpha-[(1,1-dimethylethyl)amino]methyl-, [CAS]	41570-61-0	DE 2244737	Asthma	Asthma
TV-3326	N-(Propargyl-(3R)aminoindan-5-yl)-ethyl methyl carbamate			Cognition enhancer	Alzheimer's disease
TY-11223	Acetic acid, [2-[2,3,3a,6,7,7a-hexahydro-2-hydroxy-1-(3-hydroxy-4,4-dimethyl-1,6-nonadynyl)-1H-inden-5-yl]ethoxy]-, [1S-[1Alpha(R*),2B,3aAlpha,7aAlpha]]- [CAS]	140694-43-5	US 4837342	Antithrombotic	Unspecified
TY-12533	6,7,8,9-Tetrahydro-2-methyl-5H-cyclohepta[b]pyridine-3-carbonylguanidine maleate				
TYB-3215	D-Glucitol, 1,4:3,6-diannhydro-, dinitrate [CAS]	87-33-2	US 6258829	Antiarrhythmic	Unspecified
Tybamate		4268-36-4		Formulation, modified-release, other	Angina, general
tyloxapol	4-(1,1,3,3-Tetramethylbutyl)phenol polymer with formaldehyde and oxirane [CAS]	25301-02-4		Formulation, inhalable, topical	Cystic fibrosis
Tymazoline		24243-97-8			
Tyramine		51-67-2			
Tyropanoate		7246-21-1			
Ubenimex		58970-76-6			
ufenamate	Benzoic acid, 2-[[3-(trifluoromethyl)phenyl]amino]-, butyl ester [CAS]	67330-25-0	BE 861852	Antipruritic/Inflamm, non-allergic	
Undecylenic Acid		112-38-9			
Unoprostone		120373-36-6			

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
UR-8880	4-[4-Chloro-5-(3-fluoro-4-methoxyphenyl)imidazol-1-yl]benzenesulfonamide- [CAS]				
Uracil Mustard		66-75-1		Anti-inflammatory	Inflammation, general
Uralyt-U	1,2,3-Propanetricarboxylic acid, 2-hydroxy-, potassium sodium salt (5:6:6), hydrate [CAS]	55049-48-4	US 4400535	Urological	
urapidil	2,4-(1H,3H)-Pyrimidinone, 6-[3-[4-(2-methoxyphenyl)-1-piperazinyl]propylamino]-1,3-dimethyl- [CAS]	34661-75-1	GB 1309324	Antihypertensive, adrenergic	Hypertension, general
urea	Urea [CAS]	57-13-6		Antipsoriasis	
Uredepa		302-49-8			
Urethan		51-79-6			
Uridine 5'-Triphosphate		63-39-8			
Urinastatin		80449-31-6			
ursodeoxycholic acid	3Alpha,7beta-dihydroxy-5beta-cholan-24-oiic acid [CAS]	128-13-2		Formulation, other, Cirrhosis, primary biliary, hepatic dysfunction, biliary calculus	Cirrhosis, primary biliary
Ursodiol		128-13-2			
Usher cell					
Uzarin		20231-81-6	US 6063773	Formulation, mucosal, topical	Contraceptive, female
valaciclovir	L-Valine, 2-[(2-amino-1,6-dihydro-6-oxo-9H-purin-9-yl)methoxy]ethyl ester [CAS]	124832-26-4	EP 308065	Antiviral, other	Infection, herpes simplex virus
Valacyclovir		124832-26-4			
valdecoxib	Benzenesulfonamide, 4-(5-methyl-3-phenyl-4-isoxazolyl)- [CAS]	181695-72-7	US 5859257	Antiarthritic, other	Arthritis, rheumatoid
Valdetamide		512-48-1			
Valethamate		90-22-2			
valganciclovir	L-Valine, 2-[(2-amino-1,6-dihydro-6-oxo-9H-purin-9-yl)methoxy]-3-hydroxypropyl ester [CAS]	175865-59-5 175865-60-8			
Valnoctamide		4171-13-5	EP 694547	Antiviral, other	Infection, cytomegalovirus

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
valomacido vir	L-Valine (3R)-3-((2-amino-1,6-dihydro-6-oxo-9H-purin-9-yl)methyl)-4-((1-oxooctadecyl)oxy)butyl ester [CAS]	195156-77-5			Infection, herpes simplex virus
valproate	Pentanoic acid, 2-propyl-, [CAS]	76584-70-8 1069-66-5	US 4988731	Antiviral, other	Epilepsy, generalized, tonic-clonic
Valproic Acid		99-66-1		Antiepileptic	
Valpromide		2430-27-5			
valroceamide	Pentanamide, N-(2-amino-2-oxoethyl)-2-propyl-, [CAS]	92262-58-3	US 5585358	Antiepileptic	Epilepsy, general
valrubicin	Pentanoic acid, 2-(1,2,3,4,6,11-hexahydro-2,5,12-trihydroxy-7-methoxy-6,11-dioxo-4-((2,3,6-trideoxy-3-((trifluoroacetyl)amino)-Alpha-L-lyxo-hexopyranosyl)oxy)-2-naphthacetyl)-2-oxoethyl ester (2S-cis)-[CAS]	56124-62-0	US 4035566	Anticancer, antibiotic	Cancer, bladder
valsartan	L-Valine, N-(1-oxopentyl)-N-[[2'-(1H-tetrazol-5-yl)[1',1'-biphenyl]-4-yl]methyl]-[CAS]	137862-53-4 121584-18-7	EP 443983	Antihypertensive, renin system	Hypertension, general
Valspodar					
varidenafil	Piperazine, 1-(3-(1,4-dihydro-5-methyl-(4-oxo-7-propylimidazo(5,1-f)(1,2,4)-triazin-2-yl)-4-ethoxyphenyl)sulfonyl)-4-ethyl-, [CAS]	224785-90-4		Male sexual dysfunction	Sexual dysfunction, male, general
varespladib	Acetic acid, ((3-(aminooxocetyl)-2-ethyl-1-(phenylmethyl)-1H-indol-4-yl)oxy)-, [CAS]	172732-68-2 172733-42-5	EP 675110	Septic shock treatment	Sepsis
<i>Varicella Vaccine</i>					
valanidipine	3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-, 2-[4-[(diphenylmethyl)-1-piperazinyl]phenyl]ethyl methyl ester, [CAS]	116308-55-5 133743-71-2	EP 257616	Neuroprotective	Hypertension, general
VFA			US 6007817	Radio/chemosensitizer	Cancer, general

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
vecuronium	Piperidinium, 1-[2-(3,3,3-trifluoro-1-phenyl-1-oxo-2-phenylethoxy)-2-(1-piperidinyl)androst-16-enyl]-1-methyl-, [CAS]	50700-72-6	US 4237126	Muscle relaxant	Anaesthesia, adjunct
Velnacrine		104675-29-8			
venlafaxine	Cyclohexanol, 1-[2-(dimethylamino)-1-(4-methoxyphenyl)ethyl]-, [CAS]	93413-69-5			
Verapride		99300-78-4	GB 2227743	Antidepressant	Depression, general
		66644-81-3			
verapamil	Benzeneacetonitrile, Alpha-[3-[[2-(3,4-dimethoxyphenyl)ethyl]methylamino]propyl]-3,4-dimethoxy-Alpha-(1-methylethyl)-, [CAS]				
verteporfin	23H,25H-Benzol[6]porphine-9,13-dipropionic acid, 18-ethenyl-4,4a-dihydro-3,4-bis(methoxycarbonyl)-4a,8,14,19-tetramethyl-, monomethyl ester, trans-, [CAS]	52-53-9		Formulation, modified-release, other	Hypertension, general
vesnarinone	Piperazine, 1-(3,4-dimethoxybenzoyl)-4-(1,2,3,4-tetrahydro-2-oxo-6-quinolinyl)-, [CAS]	129497-78-5	US 5238940	Ophthalmological	Macular degeneration
Vetrabutine					
VF-233	Benzene carboximidamide, N,3,4,5-tetrahydroxy-, [CAS]	81840-15-5	GB 2086896	Cardio stimulant	Heart failure
VI-0134		3735-45-3			
vidarabine	9H-Purin-6-amine, 9-β-D-arabinofuranosyl-, [CAS]	95933-74-7	US 4623659	Cardiovascular	Reperfusion injury
vigabatrin	5-Hexenoic acid, 4-amino-, [CAS]	24356-66-9	US 6403597	Male sexual dysfunction	Premature ejaculation
vilazodone	2-Benzofurancarboxamide, 5-[4-{4-(5-cyano-1H-indol-3-yl)butyl}-1-piperazinyl]-, [CAS]	5536-17-4	GB 1159290	Antiviral, other	Infection, herpes virus, general
Viloxazine		68506-86-5	GB 1472525	Antiepileptic	Epilepsy, partial (focal, local)
Viminol		86-9			
Vinbarbital		163521-12-8	EP 648767	Antidepressant	Depression, general
Vinblastine		46817-91-8			
		21363-18-8			
		125-44-0			
vinburnine	Eburnamenin-14(15H)-one, (3Alpha,16Alpha)-, [CAS]	865-21-4			
		474-00-0			
		4880-89-0	DE 1932245	Cognition enhancer	

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
Vincamine		1617-90-9			
Vincosate		70704-03-9			
vincristine	Vincalukoblastine, 22-oxo-, sulfate (1:1) (salt) [CAS]	2068-78-2 57-22-7	EP 207831	Formulation, parenteral, other	Cancer, general
vindesine	Vincalukoblastine, 3-(aminocarbonyl)-O4-deacetyl-3-de(methoxycarbonyl)- [CAS]	53643-48-4 59917-39-4	GB 1463575	Anticancer, other	Cancer, leukaemia, acute lymphocytic
vinflunine	Aspidospermidine-3-carboxylic acid, 4-(acetyloxy)-6,7-didehydro-15-[(2R,4R,6S,8S)-4-(1,1-difluoroethyl)-1,3,4,5,6,7,8,9-octahydro-8-(methoxycarbonyl)-2,6-methano-2H-azecino[4,3-b]indol-8-yl]-3-hydroxy-16-methoxy-1-methyl-, methyl ester, (2S,3S,4S,5Apha,12S,19Apha) - [CAS]	162652-95-1	FR 2707988	Anticancer, other	Cancer, general
vinorelbine	C'-Norvincalukoblastine, 3',4'-didehydro-4'-deoxy- [CAS]	71486-22-1	EP 10458	Anticancer, other	Cancer, lung, non-small cell
vinpocetine	Eburnamenine-14-carboxylic acid, ethyl ester, (3Apha,16Apha)- [CAS]	42971-09-5	GB 1405127	Cognition enhancer	Cognitive disorder, general
Vinyl Ether		109-93-3			
Vinylbital		2430-49-1			
Viquidil		84-55-9			
Viridin		3306-52-3			
Visnadine		477-32-7			
Vitamin A		68-26-8			
vitamin B12	Vitamin B12 [CAS]	68-19-9		Formulation, transmucosal, nasal	Anaemia, general
vitamin C	L-Ascorbic acid [CAS]	50-81-7		Formulation, modified-release, <=24hr	Nutrition
Vitamin D ₂		50-14-6			
Vitamin D ₃		67-97-0			
Vitamin K ₅		83-70-5			
Vitamins, Prenatal					

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
VLA-4 antagonists	((R,S)-4-(4-(Amino-imino-methyl)-phenyl)-3-((4-biphenyl)-methyl)-4-methyl-2,5-dioximidazolidin-1-yl)-acetyl-L-N-methyl-aspartyl-L-phenylglycine		EP 842943	Antiasthma	Asthma
VNP-40101M	1,2-Bis(methylsulfonyl)-1-(2-chloroethyl)-2-(methylamino)carbonylhydrazine		US 6040338	Anticancer, alkylating	Cancer, general
voglibose	D-epi-Inositol, 3,4-dideoxy-4-[[2-hydroxy-1-(hydroxymethyl)ethyl]amino]-2-C-(hydroxymethyl)- [CAS]	83480-29-9	EP 56194	Antidiabetic	Diabetes, Type II
voriconazole	4-Pyrimidineethanol, Alpha-(2,4-difluorophenyl)-5-fluoro-8-methyl-Alpha-(1H-1,2,4-triazol-1-yl)methyl-, (R-(R*,S*))-[CAS]	137234-62-9	EP 440372	Antifungal	Infection, fungal, general
Vorozole	7-[3-[4-(2-Quinoliny)methyl]-1-piperazinyl]propoxy]-3,4-dihydro-2H-1,4-benzothiazine-3-one	129731-10-8			
VUF-K-8788				Antiasthma	Asthma
Warfarin		81-81-2		Radio/chemoprotective	Chemotherapy-induced injury, bone marrow, general
WF-10	Tetrachlorodecaoxide [CAS]	92047-76-2			
WMC-79	2-(3-[4-[3-(6-oxo-6H-2,10b-diaza-acenanthrylen-5-ylamino)propyl]-piperazin-1-yl]propyl)-5-nitro-2-azaphenylene-1,3-dione			Anticancer, other	Cancer, colorectal
wound healing matrix			US 5897880	Formulation, transdermal, patch	Ulcer, diabetic
WP-170			US 6531121	Cytokine	Unspecified
xaliproden	Pyridine, 1,2,3,6-tetrahydro-1-[2-(2-naphthalenyl)ethyl]-4-[3-(trifluoromethyl)phenyl]-, [CAS]	90494-79-4 135354-020-8	EP 101381	Neuroprotective	Amiotrophic lateral sclerosis
xamoterol	4-Morpholinecarboxamide, N-[2-[[2-hydroxy-3-(4-hydroxyphenoxy)propyl]amino]ethyl]-, (+)-[CAS]	73210-73-8 81801-12-9	GB 2002748	Cardio stimulant	Heart failure

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
Xanomeline		131986-45-3			
Xanthinol Niacinate		437-74-1			
Xemilofiban		149820-74-6			
Xenbucin		959-10-4			
Xibenolol		81584-06-7			
xibornol	Phenol, 4,5-dimethyl-2-(1,7,7-trimethylbicyclo[2.2.1]hept-2-yl)-, exo-[CAS]	13741-18-9	GB 1206774	Antibacterial, other	Infection, general
ximelagatran	Glycine, N-((R)-cyclohexyl-2-((2S)-2-(((4-(hydroxyamino)iminomethyl)phenyl)methyl)amino)carbonyl)-1-azetidinyl)-2-oxoethyl ester [CAS]	192939-46-1		Antithrombotic	Thrombosis, venous
Ximoprofen		56187-89-4			
xipamide	Benzamide, 5-(aminosulfonyl)-4-chloro-N-(2,6-dimethylphenyl)-2-hydroxy- [CAS]	14293-44-8	US 3567777	Antihypertensive, diuretic	
xorphanol	Morphinan-3-ol, 17-(cyclobutylmethyl)-8-methyl-6-methylene-, (8S)- [CAS]	77287-89-9		Analgesic, other	Pain, cancer
	2,5-Piperazinedione, 3-[[5-[2-(dimethylamino)ethyl]thio]-2-thienyl]methylene]-6-(phenylmethylene)-, monohydrochloride, (3Z,6Z)- [CAS]				
XR-5118	N,N'-(1,2-Ethanediy)bis(imino-2,1-ethanediyl)bis(9-methylphenazine-1-carboxamide)	174766-49-5	WO 9532190	Anticancer, other	Cancer, general
XR-5944					
Xylometazoline		526-36-3	EP 934278	Anticancer, other	Cancer, general
Xylose		58-86-6			
	2-Pyrimidinamine, 4-(3,4-dihydro-1-methyl-2(1H)-isoquinolyl)-N-(4-fluorophenyl)-5,6-dimethyl-, monohydrochloride [CAS]				
YH-1885		178307-42-1	WO 9605177	Antiulcer	Ulcer, GI, general
YM-511	Benzonitrile, 4-[[[(4-bromophenyl)methyl]-4H-1,2,4-triazol-4-ylamino]- [CAS]	148869-05-0	WO 9305027	Anticancer, hormonal	Cancer, breast

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
YM-598	potassium(E)-N-[6-methoxy-5-(2-methoxyphenoxy)-2-(pyrimidin-2-yl)pyrimidin-4-yl]-2-phenylethanesulfonamide			Anticancer, other	Cancer, prostate
Yohimbine		146-48-5			
YT-146	Adenosine, 2-(1-octynyl)- [CAS]	90596-75-1	US 5270304	Anti-inflammatory	Inflammation, general
Z-321	Thiazolidine, 3-((2,3-dihydro-1H-inden-2-yl)acetyl)-4-(1-pyrrolidinylcarbonyl)-, (R)- [CAS]	130849-58-0	EP 372484	Cognition enhancer	Dementia, senile, general
Z-335	(1H-Indene-5-acetic acid, 2[[[(4-chlorophenyl)sulfonylamino]methyl]-2,3-dihydro, monosodium salt] [CAS]	146731-14-8	JP 92506077	Antithrombotic	Peripheral vascular disease
zafirlukast	Carbamic acid, [3-[[[2-methoxy-4-[[[(2-methylphenyl)sulfonylamino]carbonyl]phenyl]methyl]-1-methyl-1H-indol-5-yl], cyclopentyl ester [CAS]	107753-78-6	EP 199543	Antiasthma	Asthma
zalcitabine	Cytidine, 2',3'-dideoxy- [CAS]	7481-89-2	US 4879277	Antiviral, anti-HIV	Infection, HIV/AIDS
Zaldaride		109826-26-8			
zaleplon	Acetamide, N-[3-(3-cyanopyrazolo[1,5-a]pyrimidin-7-yl)phenyl]-N-ethyl- [CAS]	151319-34-5	EP 776898	Hypnotic/Sedative	Insomnia
zaltoprofen	Dibenzolb[thiophene]-2-acetic acid, 10,11-dihydro-Alpha-methyl-10-oxo- [CAS]	74711-43-6	JP 55053282	Anti-inflammatory	
zanamivir	5-Acetamido-2,6-anhydro-3,4,5-trideoxy-4-guanidino-D-glycero-D-galacto-non-2-enonic acid [CAS]	139110-80-8	WO 9116320	Antiviral, other	Infection, influenza virus
zanapazil	1-Propanone, 3-(1-(phenylmethyl)-4-piperidinyl)-1-(2,3,4,5-tetrahydro-1H-1-benzazepin-8-yl)- [CAS]	142852-50-4	EP 487071	Cognition enhancer	Alzheimer's disease
Zatebradine		85175-67-3			
ZD-0473	Platinum, amminedichloro(2-methylpyridine)- (SP-4-3)- [CAS]	181630-15-9	EP 727430	Anticancer, alkylating	Cancer, ovarian
ZD-0947			WO 9528388	Urological	Overactive bladder
ZD-6126	N-acetylcolchicol-O-phosphate			Anticancer, other	Cancer, general
ZD-9331	1H-Tetrazole-5-butanoic acid, Alpha-((4-(((1,4-dihydro-2,7-dimethyl-4-oxo-6-quinazolinyl)methyl)-2-propynylamino)-2-fluorobenzoyl)amino) (S)- [CAS]	153537-73-6	GB 2264946	Anticancer, antimetabolite	Cancer, pancreatic

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
zebularine	2-(1H)-Pyrimidinone, 1-β-D-ribofuranosyl- [CAS]	3690-10-6		Anticancer, other	Cancer, general
zelandopam	7,8-Isoquinolinediol, 4-(3,4-dihydroxyphenyl)-1,2,3,4-tetrahydro-, [CAS]				
Zenarestat		138086-00-7	JP 03190818	Vasodilator, renal	Hypertension, general
Ziconotide		112733-06-9			
zidovudine	Thymidine, 3'-azido-3'-deoxy- [CAS]	107452-89-1			
zileuton	Urea, N-(1-benzob[thien-2-yl)ethyl)-N-hydroxy- [CAS]	30516-87-1	US 4724232	Antiviral, anti-HIV	Infection, HIV/AIDS
Zimeldine		111406-87-2	EP 279263	Antiasthma	Asthma
zinc acetate	hexakis(m-acetato)-m4-oxotetrazinc	56775-88-3			
zinc acexamate	Hexanoic acid, 6-(acetylamino)-, zinc salt (2:1)- [CAS]	12129-82-7		Antiviral, other	Infection, herpes simplex virus prophylaxis
zinc ibuprofenate		70020-71-2	EP 369088	Anticancer	Ulcer, duodenal
Zinc p-Phenolsulfonate		78416-80-5		Anti-inflammatory, topical	Inflammation, dermal
		127-82-2			
Zinc Salicylate		16283-36-6			
Zinostatin		9014-2-2			
zinostatin stimalamer		123760-07-6	EP 136791	Anticancer, antibiotic	Cancer, liver
Zipeprol		34758-83-3			
ziprasidone	2H-Indol-2-one, 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)ethyl)-6-chloro-1,3-dihydro- [CAS]	122883-93-6			
	L-Proline, 1-[3-(benzoylthio)-2-methyl-1-oxopropyl]-4-(phenylthio)-, [1(R*), 2Alpha, 4Alpha]- [CAS]	146939-27-7	EP 281309	Neuroleptic	Schizophrenia
zofenopril		75176-37-3			
	L-Proline, 1-[3-(benzoylthio)-2-methyl-1-oxopropyl]-4-(phenylthio)-, [1(R*), 2Alpha, 4Alpha]- + 6-Chloro-3,4-dihydro-2H-1,2,4-benzothiazide-7-sulfonamide 1,1-dioxide [CAS]	81872-10-8			
		81938-43-4	GB 2028327	Antihypertensive, renin system	Hypertension, general
zofenopril + HCTZ					
zoledronic acid	Phosphonic acid, [1-hydroxy-2-(1H-imidazol-1-yl)ethylidene]bis- [CAS]	118072-93-8		Formulation, fixed-dose combinations	Hypertension, general
		165800-06-6	EP 531253	Osteoporosis treatment	Hypercalcaemia of malignancy

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
zolimidine	2-(p-methylsulfonylphenyl)imidazo[1,2-a]pyridine	1222-57-7	US 3318880	Antiulcer	Gastritis
zolmitriptan	2-Oxazolidinone, 4-(3-(2-(dimethylamino)ethyl)-1H-indol-5-yl)methyl-, (S)- [CAS]	139264-17-8	WO 9118897	Antimigraine	Migraine
zolpidem	Imidazo[1,2-a]pyridine-3-acetamide, N,N,6-trimethyl-2-(4-methylphenyl)-(R [*] , R [*])-2,3-dihydroxybutanediotide (2:1) [CAS]	99294-93-6 82626-48-0	EP 50563	Hypnotic/Sedative	Insomnia
Zomepirac		33369-31-2			
zonampanel	1(2H)-Quinoxalineacetic acid, 3,4-dihydro-7-(1H-imidazol-1-yl)-6-nitro-2,3-dioxo- [CAS]	210245-80-0		Neuroprotective	Ischaemia, cerebral
zoniporide	1H-pyrazole-4-carboxamide, N-(aminoimino methyl)-5-cyclopropyl-1-(5-quinolinyl)-, [CAS]	249296-45-5			
zonisamide	1,2-Benzisoxazole-3-methanesulfonamide [CAS]	68291-97-4 68291-98-5	GB 2025931	Cardiovascular Antiepileptic	Unspecified Epilepsy, generalized, tonic-clonic
zopiclone	1-Piperazinecarboxylic acid, 4-methyl-, 6-(5-chloro-2-pyridinyl)-6,7-dihydro-7-oxo-5H-pyrrolo[3,4-b]pyrazin-5-yl ester [CAS]	43200-80-2	GB 1358680	Hypnotic/Sedative	Insomnia
Zopolrestat		110703-94-1			
Zorubicin		54083-22-6			
zosuquidar	1-Piperazineethanol, 4-(1,1-difluoro-1,1a,6,10b-tetrahydrodibenzof[a,e]cyclopropa[cyclohepten-6-yl)-Alpha-[(5-quinolinyl)oxy]methyl]-, [6(R)-(1a)Alpha,6Alpha,10bAlpha)]-, [CAS]	167465-36-3		Radio/chemosensitizer	Cancer, leukaemia, acute myelogenous
zotepine	Ethanamine, 2-[(8-chlorodibenzo[b,f]thiepin-10-yl)oxy]-N,N-dimethyl-, [CAS]	26615-21-4	GB 1247067	Neuroleptic	Schizophrenia
ZP-123			WO 0162775	Antiarrhythmic	Arrhythmia, general
Z-tamoxifen	Ethanamine, 2-[4-(1,2-diphenyl-1-butenyl)phenoxy]-N,N-dimethyl-, (Z)- [CAS]	10540-29-1		Anticancer, hormonal	Cancer, colorectal

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
zuclopenthixol	1-Piperazineethanol, 4-[3-(2-chloro-9H-thioxanthen-9-ylidene)propyl]-, (Z)-[CAS]	53772-83-1	EP 270282	Neuroleptic	Psychosis, general
		982-24-1			
		85721-05-7			
		64053-00-5			

CLAIMS:

1. A pharmaceutical co-crystal composition, comprising: an API and a co-crystal former, wherein both the API and the co-crystal former are solids at room temperature and the API and co-crystal former are hydrogen bonded to each other.
2. The pharmaceutical co-crystal composition according to claim 1, wherein the co-crystal former is selected from a co-crystal former of Table I or Table II.
3. The pharmaceutical co-crystal composition according to claim 1, wherein the API is selected from an API of Table IV.
4. The pharmaceutical co-crystal composition according to claim 1, wherein the API is selected from an API of Table IV and the co-crystal former is selected from a co-crystal former of Table I or Table II.
5. A pharmaceutical co-crystal composition, comprising: an API, a co-crystal former, and a third molecule, wherein the API and the co-crystal former are solids at room temperature, and wherein the API and the third molecule are bonded to each other, and further wherein the co-crystal former and the third molecule are hydrogen bonded to each other.
6. A pharmaceutical co-crystal composition, comprising: an API and a co-crystal former, wherein the API is liquid and the co-crystal former is solid at room temperature, and wherein the API and the co-crystal former are hydrogen bonded to each other.
7. The pharmaceutical co-crystal composition according to claim 6, wherein the API is selected from an API of Table IV and the co-crystal former is selected from a co-crystal former of Table I or Table II.
8. A pharmaceutical co-crystal composition, comprising: two APIs, wherein one or both of the APIs are solids at room temperature, and wherein the two APIs are hydrogen bonded to each other.

9. The pharmaceutical co-crystal composition according to claim 8, wherein each API is selected from an API of Table IV.
-
10. A pharmaceutical co-crystal composition, comprising: two co-crystal formers, wherein both co-crystal formers are solids at room temperature, and wherein both co-crystal formers are hydrogen bonded to each other.
11. The pharmaceutical co-crystal composition according to claim 10, wherein each co-crystal former is selected from a co-crystal former of Table I or Table II.
12. The pharmaceutical co-crystal composition according to claim 1, wherein the API and the co-crystal former form an inclusion complex.
13. A pharmaceutical co-crystal composition, comprising: an API and a co-crystal former; wherein the API has at least one functional group selected from the group consisting of ether, thioether, alcohol, thiol, aldehyde, ketone, thioketone, nitrate ester, phosphate ester, thiophosphate ester, ester, thioester, sulfate ester, carboxylic acid, phosphonic acid, phosphinic acid, sulfonic acid, amide, primary amine, secondary amine, ammonia, tertiary amine, sp² amine, thiocyanate, cyanamide, oxime, nitrile diazo, organohalide, nitro, s-heterocyclic ring, thiophene, n-heterocyclic ring, pyrrole, o-heterocyclic ring, furan, epoxide, peroxide, hydroxamic acid, imidazole, and pyridine, and the co-crystal former has at least one functional group selected from ether, thioether, alcohol, thiol, aldehyde, ketone, thioketone, nitrate ester, phosphate ester, thiophosphate ester, ester, thioester, sulfate ester, carboxylic acid, phosphonic acid, phosphinic acid, sulfonic acid, amide, primary amine, secondary amine, ammonia, tertiary amine, sp² amine, thiocyanate, cyanamide, oxime, nitrile, diazo, organohalide, nitro, s-heterocyclic ring, thiophene, n-heterocyclic ring, pyrrole, o-heterocyclic ring, furan, epoxide, peroxide, hydroxamic acid, imidazole, and pyridine, such that the drug and co-crystal forming compound are capable of co-crystallizing from a solution phase under crystallization conditions and a hydrogen bond is formed between a hydrogen bond donor and a hydrogen bond acceptor.
14. The pharmaceutical composition according to claim 1, wherein (i) one of the API and co-crystal forming compound has at least one hydrogen bond donor group and (ii) the other has at least one hydrogen bond acceptor group.

15. The pharmaceutical composition according to claim 14, wherein the difference in pKa between the API and the co-crystal forming compound does not exceed 2.
-
16. The pharmaceutical composition according to claim 1, wherein the API is selected from celecoxib, carbamazepine, itraconazole, olanzapine, topiramate and modafinil.
17. The pharmaceutical composition according to claim 1, wherein the API is selected from 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin, and ibuprofen.
18. The pharmaceutical composition according to claim 1, which further comprises a pharmaceutically acceptable diluent, excipient or carrier.
19. A co-crystal comprising carbamazepine and saccharin.
20. A co-crystal comprising carbamazepine and nicotinamide.
21. A co-crystal comprising carbamazepine and trimesic acid.
22. A co-crystal comprising celecoxib and nicotinamide.
23. A co-crystal comprising olanzapine and nicotinamide.
24. A co-crystal comprising celecoxib and 18-crown-6.
25. A co-crystal comprising itraconazole and succinic acid.
26. A co-crystal comprising itraconazole and fumaric acid.
27. A co-crystal comprising itraconazole and tartaric acid.
28. A co-crystal comprising itraconazole and malic acid.

29. A co-crystal comprising itraconazoleHCl and tartaric acid.
 30. A co-crystal comprising modafinil and malonic acid.
-
31. A co-crystal comprising modafinil and benzamide.
 32. A co-crystal comprising modafinil and mandelic acid.
 33. A co-crystal comprising modafinil and glycolic acid.
 34. A co-crystal comprising modafinil and fumaric acid.
 35. A co-crystal comprising modafinil and maleic acid.
 36. A co-crystal comprising topiramate and 18-crown-6.
 37. A co-crystal comprising 5-fluorouracil and urea.
 38. A co-crystal comprising hydrochlorothiazide and nicotinic acid.
 39. A co-crystal comprising hydrochlorothiazide and 18-crown-6.
 40. A co-crystal comprising hydrochlorothiazide and piperazine.
 41. A co-crystal comprising acetaminophen and 4,4'-bipyridine.
 42. A co-crystal comprising phenytoin and pyridone.
-
43. A co-crystal comprising aspirin and 4,4'-bipyridine.
 44. A co-crystal comprising ibuprofen and 4,4'-bipyridine.
 45. A co-crystal comprising flurbiprofen and 4,4'-bipyridine.

46. A co-crystal comprising flurbiprofen and trans-1,2-bis(4-pyridyl) ethylene.
 47. A co-crystal comprising carbamazepine and p-phthalaldehyde.
-
48. A co-crystal comprising carbamazepine and 2,6-pyridinecarboxylic acid.
 49. A co-crystal comprising carbamazepine and 5-nitroisophthalic acid.
 50. A co-crystal comprising carbamazepine and 1,3,5,7-adamantane tetracarboxylic acid.
 51. A co-crystal comprising carbamazepine and benzoquinone.
 52. A process for the production of a pharmaceutical co-crystal composition, which process comprises:
 - (1) providing an API which has at least one functional group selected from the group consisting of: ether, thioether, alcohol, thiol, aldehyde, ketone, thioketone, nitrate ester, phosphate ester, thiophosphate ester, ester, thioester, sulfate ester, carboxylic acid, phosphonic acid, phosphinic acid, sulfonic acid, amide, primary amine, secondary amine, ammonia, tertiary amine, sp² amine, thiocyanate, cyanamide, oxime, nitrile, diazo, organohalide, nitro, s-heterocyclic ring, thiophene, n-heterocyclic ring, pyrrole, o-heterocyclic ring, furan, epoxide, peroxide, hydroxamic acid, imidazole, and pyridine;
 - (2) providing a co-crystal former which has at least one complementary functional group selected from the group consisting of: ether, thioether, alcohol, thiol, aldehyde, ketone, thioketone, nitrate ester, phosphate ester, thiophosphate ester, ester, thioester, sulfate ester, carboxylic acid, phosphonic acid, phosphinic acid, sulfonic acid, amide, primary amine, secondary amine, ammonia, tertiary amine, sp² amine, thiocyanate, cyanamide, oxime, nitrile, diazo, organohalide, nitro, s-heterocyclic ring, thiophene, n-heterocyclic ring, pyrrole, o-heterocyclic ring, furan, epoxide, peroxide, hydroxamic acid, imidazole, and pyridine;
 - (3) grinding, heating, or contacting in solution the API with the co-crystal former under crystallization conditions; so as to form a solid phase;
 - (4) isolating co-crystals formed thereby; and

(5) incorporating the co-crystals into a pharmaceutical composition; wherein the API is a liquid or solid at room temperature and the co-crystal former is a solid at room temperature, and wherein the API and co-crystal former are hydrogen bonded to each other.

53. The process according to claim 52, wherein:

- (a) the co-crystal former is selected from a co-crystal former of Table I or Table II;
- (b) the API is selected from an API of Table IV;
- (c) the API is selected from an API of Table IV and the co-crystal former is selected from a co-crystal former of Table I or Table II;
- (d) the API and the co-crystal former form an inclusion complex;
- (e) (i) one of the API and co-crystal forming compound has at least one hydrogen bond donor group; and
(ii) the other has at least one hydrogen bond acceptor group;
- (f) the difference in pKa between the API and the co-crystal former does not exceed 2;
- (g) the API is selected from the group consisting of celecoxib, carbamazepine, itraconazole, olanzapine, topiramate, and modafinil;
- (h) the API is selected from the group consisting of 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin, and ibuprofen; or
- (i) the pharmaceutical co-crystal composition further comprises a pharmaceutically acceptable diluent, excipient, or carrier.

54. The process for the production of a pharmaceutical co-crystal composition, which process comprises:

- (3) providing an API which has at least one functional group selected from the group consisting of ether, thioether, alcohol, thiol, aldehyde, ketone, thioketone, nitrate ester, phosphate ester, thiophosphate ester, ester, thioester, sulfate ester, carboxylic acid, phosphonic acid, phosphinic acid, sulfonic acid, amide, primary amine, secondary amine, ammonia, tertiary amine, sp² amine, thiocyanate, cyanamide, oxime, nitrile, diazo, organohalide, nitro, s-heterocyclic ring, thiophene, n-heterocyclic ring, pyrrole, o-heterocyclic ring, furan, epoxide, peroxide, hydroxamic acid, imidazole, and pyridine;

- (4) providing a co-crystal former which has at least one complementary functional group selected from the group consisting of ether, thioether, alcohol, thiol, aldehyde, ketone, thioketone, nitrate ester, phosphate ester, thiophosphate ester, ester, thioester, sulfate ester, carboxylic acid, phosphonic acid, phosphinic acid, sulfonic acid, amide, primary amine, secondary amine, ammonia, tertiary amine, sp² amine, thiocyanate, cyanamide, oxime, nitrile, diazo, organohalide, nitro, s-heterocyclic ring, thiophene, n-heterocyclic ring, pyrrole, o-heterocyclic ring, furan, epoxide, peroxide, hydroxamic acid, imidazole, and pyridine;
- (3) grinding, heating, or contacting in solution the API with the co-crystal former under crystallization conditions; so as to form a solid phase;
- (4) isolating co-crystals formed thereby; and
- (5) incorporating the co-crystals into a pharmaceutical composition; wherein the API is a liquid or solid at room temperature and the co-crystal former is a solid at room temperature, and wherein the API and a third molecule are bonded to each other, and further wherein the co-crystal former and the third molecule are hydrogen bonded to each other.

55. The process according to claim 52, wherein: the API is a liquid at room temperature.

56. The process according to claim 55, wherein the API is selected from an API of Table IV and the co-crystal former is selected from a co-crystal former of Table I or Table II.

57. A process for the production of a pharmaceutical co-crystal composition, which process comprises:

- (1) providing an API which has at least one functional group selected from the group consisting of ether, thioether, alcohol, thiol, aldehyde, ketone, thioketone, nitrate ester, phosphate ester, thiophosphate ester, ester, thioester, sulfate ester, carboxylic acid, phosphonic acid, phosphinic acid, sulfonic acid, amide, primary amine, secondary amine, ammonia, tertiary amine, sp² amine, thiocyanate, cyanamide, oxime, nitrile, diazo, organohalide, nitro, s-heterocyclic ring, thiophene, n-heterocyclic ring, pyrrole, o-heterocyclic ring, furan, epoxide, peroxide, hydroxamic acid, imidazole, and pyridine;
- (2) providing another API which has at least one complementary functional group selected from the group consisting of ether, thioether, alcohol, thiol, aldehyde, ketone,

thioketone, nitrate ester, phosphate ester, thiophosphate ester, ester, thioester, sulfate ester, carboxylic acid, phosphonic acid, phosphinic acid, sulfonic acid, amide, primary amine, secondary amine, ammonia, tertiary amine, sp² amine, thiocyanate, cyanamide, oxime, nitrile, diazo, organohalide, nitro, s-heterocyclic ring, thiophene, n-heterocyclic ring, pyrrole, o-heterocyclic ring, furan, epoxide, peroxide, hydroxamic acid, imidazole, and pyridine;

- (3) grinding, heating, or contacting in solution the APIs under crystallization conditions; so as to form a solid phase;
- (4) isolating co-crystals formed thereby; and
- (5) incorporating the co-crystals into a pharmaceutical composition; wherein one or both of the APIs are solids at room temperature, and wherein the two APIs are hydrogen bonded to each other.

58. The process according to claim 57, wherein each API is selected from an API of Table IV.

59. A process for the production of a pharmaceutical co-crystal composition, which process comprises:

- (1) providing a co-crystal former which has at least one functional group selected from the group consisting of ether, thioether, alcohol, thiol, aldehyde, ketone, thioketone, nitrate ester, phosphate ester, thiophosphate ester, ester, thioester, sulfate ester, carboxylic acid, phosphonic acid, phosphinic acid, sulfonic acid, amide, primary amine, secondary amine, ammonia, tertiary amine, sp² amine, thiocyanate, cyanamide, oxime, nitrile, diazo, organohalide, nitro, s-heterocyclic ring, thiophene, n-heterocyclic ring, pyrrole, o-heterocyclic ring, furan, epoxide, peroxide, hydroxamic acid, imidazole, and pyridine;
- (2) providing another co-crystal former which has at least one complementary functional group selected from the group consisting of ether, thioether, alcohol, thiol, aldehyde, ketone, thioketone, nitrate ester, phosphate ester, thiophosphate ester, ester, thioester, sulfate ester, carboxylic acid, phosphonic acid, phosphinic acid, sulfonic acid, amide, primary amine, secondary amine, ammonia, tertiary amine, sp² amine, thiocyanate, cyanamide, oxime, nitrile, diazo, organohalide, nitro, s-heterocyclic ring, thiophene, n-heterocyclic ring, pyrrole, o-heterocyclic ring, furan, epoxide, peroxide, hydroxamic acid, imidazole, and pyridine;

- (3) grinding, heating, or contacting in solution the co-crystal formers under crystallization conditions; so as to form a solid phase;
 - (4) isolating co-crystals formed thereby; and
 - (5) incorporating the co-crystals into a pharmaceutical composition; wherein both co-crystal formers are solids at room temperature, and wherein both co-crystal formers are hydrogen bonded to each other.
-

60. The process according to claim 59, wherein each co-crystal former is selected from a co-crystal former of Table I and Table II.

61. The process according to claim 52, wherein the co-crystal is selected from the group consisting of carbamazepine:saccharin, carbamazepine:nicotinamide, carbamazepine:trimesic acid, celecoxib:nicotinamide, olanzapine:nicotinamide, celecoxib:18-crown-6, itraconazole:succinic acid, itraconazole:fumaric acid, itraconazole:tartaric acid, itraconazole:malic acid, itraconazoleHCl:tartaric acid, modafinil:malonic acid, modafinil:benzamide, modafinil:mandelic acid, modafinil:glycolic acid, modafinil:fumaric acid, modafinil:maleic acid, topiramate:18-crown-6, 5-fluorouracil:urea, hydrochlorothiazide:nicotinic acid, hydrochlorothiazide:18-crown-6, hydrochlorothiazide:piperazine, acetaminophen:4,4'-bipyridine, phenytoin:pyridone, aspirin:4,4'-bipyridine, ibuprofen:4,4'-bipyridine, flurbiprofen:4,4'-bipyridine, flurbiprofen:trans-1,2-bis(4-pyridyl) ethylene, carbamazepine:p-phthalaldehyde, carbamazepine:2,6-pyridinecarboxylic acid, carbamazepine:5-nitroisophthalic acid, carbamazepine:1,3,5,7-adamantane tetracarboxylic acid, and carbamazepine:benzoquinone.

62. A process for the production of a pharmaceutical composition, which comprises:

- (1) contacting in solution an API with a co-crystal forming compound, under crystallization conditions, so as to form a solid phase;
- (2) isolating the solid phase;
- (3) testing the solid phase for the presence of co-crystals of the API and the co-crystal forming compound; and
- (4) incorporating the co-crystals when formed in step (3) into a pharmaceutical composition.

63. A process for the production of a pharmaceutical composition, which comprises:

(1) providing (i) an API or a plurality of different APIs, and (ii) a co-crystal forming compound or a plurality of different co-crystal forming compounds, wherein at least one of the API and the co-crystal forming compound is provided as a plurality thereof;

(2) screening for co-crystals of APIs with co-crystal forming compounds by subjecting each combination of API and co-crystal forming compound to a step comprising

(a) contacting in solution the API with the co-crystal forming compound under crystallization conditions so as to form a solid phase;

(b) isolating the solid phase; and

(c) testing the solid phase for the presence of co-crystals of the API and the co-crystal forming compound; and

(3) incorporating the co-crystals when formed in step (c) into a pharmaceutical composition.

64. A process for modulating the solubility of an API for use in a pharmaceutical composition, which process comprises:

(1) contacting in solution the API with a co-crystal forming compound under crystallization conditions, so as to form a co-crystal of the API and the co-crystal forming compound;

(2) isolating the co-crystal;

(3) testing the co-crystal for modulated solubility as compared to the API; and

(4) incorporating the co-crystal having modulated solubility into a pharmaceutical composition.

65. A process for modulating the dose response of an API for use in a pharmaceutical composition, which process comprises:

(1) contacting in solution the API with a co-crystal forming compound under crystallization conditions, so as to form a co-crystal of the API and the co-crystal forming compound;

(2) isolating the co-crystal;

(3) testing the co-crystal for modulated dose response as compared to the API;

and

(4) incorporating the co-crystal having modulated dose response into a pharmaceutical composition.

66. A process for modulating the dissolution of an API for use in a pharmaceutical composition, which process comprises:

- (1) contacting in solution the API with a co-crystal forming compound under crystallization conditions, so as to form a co-crystal of the API and the co-crystal forming compound;
- (2) isolating the co-crystal;
- (3) testing the co-crystal for modulated dissolution as compared to the API; and
- (4) incorporating the co-crystal having modulated dissolution into a pharmaceutical composition.

67. A process for modulating the bioavailability of an API for use in a pharmaceutical composition, which process comprises:

- (1) contacting in solution the API with a co-crystal forming compound under crystallization conditions, so as to form a co-crystal of the API and the co-crystal forming compound;
- (2) isolating the co-crystal;
- (3) testing the co-crystal for modulated bioavailability as compared to the API; and
- (4) incorporating the co-crystal having modulated bioavailability into a pharmaceutical composition.

68. A process for increasing the stability of an API for use in a pharmaceutical composition, which process comprises:

- (1) contacting in solution the API with a co-crystal forming compound under crystallization conditions, so as to form a co-crystal of the API and the co-crystal forming compound;
- (2) isolating the co-crystal, wherein the co-crystal has increased stability as compared to the API; and
- (3) incorporating the co-crystal having increased stability into a pharmaceutical composition.

69. A process for the incorporation of a difficult to salt or unsaltable API for use in a pharmaceutical composition, which process comprises:

(1) contacting in solution the API with a co-crystal forming compound under crystallization conditions, so as to form a co-crystal of the API and the co-crystal forming compound;

(2) isolating the co-crystal;

(3) incorporating the co-crystal having a difficult to salt or unsaltable API into a pharmaceutical composition.

70. A process for decreasing the hygroscopicity of an API for use in a pharmaceutical composition, which process comprises:

(1) contacting in solution the API with a co-crystal forming compound under crystallization conditions, so as to form a co-crystal of the API and the co-crystal forming compound;

(2) isolating the co-crystal, wherein the co-crystal has decreased hygroscopicity as compared to the API; and

(3) incorporating the co-crystal having decreased hygroscopicity into a pharmaceutical composition.

71. A process for crystallizing an amorphous API for use in a pharmaceutical composition, which process comprises:

(1) contacting in solution the API with a co-crystal forming compound under crystallization conditions, so as to form a co-crystal of the API and the co-crystal forming compound;

(2) isolating the co-crystal;

(4) incorporating the co-crystal into a pharmaceutical composition.

72. A process for decreasing the form diversity of an API for use in a pharmaceutical composition, which process includes:

(1) contacting in solution the API with a co-crystal forming compound under crystallization conditions, so as to form a co-crystal of the API and the co-crystal forming compound;

(2) isolating the co-crystal wherein the co-crystal has decreased form diversity as compared to the API; and

(3) incorporating the co-crystal having decreased form diversity into a pharmaceutical composition.

73. A process for modulating the morphology of an API for use in a pharmaceutical composition, which process includes:

- (1) contacting in solution the API with a co-crystal forming compound under crystallization conditions, so as to form a co-crystal of the API and the co-crystal forming compound;
- (2) isolating the co-crystal, wherein the co-crystal has a different morphology as compared to the API; and
- (3) incorporating the co-crystal having modulated morphology into a pharmaceutical composition.

74. The co-crystal of claim 1, specifically excluding co-crystals selected from the group consisting of: nabumetone:2,3-naphthalenediol, fluoxetine HCl:benzoic acid, fluoxetine HCl:succinic acid, acetaminophen:piperazine, acetaminophen:theophylline, theophylline:salicylic acid, theophylline:p-hydroxybenzoic acid, theophylline:sorbic acid, theophylline:1-hydroxy-2-naphthoic acid, theophylline:glycolic acid, theophylline:2,5-dihydroxybenzoic acid, theophylline:chloroacetic acid, bis(diphenylhydantoin):9-ethyladenine acetylacetone solvate, bis(diphenylhydantoin):9-ethyladenine 2,4-pentanedione solvate, 5,5-diphenylbarbituric acid:9-ethyladenine, bis(diphenylhydantoin):9-ethyladenine, 4-aminobenzoic acid:4-aminobenzonitrile, sulfadimidine:salicylic acid, 8-hydroxyquinolinium 4-nitrobenzoate:4-nitrobenzoic acid, sulfaproxyline:caffeine, retro-inverso-isopropyl (2R,3S)-4-cyclohexyl-2-hydroxy-3-(N-((2R)-2-morpholinocarbonylmethyl-3-(1-naphthyl)propionyl)-L-histidylamino)butyrate:cinnamic acid monohydrate, benzoic acid:isonicotinamide, 3-(2-N',N'-(dimethylhydrazino)-4-thiazolylmethylthio)-N''-sulfamoylpropionamide:maleic acid, diglycine hydrochloride ($C_2H_5NO_2:C_2H_6NO_2^+Cl^-$), octadecanoic acid:3-pyridinecarboxamide, cis-N-(3-methyl-1-(2-(1,2,3,4-tetrahydro)naphthyl)-piperidin-4-yl)-N-phenylpropanamide hydrochloride:oxalic acid, trans-N-(3-methyl-1-(2-(1,2,3,4-tetrahydro)naphthyl)-piperidin-4-yl)-N-phenylpropanamide oxalate:oxalic acid dihydrate, bis(1-(3-((4-(2-isopropoxyphenyl)-1-piperazinyl)methyl)benzoyl)piperidine) succinate:succinic acid, bis(p-cyanophenyl)imidazolymethane:succinic acid, cis-1-((4-(1-imidazolymethyl)cyclohexyl)methyl)imidazole:succinic acid, (+)-2-(5,6-dimethoxy-1,2,3,4-tetrahydro-1-naphthyl)imidazoline:(+)-dibenzoyl-D-tartaric acid, raclopride:tartaric acid, 2,6-diamino-9-ethylpurine:5,5-diethylbarbituric acid, 5,5-diethylbarbituric acid:bis(2-

aminopyridine), 5,5-diethylbarbituric acid:acetamide, 5,5-diethylbarbituric acid:KI₃, 5,5-diethylbarbituric acid:urea, bis(barbital):hexamethylphosphoramide, 5,5-diethylbarbituric acid:imidazole, barbital:1-methylimidazole, 5,5-diethylbarbituric acid:N-methyl-2-pyridone, 2,4-diamino-5-(3,4,5-trimethoxybenzyl)-pyrimidine:5,5-diethylbarbituric acid, bis(barbital):caffeine, bis(barbital):1-methylimidazole, bis(beta-cyclodextrin):bis(barbital) hydrate, tetrakis(beta-cyclodextrin):tetrakis(barbital), 9-ethyladenine:5,5-diethylbarbituric acid, barbital:N'-(p-cyanophenyl)-N-(p-iodophenyl)melamine, barbital:2-amino-4-(m-bromophenylamino)-6-chloro-1,3,5-triazine, 5,5-diethylbarbituric acid:N,N'-diphenylmelamine, 5,5-diethylbarbituric acid:N,N'-bis(p-chlorophenyl)melamine, N,N'-bis(p-bromophenyl)melamine:5,5-diethylbarbituric acid, 5,5-diethylbarbituric acid:N,N'-bis(p-iodophenyl)melamine, 5,5-diethylbarbituric acid:N,N'-bis(p-tolyl)melamine, 5,5-diethylbarbituric acid:N,N'-bis(m-tolyl)melamine, 5,5-diethylbarbituric acid:N,N'-bis(m-chlorophenyl)melamine, N,N'-Bis(m-methylphenyl)melamine:barbital, N,N'-bis(m-chlorophenyl)melamine:barbital tetrahydrofuran solvate, 5,5-diethylbarbituric acid:N,N'-bis(t-butyl)melamine, 5,5-diethylbarbituric acid:N,N'-di(t-butyl)melamine, 6,6'-diquinolyl ether:5,5-diethylbarbituric acid, 5-t-butyl-2,4,6-triaminopyrimidine:diethylbarbituric acid, N,N'-bis(4-carboxymethylphenyl)melamine:barbital ethanol solvate, N,N'-bis(4-t-butylphenyl)melamine:barbital, tris(5,17-N,N'-bis(4-amino-6-(butylamino)-1,3,5-triazin-2-yl)diamino-11,23-dinitro-25,26,27,28-tetrapropoxycalix(4)arene):hexakis(diethylbarbituric acid) toluene solvate, N,N'-bis(m-fluorophenyl)melamine:barbital, N,N'-bis(m-bromophenyl)melamine:barbital acetone solvate, N,N'-bis(m-iodophenyl)melamine:barbital acetonitrile solvate, N,N'-bis(m-trifluoromethylphenyl)melamine:barbital acetonitrile solvate, aminopyrine:barbital, N,N'-bis(4-fluorophenyl)melamine:barbital, N,N'-bis(4-trifluoromethylphenyl)melamine:barbital, 2,4-diamino-5-(3,4,5-trimethoxybenzyl)pyrimidine:barbital, hydroxybutyrate:hydroxyvalerate, 2-aminopyrimidine:succinic acid, 1,3-bis(((6-methylpyrid-2-yl)amino)carbonyl)benzene:glutaric acid, 5-t-butyl-2,4,6-triaminopyrimidine:diethylbarbituric acid, bis(dithiobiuret-S,S')nickel(II):diuracil, platinum 3,3'-dihydroxymethyl-2,2'-bipyridine dichloride:AgF₃CSO₃, 4,4'-bipyridyl:isophthalic acid, 4,4'-bipyridyl:1,4-naphthalenedicarboxylic acid, 4,4'-bipyridyl:1,3,5-cyclohexanetricarboxylic acid, 4,4'-bipyridyl:tricarballic acid, urotropin:azelaic acid, insulin:C8-HI (octanoyl-N^c-LysB29-human insulin), isonicotinamide:cinnamic acid, isonicotinamide:3-hydroxybenzoic acid, isonicotinamide:3-N,N-dimethylaminobenzoic acid, isonicotinamide:3,5-bis(trifluoromethyl)-benzoic acid, isonicotinamide:d,l-mandelic acid,

isonicotinamide:chloroacetic acid, isonicotinamide:fumaric acid monoethyl ester,
isonicotinamide:12-bromododecanoic acid, isonicotinamide:fumaric acid,
isonicotinamide:succinic acid, isonicotinamide:4-ketopimelic acid,
isonicotinamide:thiodiglycolic acid, 1,3,5-cyclohexane-tricarboxylic
acid:hexamethyltetramine, 1,3,5-cyclohexane-tricarboxylic acid:4,7-phenanthroline, 4,7-
phenanthroline:oxalic acid, 4,7-phenanthroline:terephthalic acid, 4,7-phenanthroline: 1,3,5-
cyclohexane-tricarboxylic acid, 4,7-phenanthroline:1,4-naphthalenedicarboxylic acid,
pyrazine:methanoic acid, pyrazine:ethanoic acid, pyrazine:propanoic acid, pyrazine:butanoic
acid, pyrazine:pentanoic acid, pyrazine:hexanoic acid, pyrazine:heptanoic acid,
pyrazine:octanoic acid, pyrazine:nonanoic acid, pyrazine:decanoic acid, diammine-(deoxy-
quanyl-quanyl-N⁷,N⁷)-platinum:tris(glycine) hydrate, 2-aminopyrimidine:p-
phenylenediacetic acid, bis(2-aminopyrimidin-1-ium)fumarate:fumaric acid, 2-
aminopyrimidine:indole-3-acetic acid, 2-aminopyrimidine:N-methylpyrrole-2-carboxylic
acid, 2-aminopyrimidine:thiophen-2-carboxylic acid, 2-aminopyrimidine:(+)-camphoric acid,
2,4,6-Trinitrobenzoic acid: 2-aminopyrimidine, 2-aminopyrimidine:4-aminobenzoic acid, 2-
aminopyrimidine:bis(phenoxyacetic acid), 2-aminopyrimidine:(2,4-dichlorophenoxy)acetic
acid, 2-aminopyrimidine:(3,4-dichlorophenoxy)acetic acid, 2-aminopyrimidine:indole-2-
carboxylic acid, 2-aminopyrimidine:terephthalic acid, 2-aminopyrimidine:bis(2-nitrobenzoic
acid), 2-aminopyrimidine:bis(2-aminobenzoic acid), 2-aminopyrimidine:3-aminobenzoic
acid, 2-hexenoic acid:isonicotinamide, 4-nitrobenzoic acid:isonicotinamide, 3,5-
dinitrobenzoic acid:isonicotinamide:4-methylbenzoic acid, 2-amino-5-nitropyrimidine:2-
amino-3-nitropyridine, 3,5-dinitrobenzoic acid:4-chlorobenzamide, 3-dimethylaminobenzoic
acid:4-chlorobenzamide, fumaric acid:4-chlorobenzamide, oxine:4-nitrobenzoic acid,
oxine:3,5-dinitrobenzoic acid, oxine:3,5-dinitrosalicylic acid, 3-[2-(N⁷,N⁷-
dimethylhydrazino)-4-thiazolylmethylthio]-N²-sulfamoylpropionamidine:maleic acid, 5-
fluorouracil:9-ethylhypoxanthine, 5-fluorouracil:cytosine dihydrate, 5-
fluorouracil:theophylline monohydrate, stearic acid:nicotinamide, cis-1-{{4-(1-
imidazolylmethyl)cyclohexyl}methyl}imidazole:succinic acid, CGS18320B:succinic acid,
sulfaproxyline:caffeine, 4-aminobenzoic acid:4-aminobenzonitrile, 3,5-dinitrobenzoic
acid:isonicotinamide:3-methylbenzoic acid, 3,5-dinitrobenzoic acid:isonicotinamide:4-
(dimethylamino)benzoic acid, 3,5-dinitrobenzoic acid:isonicotinamide:4-hydroxy-3-
methoxycinnamic acid, isonicotinamide:oxalic acid, isonicotinamide:malonic acid,
isonicotinamide:succinic acid, isonicotinamide:glutaric acid, isonicotinamide:adipic acid,
benzoic acid:isonicotinamide, mazapertine:succinate, betaine:dichloronitrophenol,

betainepyridine:dichloronitrophenol, betainepyridine:pentachlorophenol, 4-{2-[1-(2-hydroxyethyl)-4-pyridylidene]-ethylidene}-cyclo-hexa-2,5-dien-1-one:methyl 2,4-dihydroxybenzoate, 4-{2-[1-(2-hydroxyethyl)-4-pyridylidene]-ethylidene}-cyclo-hexa-2,5-dien-1-one:2,4-dihydroxypropiophenone, 4-{2-[1-(2-hydroxyethyl)-4-pyridylidene]-ethylidene}-cyclo-hexa-2,5-dien-1-one:2,4-dihydroxyacetophenone, squaric acid:4,4'-dipyridylacetylene, squaric acid:1,2-bis(4-pyridyl)ethylene, chloranilic acid:1,4-bis[(4-pyridyl)ethynyl]benzene, 4,4'-bipyridine:phthalic acid, 4,4'-dipyridylacetylene:phthalic acid, bis(pentamethylcyclopentadienyl)iron:bromanilic acid, bis(pentamethylcyclopentadienyl)iron:chloranilic acid, bis(pentamethylcyclopentadienyl)iron:cyananilic acid, pyrazinotetrathiafulvalene:chloranilic acid, phenol:pentafluorophenol, co-crystals of itraconazole, and co-crystals of topiramate.




Figure 1

Sample: carb_389_285E6
Size: 0.1440 mg
Method: Ramp

DSC

File: Y:\...carb_389_285E6.001
Operator: MBH
Run Date: 03-Dec-02 10:43
Instrument: DSC Q1000 V6.10 Build 227




Figure 2




Figure 3

Sample: carb_389_278_C4
Size: 0.1340 mg
Method: Ramp

DSC

File: Y:\Carb_389_278\carb_389_278_C4.001
Operator: MBH
Run Date: 18-Nov-02 16:40
Instrument: DSC Q1000 V6.19 Build 227




Figure 4




Figure 5




Figure 6

Sample: topiramate_18crown6
Size: 0.8210 mg
Method: Ramp

DSC

File: Y:\DSC\Magall\topiramate_18crown6.001
Operator: MBH
Run Date: 19-May-03 05:35
Instrument: DSC Q1000 V6.19 Build 227




Figure 7




Figure 8

Sample: 1102_204_D2
Size: 0.7500 mg
Method: Ramp

DSC

File: Y:\...\Olanzapine\1102\1102_204_D2.002
Operator: MEH
Run Date: 14-May-03 08:58
Instrument: DSC Q1000 V8.19 Build 227




Figure 9




Figure 10

Sample: Celecoxib/18-crown-6
Size: 0.9800 mg
Method: Ramp

DSC

File: \\...MT_143_45_A; Celecoxib 18-C-6.001
Operator: MDT
Run Date: 17-Mar-03 13:42
Instrument: DSC Q1000 V6.19 Build 227




Figure 11

TransForm Pharmaceuticals, Inc.

[D:\MRAPID\Administrator\14\DATA\ Monday, Jul 08, 2002 08:17a (MMJJAD05)




Figure 12

Sample: MM_90_110_A
Size: 1.8060 mg
Method: Ramp

DSC

File: \\...Utraconazole\MM_90_110_A.001
Operator: MM
Run Date: 08-Jul-02 08:11
Instrument: DSC Q1000 V5.1 Build 191




Figure 13




Figure 14

Sample: MM_90_48_B_DSC
Size: 2.3690 mg
Method: Ramp

DSC

File: \\...\\JR_81_53_D_Mg_open_DSC.004
Operator: MM
Run Date: 11-Jun-02 10:46
Instrument: DSC Q1000 V5.1 Build 191




Figure 15




Figure 16

Sample: MM_109_15_Tar
Size: 1.8790 mg
Method: Ramp

DSC

File: \\...Uraconazole\MM_109_15_Tar.001
Operator: MM
Run Date: 01-Aug-02 15:15
Instrument: DSC Q1000 V6.1 Build 191




Figure 17




Figure 18

Sample: MM_109_15_Tar
Size: 1.2140 mg
Method: Ramp

DSC

File: Y:\...Ultraconazole\MM_109_15_Mal.001
Operator: MM
Run Date: 01-Aug-02 14:18
Instrument: DSC Q1000 V5.1 Build 191




Figure 19




Figure 20

Sample: MM_109_38_A
Size: 1.5080 mg
Method: Ramp

DSC

File: \\...Uraconazole\MM_109_38_A.001
Operator: MM
Run Date: 11-Sep-02 10:57
Instrument: DSC Q1000 V6.19 Build 227




Figure 21




Figure 22




Figure 23




Figure 24




Figure 25




Figure 26





Figure 27



Dissolution profiles into 0.1 N HCl at 25 °C

Sporanox Beads (amorphous freebase) (Rectangle)

l-Malate (Inverted triangle)

l-Tartrate (Oval)

Succinate (Triangle)

Crystalline Freebase (Diamond)

Figure 28





Figure 29



Molecular structure of the Olanzapine-nicotinamide-H₂O-IPOAc crystal:




Figure 32A





Figure 32B



The Olanzapine molecules occupy the spaces shown above and are hydrogen bonded to the water molecules.




Figure 32C

The arrangement of the Olanzapine molecules is similar to that observed from the methanol solvate and the published structures for the hydrates. The water molecules bridge the Olanzapine moieties resulting in hydrogen-bonded zigzag sheets.



Figure 32D




Figure 33




Figure 34




Figure 35





Figure 36



Materials Data, Inc.

Tuesday, Sep 02, 2003 11:10a (MDI/ADE5)

Figure 37





Figure 38



Materials Data, Inc.

Tuesday, Sep 02, 2003 11:11a (MIDIJADES)

Figure 39

Size: 1.5490 mg

Method: Ramp

Comment: after nitrogen dry

DSC




Figure 40

Sample: MO-157-72C_AfterN2Dry

Size: 5.7570 mg

Method: Ramp

Comment: 8-21-03

TGA

File: V:\...MO-157-72C_AfterN2I

Operator: MAO

Run Date: 21-Aug-03 16:19





Figure 41



FIND PEAKS:

Spectrum: MO-157-72C_Modafinil-Malonic

Region: 3432 200

Absolute threshold: 566.428

Sensitivity: 68

Peak list:

Position:	1004	Intensity:	46530.113
Position:	222	Intensity:	41031.178
Position:	533	Intensity:	30431.465
Position:	265	Intensity:	27532.348
Position:	1032	Intensity:	25424.109
Position:	1163	Intensity:	23455.441
Position:	814	Intensity:	21880.129
Position:	1501	Intensity:	20374.211
Position:	490	Intensity:	18917.469
Position:	718	Intensity:	18779.322
Position:	767	Intensity:	18691.541
Position:	381	Intensity:	15080.872
Position:	917	Intensity:	12651.283
Position:	1104	Intensity:	11708.740
Position:	889	Intensity:	11172.833
Position:	412	Intensity:	11137.415
Position:	1225	Intensity:	9027.108
Position:	1251	Intensity:	8844.533
Position:	1368	Intensity:	8252.702
Position:	1442	Intensity:	6738.694
Position:	1731	Intensity:	5730.659
Position:	1298	Intensity:	5700.058
Position:	3085	Intensity:	1835.514
Position:	2849	Intensity:	1812.835

Exposure time: 2.00 sec

Number of exposures: 15

Number of background exposures: 15

Grating: 360 lines/mm

Spectrograph aperture: 100 μ m slit

Figure 42




Figure 43




Figure 44A




Figure 44B




Figure 45A




Figure 45B




Figure 46A




Figure 46C




Figure 46B




Figure 46D

Figure 47A




Figure 47C





Figure 47B




Figure 47D

Figure 48A





Figure 48C






Figure 48B




Figure 48D




Figure 49A




Figure 49B




Figure 50A




Figure 50B




Figure 51




Figure 52




Figure 53A




Figure 53B




Figure 53C




Figure 54A




Figure 54B




Figure 55A




Figure 55B




Figure 56A




Figure 56B




Figure 57A




Figure 57B




Figure 58A




Figure 58B




Figure 59

Sample: Cxb Nic
Date: 12/10/03
Time: 10:00

DSC




Figure 60

Sample: 06-06-01-1, modified
Date: 12-18-04
Operator: H. H. H.
Generation: 06-06-01-1, modified

TGA




Figure 61






Figure 62

(Figure 63)


1. One-dimensional (linear) hydrogen-bonded chains:




2. Isolated rings:



3. Extended Networks:



4. Isolated triads:



INTERNATIONAL SEARCH REPORT

International Application No PCT/US 03/27772		
A. CLASSIFICATION OF SUBJECT MATTER IPC 7 A61K9/14 C07C233/00 C07D233/00 A61K31/00		
According to International Patent Classification (IPC) or to both national classification and IPC		
B. FIELDS SEARCHED Minimum documentation searched (classification system followed by classification symbols) IPC 7 A61K C07C C07D		
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched		
Electronic data base consulted during the International search (name of data base and, where practical, search terms used) EP0-Internal, WPI Data, PAJ, BIOSIS, EMBASE, CHEM ABS Data		
C. DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
E	WO 03/074474 A (ZAWOROTKO MICHAEL J ; MOULTON BRIAN (US); UNIV MICHIGAN (US); RODRIGUE) 12 September 2003 (2003-09-12) the whole document paragraphs [0006], [0008], [0023], [0038], [0043], [0052], [0055], [0056]; claims 1,5-11,21-24,28; examples 1-9 <div style="text-align: center;">----- -/--</div>	1-4, 13-16, 18,52, 53,62-74
<div style="display: flex; justify-content: space-between;"> <input checked="" type="checkbox"/> Further documents are listed in the continuation of box C. <input checked="" type="checkbox"/> Patent family members are listed in annex. </div>		
* Special categories of cited documents :		
<div style="display: flex; justify-content: space-between;"> <div style="width: 45%;"> <p>"A" document defining the general state of the art which is not considered to be of particular relevance</p> <p>"E" earlier document but published on or after the international filing date</p> <p>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>"O" document referring to an oral disclosure, use, exhibition or other means</p> <p>"P" document published prior to the international filing date but later than the priority date claimed</p> </div> <div style="width: 45%;"> <p>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone</p> <p>"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.</p> <p>"&" document member of the same patent family</p> </div> </div>		
Date of the actual completion of the international search <div style="text-align: center;">10 February 2004</div>		Date of mailing of the international search report <div style="text-align: center;">21. 06. 2004</div>
Name and mailing address of the ISA European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo:nl, Fax: (+31-70) 340-3016		Authorized officer <div style="text-align: center;">Luangkhon, N</div>

INTERNATIONAL SEARCH REPORT

International Application No.
PCT/US 03/27772

D. (Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P,X	WO 03/033462 A (KIM KIBUM ; UNIV MICHIGAN (US); LANG MEIDONG (US); MATZGER ADAM J (US)) 24 April 2003 (2003-04-24)	1-4, 13-16, 18,22, 24,52, 53,62-74
	the whole document page 1, lines 18-23 page 14, line 27 - page 15, line 6 claims 1-5,19,37-45	
X	WO 01/51919 A (TRANSFORM PHARMACEUTICALS INC ; CIMA MICHAEL J (US); LEMMO ANTHONY V ()) 19 July 2001 (2001-07-19)	1-4, 13-16, 18,52, 53,62-74
	the whole document page 1, lines 10-19 page 63, lines 11-16 page 63, line 23 - page 64, line 25 page 65, lines 3-6 pages 66,68 page 16, lines 4-20 claims 1,6,11 page 35, line 15	22,24
X	WEISSBUCH I ET AL: "Understanding and control of nucleation, growth, habit, dissolution and structure of two- and three-dimensional crystals using 'tailor-made' auxiliaries" 1995, ACTA CRYSTALLOGRAPHICA, SECTION B, STRUCTURAL SCIENCE, MUNKSGAARD, COPENHAGEN, DK, PAGE(S) 115-148 , XP002960386 ISSN: 0108-7681	1-4, 13-16, 18,52, 53,62-74
Y	the whole document abstract page 145, column 2, paragraph 2	22,24
X	WO 01/42222 A (MIYAKE PATRICIA J ; FERRO LEONARD J (IL); PHARMACIA CORP (US)) 14 June 2001 (2001-06-14)	22,24
Y	the whole document pages 60,61; examples 1,2 page 1, lines 19-27 page 4, lines 5-19 page 5, line 15 - page 6, line 8 page 10, line 30 - page 14, line 19 page 48, lines 9-18 page 50, line 9 - page 56, line 34 page 60, line 11 - page 64, line 4 claims 1,57-175	22,24

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US 03/27772

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
2. ☐ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this International application, as follows:

see additional sheet

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☒ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

1-4, 13-16, 18, 52-53, 62-74 (all in part), 22 and 24 (whole)

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

This International Searching Authority found multiple (groups of) inventions in this international application, as follows:

1. claims: 1-4,13-16,18, 52-53, 62-74 (all in part), 22 and 24
(whole)

A co-crystal comprising celecoxib, and nicotinamide or 18-crown-16; its use in a pharmaceutical composition and method of preparation

- 1.1. claims: 1-4,13-16,18, 52-53, 62-74 (all in part), 22 (whole)

A co-crystal comprising celecoxib and nicotinamide; its use in a pharmaceutical composition and method of preparation

- 1.2. claims: 1-4, 13-16,18, 52-53, 62-74 (all in part), 24 (whole)

A co-crystal comprising celecoxib and 18-crown-16; its use in a pharmaceutical composition and method of preparation

2. claims: 1-4,16,18, 52-53, 62-74, 13-16 (all in part), 19 (whole)

A co-crystal comprising carbamazepine and saccharin, its use in a pharmaceutical composition and method of preparation

3. claims: 1-4,16,18, 52-53, 62-74, 13-16 (all in part), 20 (whole)

A co-crystal comprising carbamazepine and nicotinamide, its use in a pharmaceutical composition and method of preparation

4. claims: 1-4,16,18, 52-53, 62-74, 13-16 (all in part), 21 (whole)

A co-crystal comprising carbamazepine and trimesic acid, its use in a pharmaceutical composition and method of preparation

5. claims: 1-4,16,18, 52-53, 62-74, 13-16 (all in part), 47 (whole)

A co-crystal comprising carbamazepine and p-phthaldehyde, its use in a pharmaceutical composition and method of preparation

6. claims: 1-4,16,18, 52-53, 62-74, 13-16 (all in part), 48 (whole)

A co-crystal comprising carbamazepine and 2,6-pyridinecarboxylic acid, its use in a pharmaceutical composition and method of preparation

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

7. claims: 1-4,16,18, 52-53, 62-74, 13-16 (all in part), 49 (whole)

A co-crystal comprising carbamazepine and 5-nitroisophthalic acid, its use in a pharmaceutical composition and method of preparation

8. claims: 1-4,16,18, 52-53, 62-74, 13-16 (all in part), 50 (whole)

A co-crystal comprising carbamazepine and 1,3,5,7-adamantane tetracarboxylic acid, its use in a pharmaceutical composition and method of preparation

9. claims: 1-4,16,18, 52-53, 62-74, 13-16 (all in part), 51 (whole)

A co-crystal comprising carbamazepine and benzoquinone, its use in a pharmaceutical composition and method of preparation

10. claims: 1-4,16,18, 52-53, 62-74, 13-16 (all in part), 25 (whole)

A co-crystal comprising itraconazole and succinic acid, its use in a pharmaceutical composition and method of preparation

11. claims: 1-4,16,18, 52-53, 62-74, 13-16 (all in part), 26 (whole)

A co-crystal comprising itraconazole and fumaric acid, its use in a pharmaceutical composition and method of preparation

12. claims: 1-4,16,18, 52-53, 62-74, 13-16 (all in part), 27 (whole)

A co-crystal comprising itraconazole and tartaric acid, its use in a pharmaceutical composition and method of preparation

13. claims: 1-4,16,18, 52-53, 62-74, 13-16 (all in part), 28 (whole)

A co-crystal comprising itraconazole and malic acid, its use in a pharmaceutical composition and method of preparation

14. claims: 1-4,16,18, 52-53, 62-74, 13-16 (all in part), 29 (whole)

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

A co-crystal comprising itraconazole and tartaric acid, its use in a pharmaceutical composition and method of preparation

15. claims: 1-4,16,18, 52-53, 62-74, 13-16 (all in part), 23
(whole)

A co-crystal comprising olanzapine and nicotinamide, its use in a pharmaceutical composition and method of preparation

16. claims: 1-4,16,18, 52-53, 62-74, 13-16 (all in part), 36
(whole)

A co-crystal comprising topiramate and 18-crown-16, its use in a pharmaceutical composition and method of preparation

17. claims: 1-4,16,18, 52-53, 62-74, 13-16 (all in part), 30-35
(whole)

A co-crystal comprising modafinil, and malonic acid or benzamide or mandelic, glycolic, fumaric or maleic acid, its use in a pharmaceutical composition and method of preparation

18. claims: 1-4, 13-15,17,18, 52-53, 62-74 (all in part), 37
(whole)

A co-crystal comprising 5-fluorouracil and uread, its use in a pharmaceutical composition and method of preparation

19. claims: 1-4, 13-15,17,18, 52-53, 62-74 (all in part), 38-40
(whole)

A co-crystal comprising hydrochlorothiazide, and nicotinic acid or 18-crown-6 or piperazine, its use in a pharmaceutical composition and method of preparation

20. claims: 1-4,13-15,17,18, 52-53, 62-74 (all in part), 41 (whole)

A co-crystal comprising acetaminophen and 4,4'-bipyridine, its use in a pharmaceutical composition and method of preparation

21. claims: 1-4,13-15,17,18, 52-53, 62-74 (all in part), 43 (whole)

A co-crystal comprising aspirine and 4,4'-bipyridine, its use in a pharmaceutical composition and method of preparation

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

22. claims: 1-4,13-15,17,18, 52-53, 62-74 (all in part), 45-46
(whole)

A co-crystal comprising flurbiprofen, and 4,4'-bipyridine or trans-1,2-bis(4-pyridyl)ethylene, its use in a pharmaceutical composition and method of preparation

23. claims: 1-4,13-15,17,18, 52-53, 62-74 (all in part), 42 (whole)

A co-crystal comprising phenytoin and pyridone, its use in a pharmaceutical composition and method of preparation

24. claims: 1-4,13-15,17,18, 52-53, 62-74 (all in part), 44 (whole)

A co-crystal comprising ibuprofen and 4,4'-bipyridine, its use in a pharmaceutical composition and method of preparation

25. claims: 5,54-56 (whole), 62-74 (in part)

A pharmaceutical co-crystal composition comprising a/ a solid active pharmaceutical ingredient (API), b/ a solid co-crystal former, c/ a third molecule, wherein the API and the third molecule are bonded to each other, and the co-crystal former and the third molecule are hydrogen bonded to each other; and its method of preparation

26. claims: 6-7 (whole), 62-72 (in part)

A pharmaceutical co-crystal composition comprising a/ an active pharmaceutical ingredient (API), b/ a co-crystal former, wherein (a) is liquid and (b) is solid at room temperature, and (a) and (b) are hydrogen bonded to each other; and its method of preparation

27. claims: 8-9,57-58 (whole), 62-74 (in part)

A pharmaceutical co-crystal composition comprising a1/ a solid active pharmaceutical ingredient (API), a2/ a second solid API, wherein (a1) and (a2) are hydrogen bonded to each other; and its method of preparation

28. claims: 10-12, 59-61 (whole), 62-72 (in part)

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

A pharmaceutical co-crystal composition comprising b1/ a solid co-crystal former, b2/ a second solid co-crystal former, wherein (b1) and (b2) are hydrogen bonded to each other; and its method of preparation

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 03/27772

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 03074474	A	12-09-2003	WO 03074474 A2	12-09-2003
			US 2003224006 A1	04-12-2003
WO 03033462	A	24-04-2003	US 2003113802 A1	19-06-2003
			WO 03033462 A2	24-04-2003
WO 0151919	A	19-07-2001	AU 2930501 A	24-07-2001
			BR 0107456 A	08-10-2002
			CA 2396079 A1	19-07-2001
			CZ 20022332 A3	15-01-2003
			EP 1248869 A2	16-10-2002
			JP 2003519698 T	24-06-2003
			NZ 519984 A	26-03-2004
			SK 9742002 A3	04-02-2003
			WO 0151919 A2	19-07-2001
			US 2003162226 A1	28-08-2003
			US 2002048610 A1	25-04-2002
WO 0142222	A	14-06-2001	AU 1805901 A	18-06-2001
			AU 1930301 A	18-06-2001
			AU 1931001 A	18-06-2001
			AU 1931101 A	18-06-2001
			AU 2041201 A	18-06-2001
			AU 750978 B2	01-08-2002
			AU 2057101 A	18-06-2001
			BG 105808 A	30-09-2002
			BG 105873 A	30-04-2002
			BR 0008058 A	26-03-2002
			BR 0008059 A	26-03-2002
			BR 0008060 A	05-02-2002
			BR 0008088 A	09-04-2002
			CA 2362673 A1	14-06-2001
			CA 2362675 A1	14-06-2001
			CA 2362815 A1	14-06-2001
			CA 2362816 A1	14-06-2001
			CN 1376146 T	23-10-2002
			CN 1379669 T	13-11-2002
			CN 1411447 T	16-04-2003
			CZ 20012875 A3	13-02-2002
			CZ 20013162 A3	12-06-2002
			CZ 20013163 A3	12-06-2002
			CZ 20013210 A3	13-03-2002
			EA 3639 B1	28-08-2003
			EA 3612 B1	26-06-2003
			EA 3464 B1	26-06-2003
			EE 200100414 A	16-12-2002
			EE 200100419 A	16-12-2002
			EP 1175214 A2	30-01-2002
			EP 1165072 A2	02-01-2002
			EP 1150959 A1	07-11-2001
			EP 1150960 A1	07-11-2001
			HR 20010582 A1	31-08-2002
			HR 20010589 A1	31-08-2002
			HU 0200409 A2	29-06-2002
			HU 0200580 A2	28-11-2002
			HU 0201450 A2	28-12-2002
			HU 0201463 A2	28-05-2004
			JP 2003523954 T	12-08-2003

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 03/27772

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 0142222	A	JP 2003516353 T	13-05-2003
		JP 2004500358 T	08-01-2004
		JP 2003516394 T	13-05-2003
		MA 25868 A1	01-10-2003
		NO 20013855 A	05-10-2001
		NO 20013858 A	08-10-2001